

# 2020 Formulary (Drug List)

Effective: November 1, 2020

Large and Small Group Health Plans  
Individual Health Plans  
Third Party Administered Health Plans

## 2020 Commercial 5-Tier Formulary (List of Covered Drugs)

### What is the Drug List?

Also called a “formulary” by doctors and pharmacists, the Drug List is an extensive list of safe and effective, FDA-approved, brand name and generic prescription drugs used to treat the most common medical conditions.

The Health First Pharmacy and Therapeutics Committee (P&T), a panel of physicians and pharmacists, developed our Drug List and updates it regularly. The list includes quality drugs available to you at a reasonable cost. Only those medications that have successfully passed federally required clinical testing and evaluation and have been proven effective are included. The P&T Committee reviews and evaluates all available literature about a drug when updating the list.

### About Tiers

Most covered prescription drugs will be categorized into one of five cost-sharing tiers. Drug costs vary widely, even though several different medications may be used to treat the same condition. What you pay for the prescription depends upon what tier the drug is listed in. Health First Health Plans and Insurance (The Plan) offers many benefit plans that can vary in coverage for each tier. Details about your specific benefit for each tier are included in The Plan’s Summary of Benefits.

Prescriptions that exceed a 30-day supply will default to a 90-day supply copay (this does not apply to coinsurances). For coinsurances, you will always pay a percentage of the total cost after the applicable deductible is met.

- **Tier 1 (T1)** - Includes low-cost preferred generic drugs.
- **Tier 2 (T2)** - Includes higher-cost generic drugs.
- **Tier 3 (T3)** - Includes preferred brand-name drugs and some higher-cost generic drugs.
- **Tier 4 (T4)** - Includes higher-cost non-preferred brand-name drugs and generic drugs (some plans may be limited to a 30-day supply).
- **Tier 5 (T5 SP)** - Includes higher-cost biologics or prescription drugs that require close monitoring for safety and efficacy. These medications must be obtained from Accredo Pharmacy when possible and are limited to a 30-day supply.
- **Preventive Care (NCS)** - Includes some select preventive products, prescription medications and specific over-the-counter (OTC) medications available to you at no cost-sharing (\$0) when applicable conditions are met.

**Generic drugs** are prescription drugs that have the same active ingredients as brand drugs and are prescribed for the same reasons. When the patent expires on a brand name drug, the FDA permits new manufacturers to produce an equivalent of the brand name drug and make it available to the public. Generally, more than one manufacturer will produce generic versions, although often the same pharmaceutical firm that produces the brand name drug also makes the generic version. This prompts competitive pricing of the generic version and usually results in a less expensive drug that is as safe and effective as the brand name drug.

## What will my expenses be?

Every plan is different, and your financial obligation will vary based on your specific plan. You are responsible for any cost sharing your plan requires.

### What is a deductible?

A deductible is a set dollar amount that you must pay each calendar year before your health plan starts paying. If your plan includes an integrated pharmacy deductible, it will accumulate with your in-network medical deductible. Refer to your plan documents to see when your deductible starts over for your plan.

### What is the difference between a copayment and coinsurance?

Copayments and coinsurance are types of member cost sharing, and they represent the portion of covered prescription expenses members must pay. A copayment is a flat dollar amount while coinsurance is a percentage of the total allowable charges.

### What does out-of-pocket maximum mean?

The out-of-pocket maximum protects you from catastrophic medical and prescription drug expenses by limiting how much you have to pay during the benefit year. Your cost sharing for covered prescription drugs (deductible, coinsurance and copayment) all accumulate with your in-network medical out-of-pocket maximum. Refer to your plan documents to see when your out-of-pocket maximum starts over for your plan and to verify the specific cost sharing you have for specific tiers.

## The Drug List is subject to change

In order to continue to offer a safe and cost effective selection of prescription drugs, The Plan periodically makes changes to the Drug List. These changes may include removing medications, adding restrictions, and/or covering a drug at a higher tier. Updated formularies are posted to the website as changes are made. The following list represents some of the most common scenarios in which changes to drug coverage will occur:

- Throughout the year, new medications are approved by the FDA. It is the policy of The Plan that new drugs will be excluded for 6 months from the date of FDA approval, during which time the Health First P&T Committee can review the drug for safety and efficacy.
- When a medication is withdrawn from the market due to safety reasons or if it becomes available over-the-counter (OTC). At the time that a medication on the HFP Drug List becomes available OTC, it may be excluded from coverage from that point forward.
- When a brand-name prescription drug loses its patent and the equivalent generic form is added to the Drug List, the brand-name drug may be moved to Tier 4 or removed from the formulary.

This formulary is current as of **September 1, 2020**. To get updated information about covered drugs, please visit our Web site at [myHFHP.org](http://myHFHP.org) or call Customer Service toll-free at 1.855.443.4735 (TTY/TDD relay: 1.800.955.8771) Monday through Friday from 8 a.m. to 6 p.m.

## Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** The Plan requires you and/or your physician to get prior authorization for certain drugs. This means that you will need to get approval from us before you fill your prescriptions. In order for The Plan to pay for these drugs, the physician ordering the prescription is required to submit all medical information to The Plan documenting the medical necessity. These drugs are identified in the Drug List.
- **Step Therapy:** In some cases, The Plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. A complete list of drugs which require Step Therapy is listed in the reference table on page 6.

- **Quantity Limits:** For some covered drugs, there is a maximum amount that will be covered by The Plan over a certain period of time. For example, The Plan covers 30 tablets every 30 days or 90 tablets every 90 days for TRADJENTA.

## How can I make the most of my prescription drug benefit?

Prescription drug costs continue to rise every year and can represent a significant part of your healthcare expenses. The Plan helps you pay for your medications by sharing the cost with you and providing substantial discounts for covered medications. To help you manage your drug costs, here are some money-saving tips to consider:

- **Use generic medications whenever possible.** Generic drugs are the chemical equivalent of brand name drugs and are just as effective in most cases. If you take generic drugs you will generally pay less. Talk to your doctor to see if switching to a generic equivalent of any brand-name drug you are taking is appropriate. Please see the list of drugs below to determine which generic drugs are included in lower cost-sharing tiers.

## What if my drug is not on the Formulary?

If your drug is not included in this formulary, you should first contact Customer Service and confirm that your drug is not covered. If you learn that The Plan does not cover your drug, you have two options:

- You can ask Customer Service for a list of similar drugs that are covered by The Plan. When you receive the list, show it to your doctor and ask if switching to a covered medication is appropriate.
- You can ask your physician to send The Plan information requesting we make an exception and cover your drug.

If The Plan approves the request for an exception to the formulary, the approved drug will be covered at the Tier 4 cost share unless the cost of the medication is greater than \$500 per month, then it will be covered at the Tier 5 cost share.

## Excluded drugs

The Plan does not provide coverage for all drugs. In addition to the drugs marked “excluded” in this drug list, newly FDA approved drugs are not covered unless the Health First P&T Committee in its sole discretion approves these drugs for coverage. The Plan will automatically exclude a particular drug if a generic version becomes available and an entire class of drugs if a particular drug within that class becomes available over the counter.

## The following are NOT covered by The Plan:

- Compounded drugs
- Cosmetics or any drugs used for cosmetic purposes
- Diabetic supplies, blood glucose monitors and test strips other than those manufactured by Abbott under the product name Freestyle, Precision, and test strips®
- Erectile dysfunction drugs (such as Viagra)
- Infertility drugs (such as Clomid)
- Some injectables (except insulin, Imitrex, and those requiring prior authorization)
- Most multivitamins and nutritional supplements (except prescription pre-natal vitamins and products covered under the Preventive Care benefit)
- Nonprescription supplies or substances
- Over-the-counter (OTC) medications (except products covered under the Preventive Care benefit), or any drug for which a similar over-the-counter version is available
- All new drugs approved by the FDA will be excluded from the preferred drug list/formulary unless the Health First P&T Committee, in its sole discretion, decides to waive this exclusion for a particular drug.
- Support garments
- Syringes, needles, or other disposable supplies (except those used with insulin)

## Preventive Care Medications: \$0 Cost-share Medications and Products

The Affordable Care Act (ACA), commonly known as health care reform, was signed into federal law in 2010. The ACA requires private insurers to cover certain preventive services without any patient cost-sharing (i.e., copayments, coinsurance and deductible) when they are delivered by a network provider.

The Department of Health and Human Services (HHS) has recognized several recommending bodies (e.g., United States Preventive Services Task Force [USPSTF], Advisory Committee on Immunization Practices [ACIP], and Health Resources and Services Administration [HRSA]) who have identified several medication categories that fall within the preventive health mandate.

The following products, prescription medications and specific over-the-counter (OTC) medications (notated in Tier NCS throughout this formulary) are available to our members at no (\$0) cost-sharing when:

- Prescribed by a health care professional (all prescription **and** OTC medications will require a prescription)
- Age and/or gender appropriate

*This list will be reviewed periodically and is subject to change.*

| Medicine/Product Category and Who is Covered                                                                                                                                                                                  | Examples of the Medicine/Product Covered                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b><u>Aspirin</u></b> <ul style="list-style-type: none"> <li>▪ Individuals &lt; 60 years</li> </ul>                                                                                                                           | <ul style="list-style-type: none"> <li>▪ Aspirin products ≤ 325 MG</li> </ul>                                                                                                                                                                                                                                                                             |
| <b><u>Fluoride</u></b> <ul style="list-style-type: none"> <li>▪ Children age 6 months through 5 years</li> </ul>                                                                                                              | <ul style="list-style-type: none"> <li>▪ Fluoride Chewable Tablet 0.25 MG and 0.5 MG;</li> <li>▪ Fluoride Drops 0.125 MG, 0.25 MG and 0.5 MG;</li> <li>▪ Multivitamin W/ Fluoride Chewable 0.25 MG and 0.5 MG;</li> <li>▪ Multivitamin W/ Fluoride Drops 0.25 MG and 0.5 MG;</li> <li>▪ Multivitamin W/ Fluoride Suspension 0.25 MG and 0.5 MG</li> </ul> |
| <b><u>Folic Acid</u></b> <ul style="list-style-type: none"> <li>▪ Women only through age 50 years</li> </ul>                                                                                                                  | <ul style="list-style-type: none"> <li>▪ Folic Acid Tablet 0.4 MG and 0.8 MG;</li> <li>▪ Prenatal Multivitamins W/ Folic Acid (0.4 MG and 0.8 MG)</li> </ul>                                                                                                                                                                                              |
| <b><u>Vitamin D Supplements</u></b> <ul style="list-style-type: none"> <li>▪ Adults ≥ 65 years of age</li> </ul>                                                                                                              | <ul style="list-style-type: none"> <li>▪ Vitamin D 1,000 Units Or Less Per Dose Unit;</li> <li>▪ Calcium With Vitamin D (1,000 Units Or Less Per Dose Unit)</li> </ul>                                                                                                                                                                                    |
| <b><u>Immunizations</u></b> <ul style="list-style-type: none"> <li>▪ The age of coverage varies based on the vaccine product prescribed and recommendations by the U.S. Centers for Disease Control and Prevention</li> </ul> | Covered immunizations include those that are routine vaccines recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and that meet the US Food and Drug Administration approved indications for age and/or gender                                                                              |

| Medicine/Product Category and Who is Covered                                                                                                                                                                        | Examples of the Medicine/Product Covered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                     | limitations. Coverage also includes non-routine immunizations used to prevent other illnesses such as typhoid, yellow fever, and Japanese encephalitis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <p data-bbox="203 667 527 699"><b><u>Contraceptive Methods</u></b></p> <ul data-bbox="251 699 755 730" style="list-style-type: none"> <li data-bbox="251 699 755 730">▪ Women only, through age 50 years</li> </ul> | <p data-bbox="844 394 1412 562">Covered products include one or more Food and Drug Administration (FDA) approved 16 contraceptive methods available through the prescription drug benefit, including:</p> <ul data-bbox="844 562 1388 995" style="list-style-type: none"> <li data-bbox="844 562 1388 625">▪ Generic OTC spermicide and legend diaphragms;</li> <li data-bbox="844 625 1388 657">▪ Today® contraceptive sponge;</li> <li data-bbox="844 657 1388 688">▪ Female condom;</li> <li data-bbox="844 688 1388 720">▪ Femcap®;</li> <li data-bbox="844 720 1388 793">▪ Generic oral, transdermal and intramuscular hormonal methods;</li> <li data-bbox="844 793 1388 825">▪ Nuvaring®;</li> <li data-bbox="844 825 1388 898">▪ Generic, OTC emergency contraceptives and Ella®;</li> <li data-bbox="844 898 1388 961">▪ The intrauterine systems Mirena® and Paragard®;</li> <li data-bbox="844 961 1388 995">▪ The intradermal agent, Nexplanon®</li> </ul> |

If you have any questions regarding your eligibility for preventive care medications and preventive contraceptive coverage, please contact your employer or call Customer Service toll-free at 1.855.443.4735 (TTY/TDD relay: 1.800.955.8771) Monday through Friday from 8 a.m. to 6 p.m.

| Step Therapy Reference Table                                                                |                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Drug Name                                                                                   | Drug that must be tried first                                                                                                                                                                 |
| ALMOTRIPTAN, FROVATRIPTAN, NARATRIPTAN, RELPAX, ZOLMITRIPTAN, ZOLMITRIPTAN ODT, ZOMIG NASAL | <i>Sumatriptan, rizatriptan in the last 180 days</i>                                                                                                                                          |
| FOSRENAL, RENAGEL, RENVELA                                                                  | <i>calcium acetate 667 mg in the last 180 days</i>                                                                                                                                            |
| OXICONAXOLE                                                                                 | <i>ketoconazole AND clotrimazole topical products in the last 180 days</i>                                                                                                                    |
| ULORIC                                                                                      | <i>Allopurinol in the last 180 days</i>                                                                                                                                                       |
| VIIBRYD                                                                                     | <i>Trial of any two (2) of the following drugs: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine in the last year</i> |
| WELCHOL                                                                                     | <i>cholestyramine or colestipol in the last 180 days</i>                                                                                                                                      |
| SYMBICORT                                                                                   | <i>Advair in the last 180 days</i>                                                                                                                                                            |

# Health First Health Plans and Insurance Formulary

---

The formulary provides coverage information about some of the drugs covered by The Plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 102. The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., PRADAXA) and generic drugs are listed in lower-case italics (e.g., *lisinopril*).

The information in the Notes column tells you if The Plan has any special requirements for coverage of your drug.

## **Specialty Pharmacy (SP):**

Must be obtained from Accredo Pharmacy and are limited to a 30-day supply. *For members who reside outside the state of Florida, an exception will be considered to allow the medication to be filled at another pharmacy.* Please contact Customer Service Department to initiate this process.

## **Prior Authorization (PA):**

The Plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from The Plan before you fill your prescriptions. If you don't get approval, the drug will not be covered.

## **Quantity Limit (QL):**

Quantity Limits may also be listed. For example, "30 EA per 30 days" would mean your coverage of this drug is limited to 30 pills every 30 days. Prescriptions written for more than the suggested Quantity Limits will only be honored up to the listed amount unless an exception is requested by your physician and approved by The Plan.

## **Step Therapy (ST):**

In some cases, The Plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. A complete list of drugs which require Step Therapy is listed in the reference table on page 6.

## **Maintenance Drug (MD):**

You may be taking these drugs on a long-term basis. Maintenance medications are generally those used to treat chronic conditions and long-term conditions. **\*\*Some exceptions may apply (i.e. certain medications used for ADHD, asthma/COPD rescue, acute pain, and acute infections).**

## **No Cost-Share (NCS):**

Select preventive products, prescription medications and specific over-the-counter (OTC) medications available to our members at no cost-sharing (\$0) when applicable conditions are met.

Health First Commercial Plans, Inc. is doing business under the name of Health First Health Plans. Health First Health Plans does not discriminate on the basis of race, color, national origin, disability, age, sex, gender identity, sexual orientation, or health status in the administration of the plan, including enrollment and benefit determinations.

|                                                                                                                                          | Status              |                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------|---------------------|-----------------------------------------------------------------------------------------------------------|
|                                                                                                                                          | NCS = No Cost Share |                                                                                                           |
| lowercase italics = Generic drugs<br>UPPERCASE BOLD = Brand name drugs                                                                   | T1 = Tier 1         | Notes<br>PA = Prior Auth<br>PA = Prior Auth New Start<br>ST = Step Therapy<br>ST = Step Therapy New Start |
|                                                                                                                                          | T2 = Tier 2         |                                                                                                           |
|                                                                                                                                          | T3 = Tier 3         |                                                                                                           |
|                                                                                                                                          | T4 = Tier 4         |                                                                                                           |
|                                                                                                                                          | T5 = Tier 5         |                                                                                                           |
| Drug                                                                                                                                     | Status              | Notes                                                                                                     |
| <i>abacavir oral solution</i>                                                                                                            | T5                  |                                                                                                           |
| <i>abacavir oral tablet</i>                                                                                                              | T3                  | PA                                                                                                        |
| <i>abacavir-lamivudine</i>                                                                                                               | T5                  | PA                                                                                                        |
| <i>abacavir-lamivudine-zidovudine</i>                                                                                                    | T5                  | PA                                                                                                        |
| <i>abiraterone</i>                                                                                                                       | T5                  | PA; QL (120 EA per 30 days)                                                                               |
| <i>acamprosate</i>                                                                                                                       | T4                  |                                                                                                           |
| <i>acarbose</i>                                                                                                                          | T2                  | QL (90 EA per 30 days)                                                                                    |
| <i>acebutolol</i>                                                                                                                        | T2                  |                                                                                                           |
| <i>acetaminophen-codeine oral solution 120 mg-12 mg /5 ml (5 ml), 120-12 mg/5 ml, 240 mg-24 mg /10 ml (10 ml), 300 mg-30 mg /12.5 ml</i> | T3                  | QL (2700 ML per 30 days)                                                                                  |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg</i>                                                                            | T3                  | QL (240 EA per 30 days)                                                                                   |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i>                                                                                       | T3                  | QL (180 EA per 30 days)                                                                                   |
| <i>acetazolamide oral tablet</i>                                                                                                         | T3                  |                                                                                                           |
| <i>acetazolamide sodium</i>                                                                                                              | T3                  |                                                                                                           |
| <i>acetic acid otic (ear)</i>                                                                                                            | T2                  |                                                                                                           |
| <i>acetylcysteine</i>                                                                                                                    | T2                  |                                                                                                           |
| <i>acitretin</i>                                                                                                                         | T5                  | PA                                                                                                        |
| <b>ACTHIB (PF)</b>                                                                                                                       | NCS                 |                                                                                                           |
| <b>ACTIMMUNE</b>                                                                                                                         | T5                  | PA                                                                                                        |
| <i>acyclovir oral capsule</i>                                                                                                            | T2                  |                                                                                                           |
| <i>acyclovir oral suspension 200 mg/5 ml</i>                                                                                             | T3                  |                                                                                                           |
| <i>acyclovir oral tablet</i>                                                                                                             | T2                  |                                                                                                           |
| <i>acyclovir topical cream</i>                                                                                                           | T5                  |                                                                                                           |
| <i>acyclovir topical ointment</i>                                                                                                        | T4                  | QL (60 GM per 30 days)                                                                                    |
| <b>ADACEL(TDAP ADOLESN/ADULT)(PF)</b>                                                                                                    | NCS                 |                                                                                                           |
| <i>adapalene topical cream</i>                                                                                                           | T3                  |                                                                                                           |
| <i>adapalene topical gel 0.1 %</i>                                                                                                       | T3                  |                                                                                                           |
| <b>ADDERALL XR</b>                                                                                                                       | T4                  | QL (30 EA per 30 days)                                                                                    |
| <i>adefovir</i>                                                                                                                          | T5                  | PA                                                                                                        |
| <b>ADEMPAS</b>                                                                                                                           | T5                  | PA                                                                                                        |
| <b>ADRUCIL INTRAVENOUS SOLUTION 500 MG/10 ML</b>                                                                                         | T3                  |                                                                                                           |
| <b>ADVAIR DISKUS</b>                                                                                                                     | T3                  | QL (60 EA per 30 days)                                                                                    |
| <b>ADVAIR HFA</b>                                                                                                                        | T3                  | QL (12 GM per 30 days)                                                                                    |
| <b>AFEDITAB CR</b>                                                                                                                       | T2                  |                                                                                                           |
| <b>AFINITOR ORAL TABLET 10 MG</b>                                                                                                        | T5                  | PA; QL (60 EA per 30 days)                                                                                |
| <b>AFINITOR ORAL TABLET 2.5 MG, 5 MG, 7.5 MG</b>                                                                                         | T5                  | PA                                                                                                        |



| Drug                                                                  | Status | Notes                       |
|-----------------------------------------------------------------------|--------|-----------------------------|
| <b>AFTERA</b>                                                         | NCS    |                             |
| <b>AIMOVIG AUTOINJECTOR</b>                                           | T4     | PA; QL (1 ML per 28 days)   |
| <b>AJOVY AUTOINJECTOR</b>                                             | T4     | PA; QL (1.5 ML per 28 days) |
| <b>AJOVY SYRINGE</b>                                                  | T4     | PA; QL (1.5 ML per 28 days) |
| <b>AK-POLY-BAC</b>                                                    | T2     |                             |
| <b>AKYNZEO (FOSNETUPITANT) INTRAVENOUS RECON SOLN</b>                 | T5     | PA                          |
| <b>AKYNZEO (NETUPITANT)</b>                                           | T5     | PA                          |
| <i>albendazole</i>                                                    | T4     |                             |
| <i>albuterol sulfate inhalation solution for nebulization</i>         | T2     |                             |
| <i>albuterol sulfate oral syrup</i>                                   | T2     |                             |
| <i>albuterol sulfate oral tablet</i>                                  | T4     |                             |
| <i>alclometasone</i>                                                  | T3     |                             |
| <b>ALECENSA</b>                                                       | T5     | PA; QL (240 EA per 30 days) |
| <i>alendronate oral tablet 10 mg, 40 mg, 5 mg</i>                     | T2     | QL (30 EA per 30 days)      |
| <i>alendronate oral tablet 35 mg, 70 mg</i>                           | T1     | QL (4 EA per 28 days)       |
| <i>alfuzosin</i>                                                      | T2     | QL (30 EA per 30 days)      |
| <b>ALINIA</b>                                                         | T4     | PA                          |
| <b>ALIQOPA</b>                                                        | T5     | PA                          |
| <i>aliskiren</i>                                                      | T3     | QL (30 EA per 30 days)      |
| <i>allopurinol</i>                                                    | T2     |                             |
| <i>almotriptan malate</i>                                             | T4     | ST; QL (18 EA per 30 days)  |
| <b>ALOCRIL</b>                                                        | T4     |                             |
| <b>ALOMIDE</b>                                                        | T4     |                             |
| <b>ALOPHEN (BISACODYL)</b>                                            | NCS    |                             |
| <i>alosetron</i>                                                      | T5     | PA; QL (60 EA per 30 days)  |
| <b>ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.1 %</b>                        | T4     | QL (15 ML per 30 days)      |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg</i>                         | T2     | QL (120 EA per 30 days)     |
| <i>alprazolam oral tablet 1 mg</i>                                    | T2     | QL (240 EA per 30 days)     |
| <i>alprazolam oral tablet 2 mg</i>                                    | T2     | QL (150 EA per 30 days)     |
| <i>alprazolam oral tablet extended release 24 hr 0.5 mg</i>           | T3     | QL (90 EA per 30 days)      |
| <i>alprazolam oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg</i> | T3     | QL (60 EA per 30 days)      |
| <b>ALREX</b>                                                          | T3     |                             |
| <b>ALTABAX</b>                                                        | T4     |                             |
| <b>ALTAVERA (28)</b>                                                  | NCS    |                             |
| <b>ALTRENO</b>                                                        | T3     | PA                          |
| <b>ALUNBRIG ORAL TABLET 180 MG, 90 MG</b>                             | T5     | PA; QL (30 EA per 30 days)  |
| <b>ALUNBRIG ORAL TABLET 30 MG</b>                                     | T5     | PA; QL (60 EA per 30 days)  |
| <b>ALUNBRIG ORAL TABLETS,DOSE PACK</b>                                | T5     | PA; QL (30 EA per 30 days)  |
| <i>alyacen 1/35 (28)</i>                                              | NCS    |                             |
| <b>ALYACEN 7/7/7 (28)</b>                                             | NCS    |                             |
| <i>amantadine hcl oral capsule</i>                                    | T3     |                             |

| Drug                                                                                                                     | Status | Notes                  |
|--------------------------------------------------------------------------------------------------------------------------|--------|------------------------|
| <i>amantadine hcl oral tablet</i>                                                                                        | T3     |                        |
| <i>ambrisentan</i>                                                                                                       | T5     | PA                     |
| <i>amcinonide topical cream</i>                                                                                          | T4     |                        |
| <b>AMETHIA</b>                                                                                                           | NCS    |                        |
| <b>AMETHIA LO</b>                                                                                                        | NCS    |                        |
| <b>AMETHYST (28)</b>                                                                                                     | NCS    |                        |
| <i>amiloride</i>                                                                                                         | T2     |                        |
| <i>amiloride-hydrochlorothiazide</i>                                                                                     | T2     |                        |
| <i>aminophylline intravenous solution 250 mg/10 ml</i>                                                                   | T2     |                        |
| <i>amiodarone oral tablet 200 mg</i>                                                                                     | T2     |                        |
| <b>AMITIZA</b>                                                                                                           | T3     | QL (60 EA per 30 days) |
| <i>amitriptyline</i>                                                                                                     | T2     |                        |
| <i>amitriptyline-chlordiazepoxide</i>                                                                                    | T2     |                        |
| <i>amlodipine</i>                                                                                                        | T1     |                        |
| <i>amlodipine-benazepril</i>                                                                                             | T2     | QL (30 EA per 30 days) |
| <i>amlodipine-olmesartan</i>                                                                                             | T3     |                        |
| <i>amlodipine-valsartan</i>                                                                                              | T2     | QL (30 EA per 30 days) |
| <i>amlodipine-valsartan-hcthiazid</i>                                                                                    | T3     | QL (30 EA per 30 days) |
| <i>ammonium chloride</i>                                                                                                 | T2     |                        |
| <i>ammonium lactate</i>                                                                                                  | T2     |                        |
| <b>AMNESTEEM</b>                                                                                                         | T5     |                        |
| <i>amoxapine</i>                                                                                                         | T2     |                        |
| <i>amoxicillin oral capsule</i>                                                                                          | T1     |                        |
| <i>amoxicillin oral suspension for reconstitution</i>                                                                    | T1     |                        |
| <i>amoxicillin oral tablet</i>                                                                                           | T1     |                        |
| <i>amoxicillin oral tablet,chewable 125 mg</i>                                                                           | T2     |                        |
| <i>amoxicillin oral tablet,chewable 250 mg</i>                                                                           | T1     |                        |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml</i> | T2     |                        |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 250-62.5 mg/5 ml</i>                                   | T3     |                        |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg</i>                                                                | T3     |                        |
| <i>amoxicillin-pot clavulanate oral tablet 500-125 mg, 875-125 mg</i>                                                    | T2     |                        |
| <i>amoxicillin-pot clavulanate oral tablet extended release 12 hr</i>                                                    | T3     |                        |
| <i>amoxicillin-pot clavulanate oral tablet,chewable</i>                                                                  | T2     |                        |
| <i>ampicillin oral capsule</i>                                                                                           | T2     |                        |
| <i>anagrelide</i>                                                                                                        | T3     |                        |
| <i>anastrozole</i>                                                                                                       | T2     | QL (30 EA per 30 days) |
| <b>ANORO ELLIPTA</b>                                                                                                     | T3     |                        |
| <b>ANUCORT-HC</b>                                                                                                        | T3     |                        |
| <i>apraclonidine</i>                                                                                                     | T2     |                        |

| Drug                                                                                                                                                                    | Status | Notes                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------|
| <i>aprepitant</i>                                                                                                                                                       | T4     | QL (60 EA per 30 days)     |
| <b>APRI</b>                                                                                                                                                             | NCS    |                            |
| <b>APRISO</b>                                                                                                                                                           | T3     | QL (120 EA per 30 days)    |
| <b>APTIOM</b>                                                                                                                                                           | T4     | PA                         |
| <b>APTIVUS</b>                                                                                                                                                          | T5     | PA                         |
| <b>APTIVUS (WITH VITAMIN E)</b>                                                                                                                                         | T5     | PA                         |
| <b>ARANELLE (28)</b>                                                                                                                                                    | NCS    |                            |
| <b>ARCALYST</b>                                                                                                                                                         | T5     | PA                         |
| <b>ARCAPTA NEOHALER</b>                                                                                                                                                 | T4     |                            |
| <i>aripiprazole oral solution</i>                                                                                                                                       | T4     |                            |
| <i>aripiprazole oral tablet</i>                                                                                                                                         | T4     | QL (30 EA per 30 days)     |
| <i>aripiprazole oral tablet, disintegrating</i>                                                                                                                         | T4     | QL (60 EA per 30 days)     |
| <b>ARISTADA</b>                                                                                                                                                         | T4     |                            |
| <b>ARISTADA INITIO</b>                                                                                                                                                  | T4     |                            |
| <i>armodafinil</i>                                                                                                                                                      | T3     | PA; QL (30 EA per 30 days) |
| <b>ARMOUR THYROID</b>                                                                                                                                                   | T3     |                            |
| <b>ARNUITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION</b>                                                                              | T3     |                            |
| <b>ASCOMP WITH CODEINE</b>                                                                                                                                              | T3     |                            |
| <b>ASHLYNA</b>                                                                                                                                                          | NCS    |                            |
| <b>ASMANEX HFA INHALATION HFA AEROSOL INHALER 100 MCG/ACTUATION, 200 MCG/ACTUATION</b>                                                                                  | T3     | QL (13 GM per 30 days)     |
| <b>ASMANEX TWISTHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60)</b> | T3     | QL (1 EA per 30 days)      |
| <i>aspirin oral tablet</i>                                                                                                                                              | NCS    |                            |
| <i>aspirin oral tablet, chewable</i>                                                                                                                                    | NCS    |                            |
| <i>aspirin oral tablet, delayed release (drlec) 325 mg, 81 mg</i>                                                                                                       | NCS    |                            |
| <i>aspirin-dipyridamole</i>                                                                                                                                             | T4     |                            |
| <b>ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"</b>                                                                                                            | T3     | QL (200 EA per 30 days)    |
| <i>atazanavir</i>                                                                                                                                                       | T3     |                            |
| <i>atenolol</i>                                                                                                                                                         | T1     |                            |
| <i>atenolol-chlorthalidone</i>                                                                                                                                          | T2     |                            |
| <i>atomoxetine oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i>                                                                                                              | T3     | QL (60 EA per 30 days)     |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i>                                                                                                                    | T3     | QL (30 EA per 30 days)     |
| <i>atorvastatin</i>                                                                                                                                                     | T2     | QL (30 EA per 30 days)     |
| <i>atovaquone</i>                                                                                                                                                       | T5     |                            |
| <i>atovaquone-proguanil</i>                                                                                                                                             | T4     |                            |
| <b>ATRIPLA</b>                                                                                                                                                          | T5     | PA; QL (30 EA per 30 days) |
| <i>atropine injection syringe 0.05 mg/ml, 0.1 mg/ml</i>                                                                                                                 | T4     |                            |

| Drug                                                   | Status | Notes                        |
|--------------------------------------------------------|--------|------------------------------|
| <i>atropine ophthalmic (eye) drops</i>                 | T2     |                              |
| <b>ATROVENT HFA</b>                                    | T4     | QL (26 GM per 30 days)       |
| <b>AUBAGIO</b>                                         | T5     | PA; QL (30 EA per 30 days)   |
| <b>AUBRA</b>                                           | NCS    |                              |
| <b>AUSTEDO ORAL TABLET 12 MG</b>                       | T5     | PA; QL (120 EA per 30 days)  |
| <b>AUSTEDO ORAL TABLET 6 MG, 9 MG</b>                  | T5     | PA; QL (60 EA per 30 days)   |
| <b>AVAR TOPICAL CLEANSER</b>                           | T4     |                              |
| <b>AVAR-E</b>                                          | T4     |                              |
| <b>AVAR-E GREEN</b>                                    | T4     |                              |
| <b>AVIANE</b>                                          | NCS    |                              |
| <b>AVONEX (WITH ALBUMIN)</b>                           | T5     | PA; QL (4 EA per 28 days)    |
| <b>AVONEX INTRAMUSCULAR PEN INJECTOR KIT</b>           | T5     | PA; QL (4 EA per 28 days)    |
| <b>AVONEX INTRAMUSCULAR SYRINGE KIT</b>                | T5     | PA; QL (1 EA per 28 days)    |
| <b>AYVAKIT</b>                                         | T5     | PA; QL (30 EA per 30 days)   |
| <b>AZASITE</b>                                         | T4     |                              |
| <i>azathioprine</i>                                    | T2     |                              |
| <i>azelastine nasal</i>                                | T3     | QL (60 ML per 30 days)       |
| <i>azelastine ophthalmic (eye)</i>                     | T2     |                              |
| <b>AZILECT</b>                                         | T4     |                              |
| <i>azithromycin oral packet</i>                        | T2     |                              |
| <i>azithromycin oral suspension for reconstitution</i> | T2     |                              |
| <i>azithromycin oral tablet 250 mg, 600 mg</i>         | T1     |                              |
| <i>azithromycin oral tablet 500 mg</i>                 | T1     | QL (5 EA per 30 days)        |
| <b>AZOPT</b>                                           | T3     | QL (15 ML per 30 days)       |
| <b>AZOR</b>                                            | T3     |                              |
| <b>AZURETTE (28)</b>                                   | NCS    |                              |
| <i>bacitracin ophthalmic (eye)</i>                     | T3     |                              |
| <i>bacitracin-polymyxin b ophthalmic (eye)</i>         | T2     |                              |
| <i>baclofen oral tablet 10 mg, 20 mg</i>               | T2     |                              |
| <i>balsalazide</i>                                     | T3     |                              |
| <b>BALVERSA</b>                                        | T5     | PA                           |
| <b>BALZIVA (28)</b>                                    | NCS    |                              |
| <b>BANZEL ORAL SUSPENSION</b>                          | T5     | PA; QL (2400 ML per 30 days) |
| <b>BANZEL ORAL TABLET 200 MG</b>                       | T5     | PA; QL (90 EA per 30 days)   |
| <b>BANZEL ORAL TABLET 400 MG</b>                       | T5     | PA; QL (240 EA per 30 days)  |
| <b>BAQSIMI</b>                                         | T3     |                              |
| <b>BARACLUDE ORAL SOLUTION</b>                         | T5     | PA                           |
| <b>BAVENCIO</b>                                        | T5     | PA                           |
| <b>BAYER ASPIRIN</b>                                   | NCS    |                              |
| <i>bcg vaccine, live (pf)</i>                          | NCS    |                              |
| <b>BD ULTRA-FINE MICRO PEN NEEDLE</b>                  | T3     |                              |
| <b>BD ULTRA-FINE MINI PEN NEEDLE</b>                   | T3     |                              |
| <b>BD ULTRA-FINE NANO PEN NEEDLE</b>                   | T3     |                              |

| Drug                                               | Status | Notes                      |
|----------------------------------------------------|--------|----------------------------|
| <b>BD ULTRA-FINE ORIG PEN NEEDLE</b>               | T3     |                            |
| <b>BD ULTRA-FINE SHORT PEN NEEDLE</b>              | T3     |                            |
| <b>BEKYREE (28)</b>                                | NCS    |                            |
| <b>BELSOMRA</b>                                    | T4     | PA                         |
| <i>benazepril</i>                                  | T1     |                            |
| <i>benazepril-hydrochlorothiazide</i>              | T2     |                            |
| <b>BENICAR</b>                                     | T3     |                            |
| <b>BENICAR HCT</b>                                 | T3     |                            |
| <b>BENLYSTA SUBCUTANEOUS AUTO-INJECTOR</b>         | T5     | PA; QL (4 ML per 28 days)  |
| <i>benznidazole</i>                                | T2     | PA                         |
| <i>benzonatate</i>                                 | T2     |                            |
| <i>benzoyl peroxide topical cleanser 6 %</i>       | T2     |                            |
| <i>benzoyl peroxide topical cleanser 7 %</i>       | T3     |                            |
| <i>benzoyl peroxide topical foam</i>               | T2     |                            |
| <i>benzoyl peroxide topical gel 10 %, 2.5 %</i>    | T2     |                            |
| <i>benztropine oral</i>                            | T2     |                            |
| <b>BEPREVE</b>                                     | T4     |                            |
| <b>BESIVANCE</b>                                   | T4     |                            |
| <i>betamethasone dipropionate topical cream</i>    | T3     |                            |
| <i>betamethasone dipropionate topical lotion</i>   | T2     |                            |
| <i>betamethasone dipropionate topical ointment</i> | T3     |                            |
| <i>betamethasone valerate topical cream</i>        | T2     |                            |
| <i>betamethasone valerate topical lotion</i>       | T3     |                            |
| <i>betamethasone valerate topical ointment</i>     | T2     |                            |
| <i>betamethasone, augmented topical cream</i>      | T2     |                            |
| <i>betamethasone, augmented topical gel</i>        | T2     |                            |
| <i>betamethasone, augmented topical lotion</i>     | T3     |                            |
| <i>betamethasone, augmented topical ointment</i>   | T2     |                            |
| <b>BETASERON SUBCUTANEOUS KIT</b>                  | T5     | PA; QL (14 EA per 28 days) |
| <i>betaxolol oral</i>                              | T2     |                            |
| <i>bethanechol chloride</i>                        | T3     |                            |
| <b>BETIMOL</b>                                     | T3     |                            |
| <b>BETOPTIC S</b>                                  | T4     |                            |
| <i>bexarotene</i>                                  | T5     | PA                         |
| <b>BEXSERO</b>                                     | NCS    |                            |
| <b>BEYAZ</b>                                       | T4     |                            |
| <i>bicalutamide</i>                                | T2     |                            |
| <b>BIKTARVY</b>                                    | T5     | QL (30 EA per 30 days)     |
| <b>BILTRICIDE</b>                                  | T4     |                            |
| <b>BIOTHRAX</b>                                    | NCS    |                            |
| <i>bisacodyl oral</i>                              | NCS    |                            |
| <b>BISA-LAX (BISACODYL)</b>                        | NCS    |                            |
| <i>bisoprolol fumarate</i>                         | T2     |                            |

| Drug                                                                    | Status | Notes                       |
|-------------------------------------------------------------------------|--------|-----------------------------|
| <i>bisoprolol-hydrochlorothiazide</i>                                   | T2     |                             |
| <b>BLEPHAMIDE S.O.P.</b>                                                | T3     |                             |
| <b>BLISOVI 24 FE</b>                                                    | NCS    |                             |
| <b>BLISOVI FE 1/20 (28)</b>                                             | NCS    |                             |
| <b>BOOSTRIX TDAP</b>                                                    | NCS    |                             |
| <i>bosentan</i>                                                         | T5     | PA                          |
| <b>BOSULIF ORAL TABLET 100 MG</b>                                       | T5     | PA; QL (90 EA per 30 days)  |
| <b>BOSULIF ORAL TABLET 400 MG, 500 MG</b>                               | T5     | PA; QL (30 EA per 30 days)  |
| <b>BRAFTOVI ORAL CAPSULE 50 MG</b>                                      | T5     | PA; QL (120 EA per 30 days) |
| <b>BRAFTOVI ORAL CAPSULE 75 MG</b>                                      | T5     | PA; QL (180 EA per 30 days) |
| <b>BREO ELLIPTA</b>                                                     | T3     |                             |
| <b>BRIELLYN</b>                                                         | NCS    |                             |
| <b>BRILINTA</b>                                                         | T3     |                             |
| <i>brimonidine ophthalmic (eye) drops 0.15 %</i>                        | T3     |                             |
| <i>brimonidine ophthalmic (eye) drops 0.2 %</i>                         | T1     |                             |
| <b>BROMFED DM</b>                                                       | T3     |                             |
| <i>bromfenac</i>                                                        | T3     |                             |
| <i>bromocriptine</i>                                                    | T4     |                             |
| <i>brompheniramine-pseudoeph-dm oral syrup</i>                          | T3     | QL (1200 ML per 30 days)    |
| <b>BROVANA</b>                                                          | T4     | PA                          |
| <b>BRUKINSA</b>                                                         | T5     | PA; QL (120 EA per 30 days) |
| <i>budesonide inhalation</i>                                            | T4     |                             |
| <i>budesonide oral capsule, delayed, extend. release</i>                | T5     |                             |
| <i>budesonide oral tablet, delayed and ext. release</i>                 | T4     | QL (30 EA per 30 days)      |
| <i>budesonide-formoterol</i>                                            | T3     | QL (10.2 GM per 30 days)    |
| <i>bumetanide oral</i>                                                  | T2     |                             |
| <b>BUPHENYL ORAL TABLET</b>                                             | T5     | PA                          |
| <i>buprenorphine hcl sublingual</i>                                     | T3     | PA; QL (90 EA per 30 days)  |
| <i>buprenorphine-naloxone sublingual film 12-3 mg</i>                   | T3     | PA; QL (60 EA per 30 days)  |
| <i>buprenorphine-naloxone sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg</i>  | T3     | PA; QL (90 EA per 30 days)  |
| <i>bupropion hcl (smoking deter)</i>                                    | NCS    | QL (336 EA per 365 days)    |
| <i>bupropion hcl oral tablet</i>                                        | T2     |                             |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg</i>          | T2     | QL (90 EA per 30 days)      |
| <i>bupropion hcl oral tablet extended release 24 hr 300 mg</i>          | T2     | QL (30 EA per 30 days)      |
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 200 mg</i> | T2     | QL (60 EA per 30 days)      |
| <i>bupropion hcl oral tablet sustained-release 12 hr 150 mg</i>         | T2     | QL (90 EA per 30 days)      |
| <i>buspirone</i>                                                        | T2     |                             |
| <b>BUSULFEX</b>                                                         | T5     | PA                          |
| <b>BUTALBITAL COMPOUND W/CODEINE</b>                                    | T4     | QL (180 EA per 30 days)     |

| Drug                                                                   | Status | Notes                      |
|------------------------------------------------------------------------|--------|----------------------------|
| <i>butalbital-acetaminop-caf-cod</i>                                   | T4     | QL (180 EA per 30 days)    |
| <i>butalbital-acetaminophen oral tablet 50-325 mg</i>                  | T4     | QL (180 EA per 30 days)    |
| <i>butalbital-acetaminophen-caff oral capsule 50-325-40 mg</i>         | T4     | QL (180 EA per 30 days)    |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i>          | T4     | QL (180 EA per 30 days)    |
| <i>butalbital-aspirin-caffeine oral capsule</i>                        | T4     | QL (180 EA per 30 days)    |
| <i>butorphanol injection</i>                                           | T3     |                            |
| <b>BUTRANS</b>                                                         | T3     | QL (4 EA per 28 days)      |
| <b>BYDUREON BCISE</b>                                                  | T3     | QL (3.4 ML per 28 days)    |
| <b>BYDUREON SUBCUTANEOUS PEN INJECTOR</b>                              | T3     | QL (4 EA per 28 days)      |
| <b>BYETTA SUBCUTANEOUS PEN INJECTOR 10 MCG/DOSE(250 MCG/ML) 2.4 ML</b> | T3     | QL (2.4 ML per 28 days)    |
| <b>BYETTA SUBCUTANEOUS PEN INJECTOR 5 MCG/DOSE (250 MCG/ML) 1.2 ML</b> | T3     | QL (1.2 ML per 30 days)    |
| <b>BYNFEZIA</b>                                                        | T5     | PA                         |
| <b>BYSTOLIC</b>                                                        | T3     |                            |
| <i>cabergoline</i>                                                     | T3     | QL (16 EA per 28 days)     |
| <b>CABOMETYX ORAL TABLET 20 MG, 60 MG</b>                              | T5     | PA; QL (30 EA per 30 days) |
| <b>CABOMETYX ORAL TABLET 40 MG</b>                                     | T5     | PA; QL (60 EA per 30 days) |
| <i>calcipotriene scalp</i>                                             | T4     |                            |
| <i>calcipotriene topical cream</i>                                     | T4     |                            |
| <i>calcipotriene topical ointment</i>                                  | T4     |                            |
| <i>calcipotriene-betamethasone topical ointment</i>                    | T4     |                            |
| <i>calcitonin (salmon)</i>                                             | T3     | QL (3.7 ML per 30 days)    |
| <i>calcitriol oral</i>                                                 | T2     |                            |
| <i>calcitriol topical</i>                                              | T5     | PA                         |
| <i>calcium acetate(phosphat bind) oral capsule</i>                     | T2     |                            |
| <b>CALQUENCE</b>                                                       | T5     | PA                         |
| <b>CAMILA</b>                                                          | NCS    |                            |
| <b>CAMRESE</b>                                                         | NCS    |                            |
| <b>CAMRESE LO</b>                                                      | NCS    |                            |
| <b>CANASA</b>                                                          | T5     |                            |
| <i>candesartan</i>                                                     | T3     | QL (30 EA per 30 days)     |
| <i>candesartan-hydrochlorothiazid</i>                                  | T3     | QL (30 EA per 30 days)     |
| <i>capecitabine</i>                                                    | T5     | PA                         |
| <b>CAPEX</b>                                                           | T3     |                            |
| <b>CAPLYTA</b>                                                         | T5     | PA; QL (30 EA per 30 days) |
| <b>CAPRELSA ORAL TABLET 100 MG</b>                                     | T5     | PA; QL (60 EA per 30 days) |
| <b>CAPRELSA ORAL TABLET 300 MG</b>                                     | T5     | PA; QL (30 EA per 30 days) |
| <i>captopril</i>                                                       | T2     |                            |
| <i>captopril-hydrochlorothiazide</i>                                   | T2     |                            |
| <b>CARAFATE ORAL SUSPENSION</b>                                        | T4     |                            |
| <i>carbamazepine oral capsule, er multiphase 12 hr</i>                 | T3     |                            |

| Drug                                                                            | Status | Notes                    |
|---------------------------------------------------------------------------------|--------|--------------------------|
| <i>carbamazepine oral suspension</i>                                            | T3     |                          |
| <i>carbamazepine oral tablet</i>                                                | T2     |                          |
| <i>carbamazepine oral tablet extended release 12 hr</i>                         | T3     |                          |
| <i>carbamazepine oral tablet, chewable</i>                                      | T2     |                          |
| <i>carbidopa</i>                                                                | T4     |                          |
| <i>carbidopa-levodopa oral tablet</i>                                           | T2     |                          |
| <i>carbidopa-levodopa oral tablet extended release</i>                          | T2     |                          |
| <i>carbinoxamine maleate oral tablet 4 mg</i>                                   | T3     |                          |
| <i>carisoprodol oral tablet 350 mg</i>                                          | T2     | QL (90 EA per 30 days)   |
| <i>carteolol</i>                                                                | T2     |                          |
| <b>CARTIA XT</b>                                                                | T2     |                          |
| <i>carvedilol</i>                                                               | T1     |                          |
| <i>carvedilol phosphate</i>                                                     | T3     |                          |
| <i>caspofungin</i>                                                              | T5     | PA                       |
| <b>CAYA CONTOURED</b>                                                           | NCS    |                          |
| <b>CAYSTON</b>                                                                  | T5     | PA                       |
| <b>CAZIENT (28)</b>                                                             | NCS    |                          |
| <i>cefaclor oral capsule</i>                                                    | T3     |                          |
| <i>cefadroxil oral capsule</i>                                                  | T2     |                          |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i>   | T3     |                          |
| <i>cefadroxil oral tablet</i>                                                   | T3     |                          |
| <i>cefazolin injection recon soln 1 gram, 300 g, 500 mg</i>                     | T2     |                          |
| <i>cefdinir oral capsule</i>                                                    | T2     |                          |
| <i>cefdinir oral suspension for reconstitution</i>                              | T3     |                          |
| <i>cefixime</i>                                                                 | T4     |                          |
| <i>cefpodoxime</i>                                                              | T3     |                          |
| <i>cefprozil oral suspension for reconstitution</i>                             | T3     |                          |
| <i>cefprozil oral tablet</i>                                                    | T2     |                          |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | T2     |                          |
| <i>cefuroxime axetil oral tablet</i>                                            | T3     |                          |
| <i>cefuroxime sodium injection recon soln 750 mg</i>                            | T2     |                          |
| <i>celecoxib</i>                                                                | T3     | QL (60 EA per 30 days)   |
| <b>CELONTIN ORAL CAPSULE 300 MG</b>                                             | T4     |                          |
| <i>cephalexin oral capsule 250 mg, 500 mg</i>                                   | T1     |                          |
| <i>cephalexin oral suspension for reconstitution</i>                            | T2     |                          |
| <b>CESAMET</b>                                                                  | T5     | PA                       |
| <b>CHANTIX</b>                                                                  | NCS    | QL (340 EA per 365 days) |
| <b>CHANTIX CONTINUING MONTH BOX</b>                                             | NCS    | QL (340 EA per 365 days) |
| <b>CHANTIX STARTING MONTH BOX</b>                                               | NCS    | QL (106 EA per 365 days) |
| <b>CHATEAL (28)</b>                                                             | NCS    |                          |
| <b>CHEMET</b>                                                                   | T4     |                          |



| Drug                                                        | Status | Notes                   |
|-------------------------------------------------------------|--------|-------------------------|
| <b>CHILDREN'S ASPIRIN</b>                                   | NCS    |                         |
| <i>chlordiazepoxide hcl</i>                                 | T2     |                         |
| <i>chlordiazepoxide-clidinium</i>                           | T3     |                         |
| <i>chlorhexidine gluconate mucous membrane</i>              | T2     |                         |
| <i>chloroquine phosphate</i>                                | T2     |                         |
| <i>chlorothiazide</i>                                       | T2     |                         |
| <i>chlorpromazine oral</i>                                  | T3     |                         |
| <i>chlorpropamide</i>                                       | T2     |                         |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i>              | T2     |                         |
| <i>chlorzoxazone oral tablet 500 mg</i>                     | T2     | QL (120 EA per 30 days) |
| <i>cholestyramine (with sugar)</i>                          | T3     |                         |
| <b>CHOLESTYRAMINE LIGHT</b>                                 | T3     |                         |
| <b>CICLODAN TOPICAL SOLUTION</b>                            | T2     |                         |
| <i>ciclopirox topical cream</i>                             | T3     |                         |
| <i>ciclopirox topical gel</i>                               | T3     |                         |
| <i>ciclopirox topical shampoo</i>                           | T3     |                         |
| <i>ciclopirox topical solution</i>                          | T2     |                         |
| <i>ciclopirox topical suspension</i>                        | T3     |                         |
| <i>cilostazol</i>                                           | T2     |                         |
| <b>CILOXAN OPHTHALMIC (EYE) OINTMENT</b>                    | T3     |                         |
| <b>CIMDUO</b>                                               | T5     | QL (30 EA per 30 days)  |
| <i>cimetidine</i>                                           | T2     |                         |
| <i>cimetidine hcl oral</i>                                  | T2     |                         |
| <i>cinacalcet oral tablet 30 mg</i>                         | T3     | PA                      |
| <i>cinacalcet oral tablet 60 mg, 90 mg</i>                  | T5     | PA                      |
| <b>CIPRO HC</b>                                             | T4     |                         |
| <b>CIPRODEX</b>                                             | T3     |                         |
| <i>ciprofloxacin</i>                                        | T3     |                         |
| <i>ciprofloxacin (mixture)</i>                              | T3     |                         |
| <i>ciprofloxacin hcl ophthalmic (eye)</i>                   | T1     |                         |
| <i>ciprofloxacin hcl oral tablet 100 mg</i>                 | T4     |                         |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i> | T1     |                         |
| <i>ciprofloxacin hcl otic (ear)</i>                         | T2     | QL (60 EA per 30 days)  |
| <i>ciprofloxacin-dexamethasone</i>                          | T3     |                         |
| <i>citalopram oral solution</i>                             | T2     | QL (600 ML per 30 days) |
| <i>citalopram oral tablet 10 mg, 40 mg</i>                  | T1     | QL (30 EA per 30 days)  |
| <i>citalopram oral tablet 20 mg</i>                         | T1     | QL (60 EA per 30 days)  |
| <b>CITRATE OF MAGNESIA</b>                                  | NCS    |                         |
| <b>CITROMA</b>                                              | NCS    |                         |
| <b>CLARAVIS</b>                                             | T4     |                         |
| <i>clarithromycin</i>                                       | T3     |                         |
| <b>CLEARLAX ORAL POWDER</b>                                 | NCS    |                         |
| <i>clemastine oral tablet 2.68 mg</i>                       | T3     |                         |

| Drug                                                       | Status | Notes                       |
|------------------------------------------------------------|--------|-----------------------------|
| <b>CLENPIQ</b>                                             | T3     |                             |
| <b>CLEOCIN VAGINAL SUPPOSITORY</b>                         | T4     |                             |
| <b>CLIMARA PRO</b>                                         | T4     |                             |
| <b>CLINDACIN ETZ TOPICAL SWAB</b>                          | T2     |                             |
| <b>CLINDACIN P</b>                                         | T2     |                             |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg</i>         | T1     |                             |
| <i>clindamycin palmitate hcl</i>                           | T3     |                             |
| <i>clindamycin phosphate topical gel</i>                   | T3     |                             |
| <i>clindamycin phosphate topical lotion</i>                | T3     |                             |
| <i>clindamycin phosphate topical solution</i>              | T3     |                             |
| <i>clindamycin phosphate topical swab</i>                  | T2     |                             |
| <i>clindamycin phosphate vaginal</i>                       | T3     |                             |
| <i>clindamycin-benzoyl peroxide topical gel</i>            | T4     |                             |
| <i>clobazam</i>                                            | T4     |                             |
| <i>clobetasol scalp</i>                                    | T3     |                             |
| <i>clobetasol topical cream</i>                            | T4     |                             |
| <i>clobetasol topical gel</i>                              | T4     |                             |
| <i>clobetasol topical lotion</i>                           | T4     |                             |
| <i>clobetasol topical ointment</i>                         | T4     |                             |
| <i>clobetasol topical shampoo</i>                          | T4     |                             |
| <i>clobetasol-emollient topical cream</i>                  | T4     |                             |
| <i>clocortolone pivalate</i>                               | T4     |                             |
| <b>CLODAN</b>                                              | T4     |                             |
| <i>clomipramine</i>                                        | T4     |                             |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i>                 | T2     | QL (90 EA per 30 days)      |
| <i>clonazepam oral tablet 2 mg</i>                         | T2     | QL (300 EA per 30 days)     |
| <i>clonidine</i>                                           | T3     | QL (4 EA per 28 days)       |
| <i>clonidine hcl oral tablet</i>                           | T1     |                             |
| <i>clopidogrel oral tablet 75 mg</i>                       | T2     | QL (30 EA per 30 days)      |
| <i>clorazepate dipotassium oral tablet 15 mg</i>           | T2     | QL (180 EA per 30 days)     |
| <i>clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg</i> | T2     | QL (90 EA per 30 days)      |
| <i>clotrimazole mucous membrane</i>                        | T2     |                             |
| <i>clotrimazole topical</i>                                | T2     |                             |
| <i>clotrimazole-betamethasone topical cream</i>            | T2     |                             |
| <i>clotrimazole-betamethasone topical lotion</i>           | T3     |                             |
| <b>CLOVIQUE</b>                                            | T5     | PA; QL (240 EA per 30 days) |
| <i>clozapine oral tablet</i>                               | T2     |                             |
| <i>clozapine oral tablet, disintegrating</i>               | T4     | PA                          |
| <i>codeine sulfate oral tablet</i>                         | T3     | QL (180 EA per 30 days)     |
| <i>codeine-butalbital-asa-caff</i>                         | T4     | QL (180 EA per 30 days)     |
| <i>colchicine</i>                                          | T3     |                             |
| <i>colesevelam</i>                                         | T3     |                             |
| <i>colestipol oral granules</i>                            | T3     |                             |

| Drug                                                       | Status | Notes                       |
|------------------------------------------------------------|--------|-----------------------------|
| <i>colestipol oral tablet</i>                              | T3     |                             |
| <b>COLY-MYCIN S</b>                                        | T3     |                             |
| <b>COMBIGAN</b>                                            | T3     | QL (10 ML per 30 days)      |
| <b>COMBIPATCH</b>                                          | T3     |                             |
| <b>COMBIVENT RESPIMAT</b>                                  | T3     | QL (8 GM per 30 days)       |
| <b>COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1)</b> | T5     | PA; QL (60 EA per 30 days)  |
| <b>COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3)</b> | T5     | PA; QL (120 EA per 30 days) |
| <b>COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY)</b>     | T5     | PA; QL (90 EA per 30 days)  |
| <b>COMPLERA</b>                                            | T5     |                             |
| <b>COMPRO</b>                                              | T4     |                             |
| <b>CONDYLOX TOPICAL GEL</b>                                | T4     |                             |
| <b>CONSTULOSE</b>                                          | T2     |                             |
| <b>COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML</b>              | T5     | PA                          |
| <b>COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML</b>              | T5     | PA; QL (12 ML per 30 days)  |
| <b>COPIKTRA</b>                                            | T5     | PA; QL (60 EA per 30 days)  |
| <b>CORDRAN TAPE LARGE ROLL</b>                             | T4     |                             |
| <b>CORDRAN TOPICAL LOTION</b>                              | T4     |                             |
| <b>COREG CR</b>                                            | T3     |                             |
| <b>CORLANOR ORAL SOLUTION</b>                              | T4     | PA                          |
| <b>CORTANE-B TOPICAL</b>                                   | T4     |                             |
| <i>cortisone</i>                                           | T2     |                             |
| <b>CORTISPORIN TOPICAL</b>                                 | T4     |                             |
| <b>COSENTYX</b>                                            | T5     | PA                          |
| <b>COSENTYX (2 SYRINGES)</b>                               | T5     | PA                          |
| <b>COSENTYX PEN</b>                                        | T5     | PA                          |
| <b>COSENTYX PEN (2 PENS)</b>                               | T5     | PA                          |
| <b>COTELLIC</b>                                            | T5     | PA; QL (90 EA per 30 days)  |
| <b>CREON</b>                                               | T3     |                             |
| <b>CRIVIVAN ORAL CAPSULE 200 MG, 400 MG</b>                | T3     | PA                          |
| <i>cromolyn inhalation</i>                                 | T2     |                             |
| <i>cromolyn ophthalmic (eye)</i>                           | T2     |                             |
| <i>cromolyn oral</i>                                       | T2     |                             |
| <b>CRYSELLE (28)</b>                                       | NCS    |                             |
| <b>CURITY GAUZE TOPICAL BANDAGE 2 X 2 "</b>                | T3     |                             |
| <b>CYCLAFEM 1/35 (28)</b>                                  | NCS    |                             |
| <b>CYCLAFEM 7/7/7 (28)</b>                                 | NCS    |                             |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i>             | T2     | QL (90 EA per 30 days)      |
| <i>cyclopentolate ophthalmic (eye) drops 1 %, 2 %</i>      | T2     |                             |
| <i>cyclophosphamide oral capsule</i>                       | T4     |                             |

| Drug                                        | Status | Notes                       |
|---------------------------------------------|--------|-----------------------------|
| <i>cycloserine</i>                          | T4     |                             |
| <b>CYCLOSET</b>                             | T4     | PA; QL (180 EA per 30 days) |
| <i>cyclosporine modified</i>                | T3     |                             |
| <i>cyclosporine oral capsule</i>            | T3     |                             |
| <i>cyproheptadine oral tablet</i>           | T2     |                             |
| <b>CYRED</b>                                | NCS    |                             |
| <b>CYSTAGON</b>                             | T4     | PA                          |
| <b>CYTRA-2</b>                              | T2     |                             |
| <b>CYTRA-3</b>                              | T4     |                             |
| <i>dalfampridine</i>                        | T5     | PA; QL (60 EA per 30 days)  |
| <i>danazol</i>                              | T4     |                             |
| <i>dantrolene oral</i>                      | T3     |                             |
| <i>dapsone oral</i>                         | T3     |                             |
| <b>DAPTACEL (DTAP PEDIATRIC) (PF)</b>       | NCS    |                             |
| <b>DARAPRIM</b>                             | T3     |                             |
| <i>darifenacin</i>                          | T4     |                             |
| <b>DASETTA 1/35 (28)</b>                    | NCS    |                             |
| <b>DASETTA 7/7/7 (28)</b>                   | NCS    |                             |
| <b>DAURISMO ORAL TABLET 100 MG</b>          | T5     | PA; QL (30 EA per 30 days)  |
| <b>DAURISMO ORAL TABLET 25 MG</b>           | T5     | PA; QL (60 EA per 30 days)  |
| <b>DAYSEE</b>                               | NCS    |                             |
| <b>DAYTRANA</b>                             | T4     | QL (30 EA per 30 days)      |
| <b>DEBLITANE</b>                            | NCS    |                             |
| <i>deferasirox oral tablet, dispersible</i> | T5     |                             |
| <b>DELSTRIGO</b>                            | T5     | QL (30 EA per 30 days)      |
| <b>DELYLA (28)</b>                          | NCS    |                             |
| <i>demeclocycline</i>                       | T3     |                             |
| <b>DENTA 5000 PLUS</b>                      | T2     |                             |
| <b>DENTAGEL</b>                             | T2     |                             |
| <b>DEPEN TITRATABS</b>                      | T5     |                             |
| <b>DEPO-ESTRADIOL</b>                       | T3     |                             |
| <b>DESCOVY</b>                              | T5     | PA                          |
| <i>desipramine</i>                          | T2     |                             |
| <i>desloratadine oral tablet</i>            | T2     | QL (30 EA per 30 days)      |
| <i>desmopressin nasal spray with pump</i>   | T3     |                             |
| <i>desmopressin nasal spray,non-aerosol</i> | T3     |                             |
| <i>desmopressin oral</i>                    | T3     |                             |
| <i>desog-e.estradiol/e.estradiol</i>        | NCS    |                             |
| <i>desogestrel-ethinyl estradiol</i>        | NCS    |                             |
| <i>desonide topical cream</i>               | T4     |                             |
| <i>desonide topical lotion</i>              | T4     |                             |
| <i>desonide topical ointment</i>            | T4     |                             |
| <i>desoximetasone topical cream</i>         | T3     |                             |

| Drug                                                                                                            | Status | Notes                   |
|-----------------------------------------------------------------------------------------------------------------|--------|-------------------------|
| <i>desoximetasone topical gel</i>                                                                               | T3     |                         |
| <i>desoximetasone topical ointment</i>                                                                          | T3     |                         |
| <i>desvenlafaxine</i>                                                                                           | T4     |                         |
| <i>desvenlafaxine succinate</i>                                                                                 | T4     |                         |
| <i>dexamethasone oral solution</i>                                                                              | T3     |                         |
| <i>dexamethasone oral tablet</i>                                                                                | T2     |                         |
| <i>dexamethasone sodium phosphate injection solution</i>                                                        | T2     |                         |
| <i>dexamethasone sodium phosphate injection syringe</i>                                                         | T3     |                         |
| <i>dexamethasone sodium phosphate ophthalmic (eye)</i>                                                          | T2     |                         |
| <i>dexmethylphenidate oral capsule,er biphasic 50-50</i>                                                        | T3     | QL (30 EA per 30 days)  |
| <i>dexmethylphenidate oral tablet</i>                                                                           | T3     | QL (60 EA per 30 days)  |
| <i>dextroamphetamine oral capsule, extended release 10 mg</i>                                                   | T4     | QL (180 EA per 30 days) |
| <i>dextroamphetamine oral capsule, extended release 15 mg</i>                                                   | T4     | QL (120 EA per 30 days) |
| <i>dextroamphetamine oral capsule, extended release 5 mg</i>                                                    | T4     | QL (90 EA per 30 days)  |
| <i>dextroamphetamine oral tablet</i>                                                                            | T3     | QL (180 EA per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule,extended release 24hr 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 5 mg</i> | T2     | QL (30 EA per 30 days)  |
| <i>dextroamphetamine-amphetamine oral capsule,extended release 24hr 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 5 mg</i> | T2     | QL (60 EA per 30 days)  |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg</i>                     | T2     | QL (90 EA per 30 days)  |
| <i>dextroamphetamine-amphetamine oral tablet 30 mg</i>                                                          | T2     | QL (60 EA per 30 days)  |
| <b>DIACOMIT ORAL CAPSULE</b>                                                                                    | T5     | PA                      |
| <b>DIAZEPAM INTENSOL</b>                                                                                        | T4     | PA                      |
| <i>diazepam oral concentrate</i>                                                                                | T4     | PA                      |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i>                                                               | T4     |                         |
| <i>diazepam oral tablet 10 mg</i>                                                                               | T2     | QL (120 EA per 30 days) |
| <i>diazepam oral tablet 2 mg, 5 mg</i>                                                                          | T2     | QL (90 EA per 30 days)  |
| <i>diazepam rectal</i>                                                                                          | T4     |                         |
| <i>diazoxide</i>                                                                                                | T5     | PA                      |
| <i>diclofenac potassium</i>                                                                                     | T2     |                         |
| <i>diclofenac sodium ophthalmic (eye)</i>                                                                       | T2     |                         |
| <i>diclofenac sodium oral</i>                                                                                   | T2     |                         |
| <i>diclofenac sodium topical gel 1 %</i>                                                                        | T3     |                         |
| <i>diclofenac sodium topical gel 3 %</i>                                                                        | T5     | PA                      |
| <i>dicloxacillin</i>                                                                                            | T2     |                         |
| <i>dicyclomine oral capsule</i>                                                                                 | T1     |                         |
| <i>dicyclomine oral solution</i>                                                                                | T2     |                         |
| <i>dicyclomine oral tablet</i>                                                                                  | T1     |                         |
| <i>didanosine</i>                                                                                               | T3     | PA                      |

| Drug                                                                                                           | Status | Notes                  |
|----------------------------------------------------------------------------------------------------------------|--------|------------------------|
| <b>DIFICID</b>                                                                                                 | T5     | PA                     |
| <i>diflorasone topical cream</i>                                                                               | T4     |                        |
| <b>DIGITEK</b>                                                                                                 | T2     |                        |
| <b>DIGOX</b>                                                                                                   | T2     |                        |
| <i>digoxin oral solution 50 mcg/ml (0.05 mg/ml)</i>                                                            | T3     |                        |
| <i>digoxin oral tablet</i>                                                                                     | T2     |                        |
| <i>dihydroergotamine injection</i>                                                                             | T3     |                        |
| <i>dihydroergotamine nasal</i>                                                                                 | T4     |                        |
| <i>diltiazem hcl oral capsule,ext.rel 24h degradable</i>                                                       | T2     |                        |
| <i>diltiazem hcl oral capsule,extended release 12 hr</i>                                                       | T2     |                        |
| <i>diltiazem hcl oral capsule,extended release 24 hr</i>                                                       | T2     |                        |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i>                         | T2     |                        |
| <i>diltiazem hcl oral tablet</i>                                                                               | T2     |                        |
| <i>diltiazem hcl oral tablet extended release 24 hr</i>                                                        | T3     |                        |
| <b>DILT-XR</b>                                                                                                 | T2     |                        |
| <b>DIPENTUM</b>                                                                                                | T5     |                        |
| <i>diphenhydramine hcl injection solution 50 mg/ml</i>                                                         | T2     |                        |
| <i>diphenhydramine hcl injection syringe</i>                                                                   | T2     |                        |
| <i>diphenoxylate-atropine</i>                                                                                  | T2     |                        |
| <i>dipyridamole oral</i>                                                                                       | T2     |                        |
| <i>disopyramide phosphate oral capsule</i>                                                                     | T2     |                        |
| <i>disulfiram</i>                                                                                              | T2     |                        |
| <i>divalproex</i>                                                                                              | T2     |                        |
| <b>DIVIGEL TRANSDERMAL GEL IN PACKET 0.25 MG/0.25 GRAM (0.1 %), 0.5 MG/0.5 GRAM (0.1 %), 1 MG/GRAM (0.1 %)</b> | T4     |                        |
| <i>dofetilide</i>                                                                                              | T4     |                        |
| <i>donepezil oral tablet 10 mg, 5 mg</i>                                                                       | T2     | QL (30 EA per 30 days) |
| <b>DONNATAL ORAL TABLET</b>                                                                                    | T4     |                        |
| <i>dorzolamide</i>                                                                                             | T2     |                        |
| <i>dorzolamide (pf)</i>                                                                                        | T4     |                        |
| <i>dorzolamide-timolol</i>                                                                                     | T2     |                        |
| <b>DOVATO</b>                                                                                                  | T5     | QL (30 EA per 30 days) |
| <i>doxazosin</i>                                                                                               | T2     | QL (60 EA per 30 days) |
| <i>doxepin oral capsule</i>                                                                                    | T2     |                        |
| <i>doxepin oral concentrate</i>                                                                                | T2     |                        |
| <i>doxercalciferol oral</i>                                                                                    | T3     | PA                     |
| <i>doxycycline hyclate oral capsule</i>                                                                        | T3     |                        |
| <i>doxycycline hyclate oral tablet 100 mg</i>                                                                  | T3     |                        |
| <i>doxycycline hyclate oral tablet 20 mg</i>                                                                   | T2     |                        |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i>                                                      | T2     |                        |
| <i>doxycycline monohydrate oral tablet 100 mg, 50 mg, 75 mg</i>                                                | T3     |                        |

| Drug                                                                                  | Status | Notes                        |
|---------------------------------------------------------------------------------------|--------|------------------------------|
| <i>dronabinol oral capsule 10 mg</i>                                                  | T5     | PA                           |
| <i>dronabinol oral capsule 10 mg</i>                                                  | T5     | PA; QL (120 EA per 30 days)  |
| <i>dronabinol oral capsule 2.5 mg, 5 mg</i>                                           | T4     | PA                           |
| <i>dronabinol oral capsule 2.5 mg, 5 mg</i>                                           | T4     | PA; QL (120 EA per 30 days)  |
| <i>drospirenone-ethinyl estradiol</i>                                                 | NCS    |                              |
| <b>DROXIA</b>                                                                         | T4     |                              |
| <b>DUAVEE</b>                                                                         | T3     |                              |
| <b>DUCODYL (BISACODYL)</b>                                                            | NCS    |                              |
| <b>DULERA INHALATION HFA AEROSOL INHALER 100-5 MCG/ACTUATION, 200-5 MCG/ACTUATION</b> | T3     | QL (13 GM per 30 days)       |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 40 mg, 60 mg</i>            | T3     | QL (60 EA per 30 days)       |
| <i>duloxetine oral capsule, delayed release(dr/ec) 30 mg</i>                          | T3     | QL (90 EA per 30 days)       |
| <b>DUPIXENT PEN</b>                                                                   | T5     | PA; QL (6 ML per 28 days)    |
| <b>DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML</b>                           | T5     | PA; QL (3.42 ML per 28 days) |
| <b>DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML</b>                              | T5     | PA                           |
| <b>DUREZOL</b>                                                                        | T4     |                              |
| <i>dutasteride</i>                                                                    | T3     | QL (30 EA per 30 days)       |
| <i>dutasteride-tamsulosin</i>                                                         | T3     | QL (30 EA per 30 days)       |
| <b>DYRENIUM</b>                                                                       | T4     |                              |
| <b>E.E.S. 400 ORAL TABLET</b>                                                         | T2     |                              |
| <b>E.E.S. GRANULES</b>                                                                | T4     |                              |
| <b>EASY TOUCH PEN NEEDLE</b>                                                          | T3     |                              |
| <i>econazole</i>                                                                      | T4     |                              |
| <b>ECONTRA EZ</b>                                                                     | NCS    |                              |
| <b>EDECIN</b>                                                                         | T5     | PA                           |
| <b>EDURANT</b>                                                                        | T5     | PA                           |
| <i>efavirenz</i>                                                                      | T4     |                              |
| <b>ELETONE</b>                                                                        | T4     |                              |
| <i>eletriptan</i>                                                                     | T4     | ST                           |
| <b>ELIGARD</b>                                                                        | T5     | PA; QL (1 EA per 28 days)    |
| <b>ELIGARD (3 MONTH)</b>                                                              | T5     | PA; QL (1 EA per 84 days)    |
| <b>ELIGARD (4 MONTH)</b>                                                              | T5     | PA; QL (1 EA per 112 days)   |
| <b>ELIGARD (6 MONTH)</b>                                                              | T5     | PA; QL (1 EA per 168 days)   |
| <b>ELINEST</b>                                                                        | NCS    |                              |
| <b>ELIQUIS</b>                                                                        | T3     |                              |
| <b>ELIQUIS DVT-PE TREAT 30D START</b>                                                 | T3     |                              |
| <b>ELLA</b>                                                                           | NCS    |                              |
| <b>ELMIRON</b>                                                                        | T4     |                              |
| <b>ELZONRIS</b>                                                                       | T5     | PA                           |
| <b>EMCYT</b>                                                                          | T5     | PA                           |
| <b>EMEND ORAL CAPSULE</b>                                                             | T4     | PA; QL (60 EA per 30 days)   |

| Drug                                                                      | Status | Notes                      |
|---------------------------------------------------------------------------|--------|----------------------------|
| <b>EMEND ORAL CAPSULE,DOSE PACK</b>                                       | T4     | PA; QL (60 EA per 30 days) |
| <b>EMOQUETTE</b>                                                          | NCS    |                            |
| <b>EMSAM</b>                                                              | T5     | PA; QL (30 EA per 30 days) |
| <b>EMTRIVA</b>                                                            | T3     | PA                         |
| <i>enalapril maleate</i>                                                  | T1     |                            |
| <i>enalapril-hydrochlorothiazide</i>                                      | T1     |                            |
| <b>ENBREL SUBCUTANEOUS RECON SOLN</b>                                     | T5     | PA; QL (8 EA per 28 days)  |
| <b>ENBREL SUBCUTANEOUS SOLUTION</b>                                       | T5     | PA; QL (4 ML per 28 days)  |
| <b>ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5)</b>                     | T5     | PA; QL (4 ML per 28 days)  |
| <b>ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML)</b>                        | T5     | PA; QL (8 ML per 28 days)  |
| <b>ENBREL SURECLICK</b>                                                   | T5     | PA; QL (8 ML per 28 days)  |
| <b>ENDARI</b>                                                             | T5     | PA                         |
| <b>ENDOCET ORAL TABLET 10-325 MG</b>                                      | T3     | QL (180 EA per 30 days)    |
| <b>ENDOCET ORAL TABLET 2.5-325 MG, 5-325 MG, 7.5-325 MG</b>               | T3     | QL (240 EA per 30 days)    |
| <b>ENGERIX-B (PF)</b>                                                     | NCS    |                            |
| <b>ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE</b>                     | NCS    |                            |
| <i>enoxaparin subcutaneous solution</i>                                   | T4     | QL (24 ML per 30 days)     |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 150 mg/ml</i>               | T4     | QL (28 ML per 30 days)     |
| <i>enoxaparin subcutaneous syringe 120 mg/0.8 ml, 80 mg/0.8 ml</i>        | T4     | QL (22.4 ML per 30 days)   |
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml</i>                       | T4     | QL (8.4 ML per 30 days)    |
| <i>enoxaparin subcutaneous syringe 40 mg/0.4 ml</i>                       | T4     | QL (11.2 ML per 30 days)   |
| <i>enoxaparin subcutaneous syringe 60 mg/0.6 ml</i>                       | T4     | QL (16.8 ML per 30 days)   |
| <b>ENPRESSE</b>                                                           | NCS    |                            |
| <b>ENSKYCE</b>                                                            | NCS    |                            |
| <i>entacapone</i>                                                         | T4     | QL (240 EA per 30 days)    |
| <i>entecavir</i>                                                          | T5     | PA; QL (30 EA per 30 days) |
| <b>ENTERIC COATED ASPIRIN</b>                                             | NCS    |                            |
| <b>ENTRESTO</b>                                                           | T4     | PA; QL (60 EA per 30 days) |
| <b>ENULOSE</b>                                                            | T2     |                            |
| <b>EPCLUSA ORAL TABLET 400-100 MG</b>                                     | T5     | PA                         |
| <b>EPICERAM</b>                                                           | T4     |                            |
| <b>EPIDIOLEX</b>                                                          | T5     | PA                         |
| <b>EPIDUO TOPICAL GEL WITH PUMP</b>                                       | T4     |                            |
| <b>EPIFOAM</b>                                                            | T4     |                            |
| <i>epinastine</i>                                                         | T3     |                            |
| <i>epinephrine injection auto-injector 0.15 mg/0.15 ml, 0.3 mg/0.3 ml</i> | T3     | QL (4 EA per 30 days)      |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml</i>                 | T3     |                            |
| <i>epinephrine injection solution 1 mg/ml</i>                             | T4     |                            |



| Drug                                                                    | Status | Notes                      |
|-------------------------------------------------------------------------|--------|----------------------------|
| <b>EPIPEN</b>                                                           | T3     | QL (4 EA per 30 days)      |
| <b>EPIPEN 2-PAK</b>                                                     | T3     | QL (4 EA per 30 days)      |
| <b>EPIPEN JR</b>                                                        | T3     | QL (4 EA per 30 days)      |
| <b>EPIPEN JR 2-PAK</b>                                                  | T3     | QL (4 EA per 30 days)      |
| <b>EPIVIR HBV ORAL SOLUTION</b>                                         | T4     | PA                         |
| <i>eplerenone</i>                                                       | T3     |                            |
| <b>EPZICOM</b>                                                          | T5     | PA                         |
| <i>ergocalciferol (vitamin d2) oral capsule 1,250 mcg (50,000 unit)</i> | NCS    | QL (4 EA per 28 days)      |
| <i>ergoloid</i>                                                         | T3     |                            |
| <b>ERGOMAR</b>                                                          | T4     |                            |
| <b>ERIVEDGE</b>                                                         | T5     | PA; QL (30 EA per 30 days) |
| <b>ERLEADA</b>                                                          | T5     | PA                         |
| <b>ERLOTINIB</b>                                                        | T5     | PA                         |
| <b>ERRIN</b>                                                            | NCS    |                            |
| <b>ERTACZO</b>                                                          | T5     | PA                         |
| <i>ertapenem</i>                                                        | T4     |                            |
| <b>ERY PADS</b>                                                         | T3     |                            |
| <b>ERY-TAB</b>                                                          | T3     |                            |
| <b>ERYTHROCIN (AS STEARATE) ORAL TABLET 250 MG</b>                      | T4     |                            |
| <i>erythromycin ethylsuccinate oral tablet</i>                          | T4     |                            |
| <i>erythromycin ophthalmic (eye)</i>                                    | T2     |                            |
| <i>erythromycin oral capsule, delayed release(dr/ec)</i>                | T4     |                            |
| <i>erythromycin oral tablet</i>                                         | T4     |                            |
| <i>erythromycin with ethanol</i>                                        | T2     |                            |
| <i>erythromycin-benzoyl peroxide</i>                                    | T4     |                            |
| <b>ESBRIET</b>                                                          | T5     | PA                         |
| <i>escitalopram oxalate oral solution</i>                               | T3     | QL (600 ML per 30 days)    |
| <i>escitalopram oxalate oral tablet</i>                                 | T2     | QL (30 EA per 30 days)     |
| <b>ESTARYLLA</b>                                                        | NCS    |                            |
| <i>estazolam</i>                                                        | T2     |                            |
| <i>estradiol oral</i>                                                   | T2     |                            |
| <i>estradiol transdermal patch semiweekly</i>                           | T4     | QL (8 EA per 28 days)      |
| <i>estradiol transdermal patch weekly</i>                               | T3     | QL (4 EA per 28 days)      |
| <i>estradiol vaginal tablet</i>                                         | T3     |                            |
| <i>estradiol-norethindrone acet</i>                                     | T2     |                            |
| <b>ESTROGEL</b>                                                         | T4     |                            |
| <i>estrogens-methyltestosterone</i>                                     | T3     |                            |
| <i>eszopiclone</i>                                                      | T2     | QL (30 EA per 30 days)     |
| <i>ethambutol</i>                                                       | T3     |                            |
| <i>ethosuximide</i>                                                     | T3     |                            |
| <i>etidronate disodium</i>                                              | T3     |                            |

| Drug                                                                                             | Status | Notes                       |
|--------------------------------------------------------------------------------------------------|--------|-----------------------------|
| <i>etodolac oral capsule</i>                                                                     | T3     |                             |
| <i>etodolac oral tablet</i>                                                                      | T3     |                             |
| <i>etodolac oral tablet extended release 24 hr</i>                                               | T4     |                             |
| <i>etonogestrel-ethinyl estradiol</i>                                                            | NCS    |                             |
| <b>EUCRISA</b>                                                                                   | T4     |                             |
| <b>EVENITY</b>                                                                                   | T5     | PA                          |
| <i>everolimus (antineoplastic)</i>                                                               | T5     | PA; QL (30 EA per 30 days)  |
| <i>everolimus (immunosuppressive)</i>                                                            | T5     | PA                          |
| <b>EVOTAZ</b>                                                                                    | T5     | PA                          |
| <i>exemestane</i>                                                                                | T4     |                             |
| <b>EXJADE</b>                                                                                    | T5     | PA                          |
| <i>ezetimibe</i>                                                                                 | T3     | QL (30 EA per 30 days)      |
| <b>FALMINA (28)</b>                                                                              | NCS    |                             |
| <i>famciclovir</i>                                                                               | T3     |                             |
| <i>famotidine oral suspension</i>                                                                | T3     |                             |
| <i>famotidine oral tablet</i>                                                                    | T2     |                             |
| <b>FANAPT ORAL TABLET</b>                                                                        | T4     | PA; QL (60 EA per 30 days)  |
| <b>FANAPT ORAL TABLETS,DOSE PACK</b>                                                             | T4     | PA; QL (8 EA per 28 days)   |
| <b>FARESTON</b>                                                                                  | T5     | QL (30 EA per 30 days)      |
| <b>FARYDAK</b>                                                                                   | T5     | PA                          |
| <b>FASENRA PEN</b>                                                                               | T5     | PA                          |
| <b>FC2 FEMALE CONDOM</b>                                                                         | NCS    |                             |
| <i>febuxostat</i>                                                                                | T3     | ST                          |
| <i>felbamate</i>                                                                                 | T5     |                             |
| <i>felodipine</i>                                                                                | T2     |                             |
| <b>FEMCAP</b>                                                                                    | NCS    |                             |
| <i>fenofibrate micronized oral capsule 134 mg, 200 mg, 67 mg</i>                                 | T2     |                             |
| <i>fenofibrate nanocrystallized oral tablet 145 mg, 48 mg</i>                                    | T2     |                             |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i>                                                     | T2     |                             |
| <i>fenofibric acid (choline) oral capsule, delayed release(dr/ec) 135 mg</i>                     | T3     |                             |
| <i>fenofibric acid (choline) oral capsule, delayed release(dr/ec) 45 mg</i>                      | T2     |                             |
| <i>fenoprofen oral tablet</i>                                                                    | T4     |                             |
| <i>fentanyl citrate buccal lozenge on a handle</i>                                               | T5     | PA; QL (120 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | T3     | QL (15 EA per 30 days)      |
| <b>FERRIPROX ORAL TABLET 500 MG</b>                                                              | T5     | PA                          |
| <b>FIASP FLEXTOUCH U-100 INSULIN</b>                                                             | T3     | QL (60 ML per 30 days)      |
| <b>FIASP U-100 INSULIN</b>                                                                       | T3     | QL (60 ML per 30 days)      |
| <b>FINACEA TOPICAL GEL</b>                                                                       | T4     |                             |
| <i>finasteride oral tablet 5 mg</i>                                                              | T2     |                             |
| <b>FINTEPLA</b>                                                                                  | T5     | PA                          |

| Drug                                                                                     | Status | Notes                       |
|------------------------------------------------------------------------------------------|--------|-----------------------------|
| <b>FIRDAPSE</b>                                                                          | T5     | PA; QL (240 EA per 30 days) |
| <b>FIRVANQ</b>                                                                           | T3     |                             |
| <i>flavoxate</i>                                                                         | T2     |                             |
| <i>flecainide</i>                                                                        | T2     |                             |
| <b>FLEET LAXATIVE (BISACODYL)</b>                                                        | NCS    |                             |
| <b>FLOVENT DISKUS INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 50 MCG/ACTUATION</b> | T3     | QL (60 EA per 30 days)      |
| <b>FLOVENT DISKUS INHALATION BLISTER WITH DEVICE 250 MCG/ACTUATION</b>                   | T3     | QL (240 EA per 30 days)     |
| <b>FLOVENT HFA INHALATION HFA AEROSOL INHALER 110 MCG/ACTUATION</b>                      | T3     | QL (12 GM per 30 days)      |
| <b>FLOVENT HFA INHALATION HFA AEROSOL INHALER 220 MCG/ACTUATION</b>                      | T3     | QL (24 GM per 30 days)      |
| <b>FLOVENT HFA INHALATION HFA AEROSOL INHALER 44 MCG/ACTUATION</b>                       | T3     | QL (10.6 GM per 30 days)    |
| <i>fluconazole oral tablet</i>                                                           | T2     |                             |
| <i>flucytosine</i>                                                                       | T5     |                             |
| <i>fludrocortisone</i>                                                                   | T2     |                             |
| <i>flunisolide nasal spray,non-aerosol 25 mcg (0.025 %)</i>                              | T3     | QL (50 ML per 30 days)      |
| <i>fluocinolone</i>                                                                      | T3     |                             |
| <i>fluocinolone acetonide oil</i>                                                        | T3     |                             |
| <i>fluocinolone and shower cap</i>                                                       | T3     |                             |
| <i>fluocinonide topical cream 0.05 %</i>                                                 | T3     |                             |
| <i>fluocinonide topical gel</i>                                                          | T3     |                             |
| <i>fluocinonide topical ointment</i>                                                     | T3     |                             |
| <i>fluocinonide topical solution</i>                                                     | T3     |                             |
| <b>FLUOCINONIDE-E</b>                                                                    | T3     |                             |
| <i>fluoride (sodium) oral drops</i>                                                      | NCS    |                             |
| <i>fluoride (sodium) oral tablet,chewable</i>                                            | NCS    |                             |
| <b>FLUORITAB ORAL TABLET,CHEWABLE</b>                                                    | NCS    |                             |
| <i>fluorometholone</i>                                                                   | T2     |                             |
| <i>fluorouracil intravenous</i>                                                          | T3     |                             |
| <i>fluorouracil topical cream 5 %</i>                                                    | T3     |                             |
| <i>fluorouracil topical solution</i>                                                     | T3     |                             |
| <i>fluoxetine oral capsule 10 mg, 20 mg</i>                                              | T2     | QL (90 EA per 30 days)      |
| <i>fluoxetine oral capsule 40 mg</i>                                                     | T2     | QL (60 EA per 30 days)      |
| <i>fluoxetine oral solution</i>                                                          | T2     | QL (600 ML per 30 days)     |
| <i>fluoxetine oral tablet 10 mg</i>                                                      | T3     | QL (240 EA per 30 days)     |
| <i>fluoxetine oral tablet 20 mg</i>                                                      | T3     | QL (120 EA per 30 days)     |
| <i>fluphenazine hcl oral concentrate</i>                                                 | T3     |                             |
| <i>fluphenazine hcl oral elixir</i>                                                      | T3     |                             |
| <i>fluphenazine hcl oral tablet</i>                                                      | T2     |                             |
| <i>flurazepam</i>                                                                        | T2     |                             |

| Drug                                                                 | Status | Notes                       |
|----------------------------------------------------------------------|--------|-----------------------------|
| <i>flurbiprofen</i>                                                  | T2     |                             |
| <i>flurbiprofen sodium</i>                                           | T2     |                             |
| <i>flutamide</i>                                                     | T3     |                             |
| <i>fluticasone propionate nasal</i>                                  | T2     | QL (16 GM per 30 days)      |
| <i>fluticasone propionate topical cream</i>                          | T2     |                             |
| <i>fluticasone propionate topical lotion</i>                         | T3     |                             |
| <i>fluticasone propionate topical ointment</i>                       | T2     |                             |
| <i>fluticasone propion-salmeterol inhalation blister with device</i> | T3     | QL (60 EA per 30 days)      |
| <i>fluvastatin oral capsule</i>                                      | T3     |                             |
| <i>fluvoxamine oral tablet</i>                                       | T2     | QL (90 EA per 30 days)      |
| <b>FML S.O.P.</b>                                                    | T4     |                             |
| <b>FOCALIN XR ORAL CAPSULE,ER BIPHASIC 50-50 25 MG, 35 MG</b>        | T4     | QL (30 EA per 30 days)      |
| <i>folic acid oral tablet</i>                                        | NCS    |                             |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml</i>                | T5     | PA; QL (24 ML per 30 days)  |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i>               | T5     | PA; QL (15 ML per 30 days)  |
| <i>fondaparinux subcutaneous syringe 5 mg/0.4 ml</i>                 | T5     | PA; QL (12 ML per 30 days)  |
| <i>fondaparinux subcutaneous syringe 7.5 mg/0.6 ml</i>               | T5     | PA; QL (18 ML per 30 days)  |
| <b>FORTEO</b>                                                        | T5     | PA; QL (2.4 ML per 28 days) |
| <i>fosamprenavir</i>                                                 | T5     | PA                          |
| <i>fosinopril</i>                                                    | T2     |                             |
| <i>fosinopril-hydrochlorothiazide</i>                                | T2     |                             |
| <b>FOSRENOL ORAL TABLET,CHEWABLE</b>                                 | T3     | ST                          |
| <b>FREESTYLE FREEDOM LITE</b>                                        | T3     |                             |
| <b>FREESTYLE INSULINX</b>                                            | T3     |                             |
| <b>FREESTYLE INSULINX TEST STRIPS</b>                                | T3     | QL (200 EA per 30 days)     |
| <b>FREESTYLE LANCETS</b>                                             | T3     | QL (200 EA per 30 days)     |
| <b>FREESTYLE LIBRE 10 DAY READER</b>                                 | T4     | QL (1 EA per 365 days)      |
| <b>FREESTYLE LIBRE 10 DAY SENSOR</b>                                 | T4     | QL (3 EA per 30 days)       |
| <b>FREESTYLE LIBRE 14 DAY READER</b>                                 | T4     | QL (1 EA per 365 days)      |
| <b>FREESTYLE LIBRE 14 DAY SENSOR</b>                                 | T4     | QL (2 EA per 28 days)       |
| <b>FREESTYLE LITE METER</b>                                          | T3     |                             |
| <b>FREESTYLE LITE STRIPS</b>                                         | T3     | QL (200 EA per 30 days)     |
| <b>FREESTYLE TEST</b>                                                | T3     | QL (200 EA per 30 days)     |
| <i>frovatriptan</i>                                                  | T4     | ST; QL (18 EA per 30 days)  |
| <i>furosemide oral solution 10 mg/ml</i>                             | T2     |                             |
| <i>furosemide oral solution 40 mg/4 ml, 40 mg/5 ml (8 mg/ml)</i>     | T1     |                             |
| <i>furosemide oral tablet</i>                                        | T1     |                             |
| <b>FUZEON SUBCUTANEOUS RECON SOLN</b>                                | T5     | PA                          |
| <b>FYCOMPA ORAL SUSPENSION</b>                                       | T4     | PA                          |
| <b>FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG, 8 MG</b>            | T4     | PA; QL (30 EA per 30 days)  |

| Drug                                                   | Status | Notes                      |
|--------------------------------------------------------|--------|----------------------------|
| <b>FYCOMPA ORAL TABLET 2 MG</b>                        | T4     | PA; QL (60 EA per 30 days) |
| <i>gabapentin oral capsule</i>                         | T2     | QL (270 EA per 30 days)    |
| <i>gabapentin oral solution</i>                        | T2     | QL (2160 ML per 30 days)   |
| <i>gabapentin oral tablet 600 mg</i>                   | T2     | QL (180 EA per 30 days)    |
| <i>gabapentin oral tablet 800 mg</i>                   | T2     | QL (120 EA per 30 days)    |
| <b>GABITRIL ORAL TABLET 12 MG, 16 MG</b>               | T5     |                            |
| <i>galantamine oral capsule,ext rel. pellets 24 hr</i> | T3     | QL (30 EA per 30 days)     |
| <i>galantamine oral solution</i>                       | T4     | QL (600 ML per 30 days)    |
| <i>galantamine oral tablet</i>                         | T3     | QL (60 EA per 30 days)     |
| <b>GAMMAGARD LIQUID</b>                                | T5     | PA                         |
| <b>GARDASIL 9 (PF)</b>                                 | NCS    |                            |
| <i>gatifloxacin</i>                                    | T3     |                            |
| <b>GAVILAX ORAL POWDER</b>                             | NCS    |                            |
| <b>GAVILYTE-C</b>                                      | NCS    |                            |
| <b>GAVILYTE-G</b>                                      | NCS    |                            |
| <b>GAVILYTE-N</b>                                      | NCS    |                            |
| <i>gemfibrozil</i>                                     | T2     |                            |
| <b>GENERESS FE</b>                                     | T4     |                            |
| <b>GENERLAC</b>                                        | T2     |                            |
| <b>GENGRAF ORAL CAPSULE 100 MG, 25 MG</b>              | T3     |                            |
| <b>GENGRAF ORAL SOLUTION</b>                           | T3     |                            |
| <b>GENTAK OPHTHALMIC (EYE) OINTMENT</b>                | T2     |                            |
| <i>gentamicin ophthalmic (eye)</i>                     | T2     |                            |
| <i>gentamicin topical</i>                              | T2     |                            |
| <b>GENTLE LAXATIVE (BISACODYL) ORAL</b>                | NCS    |                            |
| <b>GENTLELAX</b>                                       | NCS    |                            |
| <b>GENVOYA</b>                                         | T5     | PA                         |
| <b>GIANVI (28)</b>                                     | NCS    |                            |
| <b>GILENYA ORAL CAPSULE 0.5 MG</b>                     | T5     | PA; QL (30 EA per 30 days) |
| <b>GILOTRIF</b>                                        | T5     | PA; QL (30 EA per 30 days) |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i>        | T5     | QL (28 ML per 28 days)     |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i>        | T5     | QL (12 ML per 28 days)     |
| <b>GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML</b>           | T5     | QL (28 ML per 28 days)     |
| <b>GLATOPA SUBCUTANEOUS SYRINGE 40 MG/ML</b>           | T5     | QL (12 ML per 28 days)     |
| <b>GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG</b>     | T5     | PA                         |
| <i>glimepiride oral tablet 1 mg</i>                    | T1     | QL (240 EA per 30 days)    |
| <i>glimepiride oral tablet 2 mg</i>                    | T1     | QL (120 EA per 30 days)    |
| <i>glimepiride oral tablet 4 mg</i>                    | T1     | QL (60 EA per 30 days)     |
| <i>glipizide oral tablet 10 mg</i>                     | T1     | QL (120 EA per 30 days)    |
| <i>glipizide oral tablet 5 mg</i>                      | T1     | QL (240 EA per 30 days)    |
| <i>glipizide oral tablet extended release 24hr</i>     | T1     | QL (60 EA per 30 days)     |
| <i>glipizide-metformin oral tablet 2.5-250 mg</i>      | T2     | QL (240 EA per 30 days)    |

| Drug                                                                                      | Status | Notes                      |
|-------------------------------------------------------------------------------------------|--------|----------------------------|
| <i>glipizide-metformin oral tablet 2.5-500 mg, 5-500 mg</i>                               | T2     | QL (120 EA per 30 days)    |
| <b>GLUCAGEN DIAGNOSTIC KIT</b>                                                            | T3     | QL (4 EA per 30 days)      |
| <b>GLUCAGEN HYPOKIT</b>                                                                   | T3     | QL (4 EA per 30 days)      |
| <b>GLUCAGON EMERGENCY KIT (HUMAN)</b>                                                     | T3     |                            |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg</i>                                      | T2     | QL (120 EA per 30 days)    |
| <i>glyburide micronized oral tablet 6 mg</i>                                              | T2     | QL (60 EA per 30 days)     |
| <i>glyburide oral tablet 1.25 mg</i>                                                      | T2     | QL (480 EA per 30 days)    |
| <i>glyburide oral tablet 2.5 mg</i>                                                       | T2     | QL (240 EA per 30 days)    |
| <i>glyburide oral tablet 5 mg</i>                                                         | T2     | QL (60 EA per 30 days)     |
| <i>glyburide-metformin oral tablet 1.25-250 mg</i>                                        | T2     | QL (240 EA per 30 days)    |
| <i>glyburide-metformin oral tablet 2.5-500 mg, 5-500 mg</i>                               | T2     | QL (120 EA per 30 days)    |
| <b>GLYCOLAX ORAL POWDER</b>                                                               | NCS    |                            |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i>                                              | T2     |                            |
| <b>GLYXAMBI</b>                                                                           | T3     |                            |
| <i>granisetron hcl oral</i>                                                               | T3     |                            |
| <b>GRASTEK</b>                                                                            | T3     |                            |
| <i>griseofulvin microsize oral suspension</i>                                             | T2     |                            |
| <i>guanfacine oral tablet</i>                                                             | T2     |                            |
| <i>guanfacine oral tablet extended release 24 hr</i>                                      | T3     | QL (30 EA per 30 days)     |
| <i>guanidine</i>                                                                          | T2     |                            |
| <b>GYNAZOLE-1</b>                                                                         | T4     |                            |
| <b>GYNOL II</b>                                                                           | NCS    |                            |
| <i>halobetasol propionate topical cream</i>                                               | T4     |                            |
| <i>halobetasol propionate topical ointment</i>                                            | T4     |                            |
| <b>HALOG TOPICAL OINTMENT</b>                                                             | T4     |                            |
| <i>haloperidol</i>                                                                        | T2     |                            |
| <i>haloperidol decanoate</i>                                                              | T2     |                            |
| <i>haloperidol lactate injection</i>                                                      | T2     |                            |
| <i>haloperidol lactate oral</i>                                                           | T2     |                            |
| <b>HARVONI ORAL TABLET 90-400 MG</b>                                                      | T5     | PA                         |
| <b>HAVRIX (PF) INTRAMUSCULAR SUSPENSION 1,440 ELISA UNIT/ML</b>                           | NCS    |                            |
| <b>HAVRIX (PF) INTRAMUSCULAR SYRINGE</b>                                                  | NCS    |                            |
| <b>HEALTHYLAX</b>                                                                         | NCS    |                            |
| <b>HEATHER</b>                                                                            | NCS    |                            |
| <i>heparin (porcine) injection solution 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml</i> | T2     |                            |
| <i>heparin, porcine (pf) injection solution 1,000 unit/ml</i>                             | T2     |                            |
| <i>heparin, porcine (pf) injection syringe 5,000 unit/0.5 ml</i>                          | T2     |                            |
| <b>HERCEPTIN HYLECTA</b>                                                                  | T5     | PA                         |
| <b>HOMATROPAIRE</b>                                                                       | T3     |                            |
| <i>homatropine hbr</i>                                                                    | T3     |                            |
| <b>HORIZANT</b>                                                                           | T4     | PA; QL (60 EA per 30 days) |

| Drug                                                                                                | Status | Notes                      |
|-----------------------------------------------------------------------------------------------------|--------|----------------------------|
| HPR                                                                                                 | T4     |                            |
| HPR PLUS                                                                                            | T4     |                            |
| HUMIRA PEDIATRIC CROHNS START                                                                       | T5     | PA; QL (3 EA per 180 days) |
| HUMIRA PEN                                                                                          | T5     | PA; QL (4 EA per 28 days)  |
| HUMIRA PEN CROHNS-UC-HS START                                                                       | T5     | PA; QL (6 EA per 180 days) |
| HUMIRA PEN PSOR-UEVITS-ADOL HS                                                                      | T5     | PA; QL (4 EA per 180 days) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML                                          | T5     | PA; QL (2 EA per 28 days)  |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML                                                        | T5     | PA; QL (4 EA per 28 days)  |
| HUMIRA(CF) PEDI CROHNS STARTER                                                                      | T5     | PA; QL (3 EA per 180 days) |
| HUMIRA(CF) PEN CROHNS-UC-HS                                                                         | T5     | PA                         |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS                                                                      | T5     | PA                         |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML                                           | T5     | PA; QL (4 EA per 28 days)  |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML                                           | T5     | PA                         |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML                                      | T5     | PA; QL (2 EA per 28 days)  |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML                                                    | T5     | PA; QL (4 EA per 28 days)  |
| HUMULIN R U-500 (CONC) INSULIN                                                                      | T5     | QL (20 ML per 30 days)     |
| HYCANTIN                                                                                            | T5     | PA                         |
| <i>hydralazine oral</i>                                                                             | T2     |                            |
| <i>hydrochlorothiazide</i>                                                                          | T1     |                            |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i>                                     | T4     | QL (2700 ML per 30 days)   |
| <i>hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg</i>                                   | T3     | QL (180 EA per 30 days)    |
| <i>hydrocodone-acetaminophen oral tablet 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg</i> | T3     | QL (240 EA per 30 days)    |
| <i>hydrocodone-acetaminophen oral tablet 7.5-325 mg</i>                                             | T3     | QL (84 EA per 30 days)     |
| <i>hydrocodone-homatropine oral syrup 5-1.5 mg/5 ml (5 ml)</i>                                      | T2     |                            |
| <i>hydrocodone-homatropine oral tablet</i>                                                          | T2     |                            |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg</i>                            | T3     | QL (50 EA per 30 days)     |
| <i>hydrocortisone acetate rectal</i>                                                                | T3     |                            |
| <i>hydrocortisone acetate topical cream 1 %</i>                                                     | T2     |                            |
| <i>hydrocortisone butyrate topical cream</i>                                                        | T2     |                            |
| <i>hydrocortisone butyrate topical ointment</i>                                                     | T4     |                            |
| <i>hydrocortisone butyrate topical solution</i>                                                     | T4     |                            |
| <i>hydrocortisone butyr-emollient</i>                                                               | T4     |                            |
| <i>hydrocortisone oral</i>                                                                          | T2     |                            |
| <i>hydrocortisone rectal</i>                                                                        | T4     |                            |
| <i>hydrocortisone topical cream</i>                                                                 | T2     |                            |



| Drug                                                         | Status | Notes                       |
|--------------------------------------------------------------|--------|-----------------------------|
| <i>hydrocortisone topical cream with perineal applicator</i> | T2     |                             |
| <i>hydrocortisone topical lotion 1 %</i>                     | T1     |                             |
| <i>hydrocortisone topical lotion 2.5 %</i>                   | T3     |                             |
| <i>hydrocortisone topical ointment</i>                       | T2     |                             |
| <i>hydrocortisone valerate topical cream</i>                 | T4     |                             |
| <i>hydrocortisone valerate topical ointment</i>              | T2     |                             |
| <i>hydrocortisone-acetic acid</i>                            | T3     |                             |
| <i>hydrocortisone-iodoquinol</i>                             | T3     |                             |
| <i>hydrocortisone-pramoxine rectal cream 1-1 %, 2.5-1 %</i>  | T3     |                             |
| <b>HYDROMET</b>                                              | T2     |                             |
| <i>hydromorphone oral tablet</i>                             | T3     | QL (180 EA per 30 days)     |
| <i>hydroxychloroquine</i>                                    | T3     |                             |
| <i>hydroxyurea</i>                                           | T2     |                             |
| <i>hydroxyzine hcl intramuscular</i>                         | T2     |                             |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i>              | T2     |                             |
| <i>hydroxyzine hcl oral tablet</i>                           | T2     |                             |
| <i>hydroxyzine pamoate</i>                                   | T2     |                             |
| <b>HYLATOPIC</b>                                             | T4     |                             |
| <b>HYLATOPICPLUS TOPICAL CREAM</b>                           | T4     |                             |
| <b>HYLATOPICPLUS TOPICAL FOAM</b>                            | T4     |                             |
| <i>hyoscyamine sulfate oral</i>                              | T2     |                             |
| <i>hyoscyamine sulfate sublingual</i>                        | T2     |                             |
| <b>HYOSYNE ORAL DROPS</b>                                    | T2     |                             |
| <i>ibandronate oral</i>                                      | T2     | QL (1 EA per 28 days)       |
| <b>IBRANCE</b>                                               | T5     | PA; QL (21 EA per 28 days)  |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i>          | T1     |                             |
| <i>ibuprofen-oxycodone</i>                                   | T3     | QL (28 EA per 30 days)      |
| <b>ICATIBANT</b>                                             | T5     | PA                          |
| <b>ICLUSIG ORAL TABLET 15 MG</b>                             | T5     | PA; QL (60 EA per 30 days)  |
| <b>ICLUSIG ORAL TABLET 45 MG</b>                             | T5     | PA; QL (30 EA per 30 days)  |
| <b>IDAMYCIN PFS</b>                                          | T5     | PA                          |
| <b>IDHIFA</b>                                                | T5     | PA                          |
| <b>ILEVRO</b>                                                | T3     |                             |
| <i>imatinib oral tablet 100 mg</i>                           | T5     | PA; QL (180 EA per 30 days) |
| <i>imatinib oral tablet 400 mg</i>                           | T5     | PA; QL (60 EA per 30 days)  |
| <b>IMBRUVICA ORAL CAPSULE 140 MG</b>                         | T5     | PA; QL (120 EA per 30 days) |
| <b>IMBRUVICA ORAL CAPSULE 70 MG</b>                          | T5     | PA; QL (30 EA per 30 days)  |
| <b>IMBRUVICA ORAL TABLET</b>                                 | T5     | PA; QL (30 EA per 30 days)  |
| <i>imipramine hcl</i>                                        | T2     |                             |
| <i>imipramine pamoate</i>                                    | T4     |                             |
| <i>imiquimod topical cream in packet</i>                     | T4     | QL (20 EA per 28 days)      |
| <b>IMOVAX RABIES VACCINE (PF)</b>                            | NCS    |                             |



| Drug                                                                                               | Status | Notes                       |
|----------------------------------------------------------------------------------------------------|--------|-----------------------------|
| <b>INBRIJA</b>                                                                                     | T5     | PA; QL (60 EA per 30 days)  |
| <b>INCRELEX</b>                                                                                    | T5     | PA                          |
| <i>indapamide</i>                                                                                  | T2     |                             |
| <i>indomethacin oral capsule</i>                                                                   | T2     |                             |
| <b>INFANRIX (DTAP) (PF)</b>                                                                        | NCS    |                             |
| <b>INFLECTRA</b>                                                                                   | T5     |                             |
| <b>INLYTA</b>                                                                                      | T5     | PA                          |
| <b>INREBIC</b>                                                                                     | T5     | PA; QL (120 EA per 30 days) |
| <i>insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28 gauge</i> | T3     | QL (200 EA per 30 days)     |
| <b>INTELENCE ORAL TABLET 100 MG</b>                                                                | T5     | PA; QL (120 EA per 30 days) |
| <b>INTELENCE ORAL TABLET 200 MG</b>                                                                | T5     | PA; QL (60 EA per 30 days)  |
| <b>INTELENCE ORAL TABLET 25 MG</b>                                                                 | T4     | PA                          |
| <b>INTRON A INJECTION</b>                                                                          | T5     | PA                          |
| <b>INTROVALE</b>                                                                                   | NCS    |                             |
| <b>INVEGA SUSTENNA</b>                                                                             | T4     | PA                          |
| <b>INVIRASE ORAL TABLET</b>                                                                        | T5     | PA                          |
| <b>IPOL</b>                                                                                        | NCS    |                             |
| <i>ipratropium bromide inhalation</i>                                                              | T2     |                             |
| <i>ipratropium bromide nasal</i>                                                                   | T2     | QL (30 ML per 30 days)      |
| <i>ipratropium-albuterol</i>                                                                       | T2     |                             |
| <i>irbesartan</i>                                                                                  | T1     |                             |
| <i>irbesartan-hydrochlorothiazide</i>                                                              | T1     |                             |
| <b>IRESSA</b>                                                                                      | T5     | PA; QL (60 EA per 30 days)  |
| <b>ISENTRESS HD</b>                                                                                | T5     | PA                          |
| <b>ISENTRESS ORAL POWDER IN PACKET</b>                                                             | T5     | PA; QL (180 EA per 30 days) |
| <b>ISENTRESS ORAL TABLET</b>                                                                       | T5     | PA; QL (60 EA per 30 days)  |
| <b>ISENTRESS ORAL TABLET,CHEWABLE</b>                                                              | T5     | PA; QL (180 EA per 30 days) |
| <b>ISOLYTE S PH 7.4</b>                                                                            | T2     |                             |
| <i>isoniazid oral</i>                                                                              | T2     |                             |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i>                                  | T3     |                             |
| <i>isosorbide dinitrate oral tablet extended release</i>                                           | T3     |                             |
| <i>isosorbide mononitrate</i>                                                                      | T2     |                             |
| <i>isotretinoin</i>                                                                                | T4     |                             |
| <i>isradipine</i>                                                                                  | T3     |                             |
| <b>ISTALOL</b>                                                                                     | T4     |                             |
| <b>ISTURISA ORAL TABLET 1 MG</b>                                                                   | T5     | PA; QL (120 EA per 30 days) |
| <b>ISTURISA ORAL TABLET 10 MG</b>                                                                  | T5     | PA; QL (180 EA per 30 days) |
| <b>ISTURISA ORAL TABLET 5 MG</b>                                                                   | T5     | PA; QL (90 EA per 30 days)  |
| <i>itraconazole oral capsule</i>                                                                   | T4     | PA; QL (120 EA per 30 days) |
| <i>ivermectin oral</i>                                                                             | T2     |                             |
| <b>IXIARO (PF)</b>                                                                                 | NCS    |                             |

| Drug                                                                                                     | Status | Notes                      |
|----------------------------------------------------------------------------------------------------------|--------|----------------------------|
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG                                                             | T5     | PA                         |
| JAKAFI ORAL TABLET 25 MG                                                                                 | T5     | PA; QL (60 EA per 30 days) |
| JANTOVEN                                                                                                 | T1     |                            |
| JARDIANCE                                                                                                | T3     | QL (30 EA per 30 days)     |
| JENCYCLA                                                                                                 | NCS    |                            |
| JENTADUETO                                                                                               | T3     | QL (60 EA per 30 days)     |
| JINTELI                                                                                                  | T3     |                            |
| JOLESSA                                                                                                  | NCS    |                            |
| JULEBER                                                                                                  | NCS    |                            |
| JULUCA                                                                                                   | T5     | QL (30 EA per 30 days)     |
| JUNEL 1.5/30 (21)                                                                                        | NCS    |                            |
| JUNEL 1/20 (21)                                                                                          | NCS    |                            |
| JUNEL FE 1.5/30 (28)                                                                                     | NCS    |                            |
| JUNEL FE 1/20 (28)                                                                                       | NCS    |                            |
| JUNEL FE 24                                                                                              | NCS    |                            |
| JYNARQUE ORAL TABLETS, SEQUENTIAL 45 MG (AM)/ 15 MG (PM), 60 MG (AM)/ 30 MG (PM), 90 MG (AM)/ 30 MG (PM) | T5     | PA; QL (60 EA per 30 days) |
| KALETRA ORAL SOLUTION                                                                                    | T4     | PA                         |
| KALETRA ORAL TABLET 100-25 MG                                                                            | T4     | PA                         |
| KALETRA ORAL TABLET 200-50 MG                                                                            | T5     | PA                         |
| KALYDECO ORAL GRANULES IN PACKET 50 MG, 75 MG                                                            | T5     | PA; QL (56 EA per 28 days) |
| KALYDECO ORAL TABLET                                                                                     | T5     | PA; QL (60 EA per 30 days) |
| KARIVA (28)                                                                                              | NCS    |                            |
| KELNOR 1/35 (28)                                                                                         | NCS    |                            |
| KEPIVANCE                                                                                                | T5     |                            |
| KESIMPTA PEN                                                                                             | T5     | PA                         |
| <i>ketoconazole oral</i>                                                                                 | T2     |                            |
| <i>ketoconazole topical cream</i>                                                                        | T2     |                            |
| <i>ketoconazole topical shampoo</i>                                                                      | T2     |                            |
| <i>ketoprofen oral capsule 50 mg, 75 mg</i>                                                              | T2     |                            |
| <i>ketorolac ophthalmic (eye)</i>                                                                        | T2     |                            |
| <i>ketorolac oral</i>                                                                                    | T2     |                            |
| KINRIX (PF)                                                                                              | NCS    |                            |
| KISQALI                                                                                                  | T5     | PA                         |
| KISQALI FEMARA CO-PACK                                                                                   | T5     | PA                         |
| KLOR-CON                                                                                                 | T2     |                            |
| KLOR-CON 10                                                                                              | T2     |                            |
| KLOR-CON 8                                                                                               | T2     |                            |
| KLOR-CON M10                                                                                             | T2     |                            |
| KLOR-CON M15                                                                                             | T2     |                            |
| KLOR-CON M20                                                                                             | T2     |                            |

| Drug                                                                                                                                | Status | Notes                       |
|-------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------|
| <b>KLOR-CON SPRINKLE ORAL CAPSULE, EXTENDED RELEASE 8 MEQ</b>                                                                       | T2     |                             |
| <b>KOSELUGO ORAL CAPSULE 10 MG</b>                                                                                                  | T5     | PA; QL (240 EA per 30 days) |
| <b>KOSELUGO ORAL CAPSULE 25 MG</b>                                                                                                  | T5     | PA; QL (120 EA per 30 days) |
| <b>KRINTAFEL</b>                                                                                                                    | T3     | QL (2 EA per 28 days)       |
| <b>KRISTALOSE</b>                                                                                                                   | T3     |                             |
| <b>KURVELO (28)</b>                                                                                                                 | NCS    |                             |
| <b>KUVAN ORAL TABLET,SOLUBLE</b>                                                                                                    | T5     | PA                          |
| <i>l norgest/e.estradiol-e.estrad oral tablets,dose pack,3 month 0.10 mg-20 mcg (84)/10 mcg (7), 0.15 mg-30 mcg (84)/10 mcg (7)</i> | NCS    |                             |
| <i>labetalol oral</i>                                                                                                               | T2     |                             |
| <i>lactulose oral solution</i>                                                                                                      | T2     |                             |
| <i>lamivudine oral solution</i>                                                                                                     | T3     | PA                          |
| <i>lamivudine oral tablet 100 mg</i>                                                                                                | T4     | PA                          |
| <i>lamivudine oral tablet 150 mg, 300 mg</i>                                                                                        | T3     | PA                          |
| <i>lamivudine-zidovudine</i>                                                                                                        | T4     |                             |
| <i>lamotrigine oral tablet</i>                                                                                                      | T2     |                             |
| <i>lamotrigine oral tablet disintegrating, dose pk</i>                                                                              | T3     |                             |
| <i>lamotrigine oral tablet, chewable dispersible</i>                                                                                | T2     |                             |
| <i>lamotrigine oral tablet,disintegrating</i>                                                                                       | T3     | QL (90 EA per 30 days)      |
| <i>lamotrigine oral tablets,dose pack</i>                                                                                           | T3     |                             |
| <i>lancets</i>                                                                                                                      | T3     | QL (200 EA per 30 days)     |
| <i>lansoprazole oral capsule,delayed release(dr/ec)</i>                                                                             | T2     | QL (30 EA per 30 days)      |
| <b>LANTUS SOLOSTAR U-100 INSULIN</b>                                                                                                | T3     | QL (60 ML per 30 days)      |
| <b>LANTUS U-100 INSULIN</b>                                                                                                         | T3     | QL (60 ML per 30 days)      |
| <b>LARIN 1.5/30 (21)</b>                                                                                                            | NCS    |                             |
| <b>LARIN 1/20 (21)</b>                                                                                                              | NCS    |                             |
| <b>LARIN 24 FE</b>                                                                                                                  | NCS    |                             |
| <b>LARIN FE 1.5/30 (28)</b>                                                                                                         | NCS    |                             |
| <b>LARIN FE 1/20 (28)</b>                                                                                                           | NCS    |                             |
| <b>LASTACRAFT</b>                                                                                                                   | T4     | QL (6 ML per 30 days)       |
| <i>latanoprost</i>                                                                                                                  | T1     |                             |
| <b>LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG</b>                                                                               | T4     | QL (30 EA per 30 days)      |
| <b>LATUDA ORAL TABLET 80 MG</b>                                                                                                     | T4     | QL (60 EA per 30 days)      |
| <b>LAXACLEAR</b>                                                                                                                    | NCS    |                             |
| <b>LAXATIVE (BISACODYL) ORAL</b>                                                                                                    | NCS    |                             |
| <b>LAXATIVE FEMININE</b>                                                                                                            | NCS    |                             |
| <b>LAXATIVE PEG 3350 ORAL POWDER</b>                                                                                                | NCS    |                             |
| <b>LAYOLIS FE</b>                                                                                                                   | NCS    |                             |
| <b>LEDIPASVIR-SOFOSBUVIR</b>                                                                                                        | T5     | PA; QL (28 EA per 28 days)  |
| <b>LEENA 28</b>                                                                                                                     | NCS    |                             |
| <i>leflunomide</i>                                                                                                                  | T3     | QL (30 EA per 30 days)      |

| Drug                                                                                                                     | Status | Notes                   |
|--------------------------------------------------------------------------------------------------------------------------|--------|-------------------------|
| <b>LENVIMA</b>                                                                                                           | T5     | PA                      |
| <b>LESSINA</b>                                                                                                           | NCS    |                         |
| <b>LETAIRIS</b>                                                                                                          | T5     | PA                      |
| <i>letrozole</i>                                                                                                         | T2     |                         |
| <i>leucovorin calcium oral</i>                                                                                           | T4     |                         |
| <b>LEUKERAN</b>                                                                                                          | T4     |                         |
| <b>LEUKINE INJECTION RECON SOLN</b>                                                                                      | T5     | PA                      |
| <i>leuprolide</i>                                                                                                        | T5     | PA                      |
| <i>levalbuterol hcl</i>                                                                                                  | T4     |                         |
| <b>LEVATOL</b>                                                                                                           | T4     |                         |
| <b>LEVEMIR FLEXTOUCH U-100 INSULN</b>                                                                                    | T3     | QL (60 ML per 30 days)  |
| <b>LEVEMIR U-100 INSULIN</b>                                                                                             | T3     | QL (60 ML per 30 days)  |
| <i>levetiracetam oral solution</i>                                                                                       | T2     |                         |
| <i>levetiracetam oral tablet</i>                                                                                         | T2     |                         |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg</i>                                                           | T2     | QL (180 EA per 30 days) |
| <i>levetiracetam oral tablet extended release 24 hr 750 mg</i>                                                           | T2     | QL (120 EA per 30 days) |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i>                                                                          | T2     |                         |
| <i>levocarnitine (with sugar)</i>                                                                                        | T3     |                         |
| <i>levocarnitine oral tablet</i>                                                                                         | T3     |                         |
| <i>levocetirizine oral solution</i>                                                                                      | T4     |                         |
| <i>levocetirizine oral tablet</i>                                                                                        | T2     | QL (30 EA per 30 days)  |
| <i>levofloxacin ophthalmic (eye)</i>                                                                                     | T2     |                         |
| <i>levofloxacin oral solution</i>                                                                                        | T4     |                         |
| <i>levofloxacin oral tablet</i>                                                                                          | T2     |                         |
| <b>LEVONEST (28)</b>                                                                                                     | NCS    |                         |
| <i>levonorgestrel-ethinyl estrad</i>                                                                                     | NCS    |                         |
| <i>levonorg-eth estrad triphasic</i>                                                                                     | NCS    |                         |
| <b>LEVORA-28</b>                                                                                                         | NCS    |                         |
| <i>levorphanol tartrate oral tablet 2 mg</i>                                                                             | T4     | QL (180 EA per 30 days) |
| <i>levothyroxine oral</i>                                                                                                | T2     |                         |
| <b>LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG</b> | T2     |                         |
| <b>LEXIVA ORAL SUSPENSION</b>                                                                                            | T4     | PA                      |
| <b>LEXIVA ORAL TABLET</b>                                                                                                | T5     | PA                      |
| <b>LIALDA</b>                                                                                                            | T3     | QL (120 EA per 30 days) |
| <i>lidocaine hcl laryngotracheal</i>                                                                                     | T2     |                         |
| <i>lidocaine hcl mucous membrane jelly</i>                                                                               | T2     |                         |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i>                                                             | T2     |                         |
| <i>lidocaine hcl topical cream 3 %</i>                                                                                   | T2     |                         |
| <i>lidocaine hcl topical lotion</i>                                                                                      | T2     |                         |

| Drug                                                                     | Status | Notes                       |
|--------------------------------------------------------------------------|--------|-----------------------------|
| <i>lidocaine hcl-hydrocortison ac rectal cream 3-0.5 %</i>               | T2     |                             |
| <i>lidocaine hcl-hydrocortison ac rectal kit 3-0.5 %, 3-1 % (7 gram)</i> | T4     | QL (4 EA per 30 days)       |
| <i>lidocaine topical adhesive patch,medicated 5 %</i>                    | T4     | PA; QL (90 EA per 30 days)  |
| <i>lidocaine topical ointment</i>                                        | T4     | PA; QL (150 GM per 30 days) |
| <b>LIDOCAINE VISCOUS</b>                                                 | T2     |                             |
| <i>lidocaine-hydrocortisone-aloe rectal gel</i>                          | T2     |                             |
| <i>lidocaine-hydrocortisone-aloe rectal kit 3-2.5 % (7 gram)</i>         | T4     | QL (4 EA per 30 days)       |
| <i>lidocaine-prilocaine</i>                                              | T2     |                             |
| <i>lindane topical shampoo</i>                                           | T3     |                             |
| <i>linezolid</i>                                                         | T5     | PA                          |
| <b>LINZESS ORAL CAPSULE 145 MCG, 290 MCG</b>                             | T3     |                             |
| <b>LINZESS ORAL CAPSULE 72 MCG</b>                                       | T3     | QL (30 EA per 30 days)      |
| <i>liothyronine oral</i>                                                 | T2     |                             |
| <i>lisinopril</i>                                                        | T1     |                             |
| <i>lisinopril-hydrochlorothiazide</i>                                    | T1     |                             |
| <b>LITE COAT ASPIRIN</b>                                                 | NCS    |                             |
| <i>lithium carbonate oral capsule</i>                                    | T1     |                             |
| <i>lithium carbonate oral tablet</i>                                     | T2     |                             |
| <i>lithium carbonate oral tablet extended release</i>                    | T2     |                             |
| <i>lithium citrate oral solution 8 meq/5 ml</i>                          | T2     |                             |
| <b>LO LOESTRIN FE</b>                                                    | T4     |                             |
| <b>LOCOID TOPICAL LOTION</b>                                             | T4     |                             |
| <b>LOKELMA</b>                                                           | T4     | PA                          |
| <b>LONSURF</b>                                                           | T5     | PA                          |
| <i>loperamide oral capsule</i>                                           | T2     |                             |
| <b>LOPREEZA</b>                                                          | T3     |                             |
| <i>lorazepam oral concentrate</i>                                        | T2     |                             |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i>                                | T2     | QL (180 EA per 30 days)     |
| <i>lorazepam oral tablet 2 mg</i>                                        | T2     | QL (150 EA per 30 days)     |
| <b>LORBRENA ORAL TABLET 100 MG</b>                                       | T5     | PA; QL (30 EA per 30 days)  |
| <b>LORBRENA ORAL TABLET 25 MG</b>                                        | T5     | PA; QL (90 EA per 30 days)  |
| <b>LORYNA (28)</b>                                                       | NCS    |                             |
| <i>losartan oral tablet 100 mg</i>                                       | T1     | QL (30 EA per 30 days)      |
| <i>losartan oral tablet 25 mg, 50 mg</i>                                 | T1     | QL (60 EA per 30 days)      |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg</i>   | T1     | QL (30 EA per 30 days)      |
| <i>losartan-hydrochlorothiazide oral tablet 50-12.5 mg</i>               | T1     | QL (60 EA per 30 days)      |
| <b>LOTEMAX</b>                                                           | T4     |                             |
| <i>loteprednol etabonate</i>                                             | T4     |                             |
| <i>lovastatin oral tablet 10 mg</i>                                      | T1     | QL (30 EA per 30 days)      |
| <i>lovastatin oral tablet 20 mg, 40 mg</i>                               | T1     | QL (60 EA per 30 days)      |

| Drug                                                                                                 | Status | Notes                      |
|------------------------------------------------------------------------------------------------------|--------|----------------------------|
| <b>LOW-OGESTREL (28)</b>                                                                             | NCS    |                            |
| <i>loxapine succinate</i>                                                                            | T2     |                            |
| <b>LUDENT FLUORIDE</b>                                                                               | NCS    |                            |
| <b>LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 %</b>                                                         | T3     | QL (5 ML per 30 days)      |
| <b>LUPRON DEPOT</b>                                                                                  | T5     | PA; QL (1 EA per 28 days)  |
| <b>LUPRON DEPOT (3 MONTH)</b>                                                                        | T5     | PA; QL (1 EA per 84 days)  |
| <b>LUPRON DEPOT (4 MONTH)</b>                                                                        | T5     | PA; QL (1 EA per 112 days) |
| <b>LUPRON DEPOT (6 MONTH)</b>                                                                        | T5     | PA; QL (1 EA per 168 days) |
| <b>LUPRON DEPOT-PED</b>                                                                              | T5     | PA; QL (1 EA per 28 days)  |
| <b>LUPRON DEPOT-PED (3 MONTH)</b>                                                                    | T5     | PA; QL (1 EA per 84 days)  |
| <b>LUTERA (28)</b>                                                                                   | NCS    |                            |
| <b>LYNPARZA ORAL TABLET</b>                                                                          | T5     | PA                         |
| <b>LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG</b>                               | T4     | QL (90 EA per 30 days)     |
| <b>LYRICA ORAL CAPSULE 225 MG, 300 MG</b>                                                            | T4     | QL (60 EA per 30 days)     |
| <b>LYSODREN</b>                                                                                      | T3     |                            |
| <b>LYZA</b>                                                                                          | NCS    |                            |
| <i>magnesium citrate oral solution</i>                                                               | NCS    |                            |
| <b>MAKENA (PF)</b>                                                                                   | T5     | PA                         |
| <b>MAKENA INTRAMUSCULAR OIL 250 MG/ML (1 ML)</b>                                                     | T5     | PA                         |
| <i>malathion</i>                                                                                     | T3     |                            |
| <i>maprotiline</i>                                                                                   | T3     |                            |
| <b>MARLISSA (28)</b>                                                                                 | NCS    |                            |
| <b>MARPLAN</b>                                                                                       | T4     |                            |
| <b>MATULANE</b>                                                                                      | T5     |                            |
| <b>MATZIM LA</b>                                                                                     | T3     |                            |
| <b>MAVENCLAD (10 TABLET PACK)</b>                                                                    | T5     | PA                         |
| <b>MAVENCLAD (4 TABLET PACK)</b>                                                                     | T5     | PA                         |
| <b>MAVENCLAD (5 TABLET PACK)</b>                                                                     | T5     | PA                         |
| <b>MAVENCLAD (6 TABLET PACK)</b>                                                                     | T5     | PA                         |
| <b>MAVENCLAD (7 TABLET PACK)</b>                                                                     | T5     | PA                         |
| <b>MAVENCLAD (8 TABLET PACK)</b>                                                                     | T5     | PA                         |
| <b>MAVENCLAD (9 TABLET PACK)</b>                                                                     | T5     | PA                         |
| <b>MAVYRET</b>                                                                                       | T5     | PA                         |
| <i>meclizine oral tablet 12.5 mg, 25 mg</i>                                                          | T2     |                            |
| <i>meclofenamate</i>                                                                                 | T4     |                            |
| <i>medroxyprogesterone intramuscular</i>                                                             | NCS    |                            |
| <i>medroxyprogesterone oral</i>                                                                      | T2     |                            |
| <i>mefenamic acid</i>                                                                                | T4     |                            |
| <i>mefloquine</i>                                                                                    | T2     |                            |
| <i>megestrol oral suspension 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 800 mg/20 ml (20 ml)</i> | T2     |                            |
| <i>megestrol oral suspension 625 mg/5 ml (125 mg/ml)</i>                                             | T4     |                            |

| Drug                                                       | Status | Notes                       |
|------------------------------------------------------------|--------|-----------------------------|
| <i>megestrol oral tablet</i>                               | T2     |                             |
| <b>MEKINIST ORAL TABLET 0.5 MG</b>                         | T5     | PA; QL (90 EA per 30 days)  |
| <b>MEKINIST ORAL TABLET 2 MG</b>                           | T5     | PA; QL (30 EA per 30 days)  |
| <b>MEKTOVI</b>                                             | T5     | PA; QL (180 EA per 30 days) |
| <i>meloxicam</i>                                           | T2     |                             |
| <i>melphalan hcl</i>                                       | T5     |                             |
| <i>memantine oral capsule,sprinkle,er 24hr</i>             | T3     | QL (30 EA per 30 days)      |
| <i>memantine oral solution</i>                             | T4     | QL (300 ML per 30 days)     |
| <i>memantine oral tablet</i>                               | T2     | QL (60 EA per 30 days)      |
| <i>memantine oral tablets,dose pack</i>                    | T2     |                             |
| <b>MENACTRA (PF) INTRAMUSCULAR SOLUTION</b>                | NCS    |                             |
| <b>MENEST</b>                                              | T4     | PA                          |
| <b>MENTAX</b>                                              | T3     |                             |
| <b>MENVEO A-C-Y-W-135-DIP (PF)</b>                         | NCS    |                             |
| <b>MENVEO MENA COMPONENT (PF)</b>                          | NCS    |                             |
| <b>MENVEO MENCYW-135 COMPNT (PF)</b>                       | NCS    |                             |
| <i>meperidine oral tablet</i>                              | T3     | QL (180 EA per 30 days)     |
| <i>meprobamate</i>                                         | T3     |                             |
| <i>mercaptopurine</i>                                      | T3     |                             |
| <i>mesalamine oral capsule,extended release 24hr</i>       | T3     | QL (120 EA per 30 days)     |
| <i>mesalamine rectal enema</i>                             | T4     |                             |
| <i>mesalamine with cleansing wipe</i>                      | T4     |                             |
| <i>metaproterenol oral syrup</i>                           | T2     |                             |
| <i>metaxalone oral tablet 800 mg</i>                       | T4     | QL (120 EA per 30 days)     |
| <i>metformin oral tablet 1,000 mg</i>                      | T1     | QL (60 EA per 30 days)      |
| <i>metformin oral tablet 500 mg</i>                        | T1     | QL (150 EA per 30 days)     |
| <i>metformin oral tablet 850 mg</i>                        | T1     | QL (90 EA per 30 days)      |
| <i>metformin oral tablet extended release 24 hr 500 mg</i> | T1     | QL (120 EA per 30 days)     |
| <i>metformin oral tablet extended release 24 hr 750 mg</i> | T1     | QL (60 EA per 30 days)      |
| <i>methadone oral tablet</i>                               | T3     | QL (240 EA per 30 days)     |
| <i>methamphetamine</i>                                     | T3     | QL (90 EA per 30 days)      |
| <i>methazolamide</i>                                       | T4     |                             |
| <i>methenamine hippurate</i>                               | T2     |                             |
| <i>methimazole oral tablet 10 mg, 5 mg</i>                 | T1     |                             |
| <i>methocarbamol oral</i>                                  | T2     |                             |
| <i>methotrexate sodium</i>                                 | T2     |                             |
| <i>methotrexate sodium (pf)</i>                            | T2     |                             |
| <i>methoxsalen</i>                                         | T5     |                             |
| <i>methscopolamine</i>                                     | T2     |                             |
| <i>methyclothiazide</i>                                    | T3     |                             |
| <i>methyl dopa</i>                                         | T2     |                             |
| <i>methyl dopa-hydrochlorothiazide</i>                     | T2     |                             |
| <i>methyl ergonovine oral</i>                              | T3     |                             |

| Drug                                                                                    | Status | Notes                   |
|-----------------------------------------------------------------------------------------|--------|-------------------------|
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 20 mg, 30 mg</i>                  | T3     | QL (60 EA per 30 days)  |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 40 mg</i>                         | T3     | QL (30 EA per 30 days)  |
| <i>methylphenidate hcl oral solution</i>                                                | T2     |                         |
| <i>methylphenidate hcl oral tablet</i>                                                  | T2     | QL (90 EA per 30 days)  |
| <i>methylphenidate hcl oral tablet extended release 10 mg</i>                           | T3     | QL (180 EA per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 20 mg</i>                           | T4     | QL (90 EA per 30 days)  |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 27 mg, 36 mg, 54 mg</i> | T3     | QL (30 EA per 30 days)  |
| <i>methylprednisolone</i>                                                               | T2     |                         |
| <i>methylprednisolone acetate</i>                                                       | T2     |                         |
| <i>metipranolol</i>                                                                     | T2     |                         |
| <i>metoclopramide hcl oral solution</i>                                                 | T2     |                         |
| <i>metoclopramide hcl oral tablet</i>                                                   | T2     |                         |
| <i>metolazone</i>                                                                       | T2     |                         |
| <i>metoprolol succinate</i>                                                             | T2     | QL (60 EA per 30 days)  |
| <i>metoprolol ta-hydrochlorothiaz</i>                                                   | T2     |                         |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg</i>                             | T1     |                         |
| <i>metronidazole oral tablet</i>                                                        | T2     |                         |
| <i>metronidazole topical cream</i>                                                      | T3     |                         |
| <i>metronidazole topical gel 0.75 %</i>                                                 | T3     |                         |
| <i>metronidazole topical gel 1 %</i>                                                    | T4     |                         |
| <i>metronidazole topical gel with pump</i>                                              | T4     |                         |
| <i>metronidazole topical lotion</i>                                                     | T4     |                         |
| <i>metronidazole vaginal</i>                                                            | T2     |                         |
| <i>mexiletine</i>                                                                       | T2     |                         |
| <b>MICROGESTIN 1.5/30 (21)</b>                                                          | NCS    |                         |
| <b>MICROGESTIN 1/20 (21)</b>                                                            | NCS    |                         |
| <b>MICROGESTIN FE 1.5/30 (28)</b>                                                       | NCS    |                         |
| <b>MICROGESTIN FE 1/20 (28)</b>                                                         | NCS    |                         |
| <i>midodrine</i>                                                                        | T3     |                         |
| <b>MIGERGOT</b>                                                                         | T4     | QL (20 EA per 28 days)  |
| <i>miglitol</i>                                                                         | T4     | QL (90 EA per 30 days)  |
| <i>miglustat</i>                                                                        | T5     | PA                      |
| <b>MILK OF MAGNESIA</b>                                                                 | NCS    |                         |
| <b>MILK OF MAGNESIA CONCENTRATED</b>                                                    | NCS    |                         |
| <b>MILLIPRED DP ORAL TABLETS,DOSE PACK 5 MG (21 TABS)</b>                               | T3     |                         |
| <b>MIMVEY</b>                                                                           | T3     |                         |
| <b>MIMVEY LO</b>                                                                        | T3     |                         |
| <b>MINASTRIN 24 FE</b>                                                                  | T4     |                         |



| Drug                                                                     | Status | Notes                      |
|--------------------------------------------------------------------------|--------|----------------------------|
| <b>MINITRAN</b>                                                          | T2     |                            |
| <i>minocycline oral capsule</i>                                          | T2     |                            |
| <i>minoxidil oral</i>                                                    | T2     |                            |
| <b>MIRALAX ORAL POWDER IN PACKET</b>                                     | NCS    |                            |
| <b>MIRENA</b>                                                            | NCS    |                            |
| <i>mirtazapine oral tablet 15 mg, 7.5 mg</i>                             | T2     | QL (90 EA per 30 days)     |
| <i>mirtazapine oral tablet 30 mg, 45 mg</i>                              | T2     | QL (30 EA per 30 days)     |
| <i>mirtazapine oral tablet, disintegrating</i>                           | T2     | QL (30 EA per 30 days)     |
| <i>misoprostol</i>                                                       | T2     |                            |
| <b>M-M-R II (PF)</b>                                                     | NCS    |                            |
| <i>modafinil</i>                                                         | T3     | PA; QL (30 EA per 30 days) |
| <b>MODERIBA</b>                                                          | T4     | PA                         |
| <i>moexipril</i>                                                         | T3     |                            |
| <i>mometasone nasal</i>                                                  | T4     |                            |
| <i>mometasone topical</i>                                                | T2     |                            |
| <b>MONO-LINYAH</b>                                                       | NCS    |                            |
| <i>montelukast oral granules in packet</i>                               | T2     |                            |
| <i>montelukast oral tablet</i>                                           | T2     | QL (30 EA per 30 days)     |
| <i>montelukast oral tablet, chewable</i>                                 | T2     | QL (30 EA per 30 days)     |
| <b>MONUROL</b>                                                           | T4     |                            |
| <i>morphine concentrate oral solution</i>                                | T3     | QL (600 ML per 30 days)    |
| <i>morphine concentrate oral syringe 20 mg/ml</i>                        | T3     | QL (600 ML per 30 days)    |
| <i>morphine oral solution 10 mg/5 ml</i>                                 | T3     | QL (2700 ML per 30 days)   |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i>                       | T3     | QL (1350 ML per 30 days)   |
| <i>morphine oral tablet</i>                                              | T3     | QL (180 EA per 30 days)    |
| <i>morphine oral tablet extended release 100 mg, 15 mg, 30 mg, 60 mg</i> | T3     | QL (90 EA per 30 days)     |
| <i>morphine oral tablet extended release 200 mg</i>                      | T3     | QL (60 EA per 30 days)     |
| <b>MOTOFEN</b>                                                           | T4     |                            |
| <b>MOVANTIK</b>                                                          | T4     | PA                         |
| <b>MOVIPREP</b>                                                          | T4     |                            |
| <b>MOXEZA</b>                                                            | T3     |                            |
| <i>moxifloxacin ophthalmic (eye) drops</i>                               | T3     |                            |
| <b>MULPLETA</b>                                                          | T5     | PA; QL (7 EA per 90 days)  |
| <b>MULTAQ</b>                                                            | T3     |                            |
| <b>MULTI-VITAMIN WITH FLUORIDE ORAL DROPS</b>                            | NCS    |                            |
| <b>MULTIVITAMINS WITH FLUORIDE</b>                                       | NCS    |                            |
| <i>mupirocin</i>                                                         | T2     |                            |
| <b>MY WAY</b>                                                            | NCS    |                            |
| <i>mycophenolate mofetil oral capsule</i>                                | T3     |                            |
| <i>mycophenolate mofetil oral suspension for reconstitution</i>          | T4     |                            |
| <i>mycophenolate mofetil oral tablet</i>                                 | T3     |                            |

| Drug                                                        | Status | Notes                       |
|-------------------------------------------------------------|--------|-----------------------------|
| <i>mycophenolate sodium</i>                                 | T4     |                             |
| <b>MYORISAN</b>                                             | T4     |                             |
| <i>nabumetone</i>                                           | T2     |                             |
| <i>nadolol</i>                                              | T2     | QL (30 EA per 30 days)      |
| <i>naftifine</i>                                            | T4     |                             |
| <b>NAFTIN TOPICAL GEL 1 %</b>                               | T4     |                             |
| <b>NAGLAZYME</b>                                            | T5     | PA                          |
| <i>naloxone injection syringe 1 mg/ml</i>                   | T2     |                             |
| <i>naltrexone</i>                                           | T2     |                             |
| <i>naproxen oral tablet</i>                                 | T1     |                             |
| <i>naproxen oral tablet, delayed release (dr/ec)</i>        | T2     |                             |
| <i>naratriptan</i>                                          | T2     | ST; QL (18 EA per 30 days)  |
| <b>NATACYN</b>                                              | T3     |                             |
| <b>NATAZIA</b>                                              | T3     |                             |
| <i>nateglinide</i>                                          | T3     | QL (90 EA per 30 days)      |
| <b>NATURE-THROID</b>                                        | T2     |                             |
| <b>NAYZILAM</b>                                             | T5     | QL (10 EA per 30 days)      |
| <b>NECON 0.5/35 (28)</b>                                    | NCS    |                             |
| <i>nefazodone oral tablet 100 mg, 150 mg, 250 mg, 50 mg</i> | T2     | QL (60 EA per 30 days)      |
| <i>nefazodone oral tablet 200 mg</i>                        | T2     | QL (90 EA per 30 days)      |
| <i>neomycin</i>                                             | T2     |                             |
| <i>neomycin-bacitracin-poly-hc</i>                          | T2     |                             |
| <i>neomycin-bacitracin-polymyxin</i>                        | T2     |                             |
| <i>neomycin-polymyxin b-dexameth</i>                        | T2     |                             |
| <i>neomycin-polymyxin-gramicidin</i>                        | T2     |                             |
| <i>neomycin-polymyxin-hc otic (ear)</i>                     | T2     |                             |
| <b>NEOSALUS TOPICAL FOAM</b>                                | T4     |                             |
| <b>NERLYNX</b>                                              | T5     | PA                          |
| <b>NEULASTA</b>                                             | T5     | PA                          |
| <b>NEUPOGEN</b>                                             | T5     | PA                          |
| <b>NEVANAC</b>                                              | T3     |                             |
| <i>nevirapine oral suspension</i>                           | T3     | PA                          |
| <i>nevirapine oral tablet</i>                               | T3     | PA                          |
| <i>nevirapine oral tablet extended release 24 hr</i>        | T4     | PA                          |
| <b>NEXAVAR</b>                                              | T5     | PA; QL (120 EA per 30 days) |
| <b>NEXLETOL</b>                                             | T4     | PA; QL (30 EA per 30 days)  |
| <b>NEXLIZET</b>                                             | T4     | PA; QL (30 EA per 30 days)  |
| <b>NEXPLANON</b>                                            | NCS    |                             |
| <b>NEXT CHOICE ONE DOSE</b>                                 | NCS    |                             |
| <i>niacin oral tablet 500 mg</i>                            | T2     |                             |
| <i>niacin oral tablet extended release 24 hr</i>            | T3     |                             |
| <i>niacin oral tablet extended release 750 mg</i>           | T3     |                             |

| Drug                                                                                                     | Status | Notes                     |
|----------------------------------------------------------------------------------------------------------|--------|---------------------------|
| <b>NIACOR</b>                                                                                            | T2     |                           |
| <i>nicardipine oral</i>                                                                                  | T3     |                           |
| <i>nicotine (polacrilex) buccal gum</i>                                                                  | NCS    | QL (2800 EA per 365 days) |
| <i>nicotine (polacrilex) buccal lozenge</i>                                                              | NCS    | QL (2448 EA per 365 days) |
| <i>nicotine transdermal patch 24 hour 14 mg/24 hr, 21 mg/24 hr</i>                                       | NCS    | QL (84 EA per 365 days)   |
| <i>nicotine transdermal patch 24 hour 7 mg/24 hr</i>                                                     | NCS    | QL (28 EA per 365 days)   |
| <b>NICOTROL</b>                                                                                          | NCS    | QL (2688 EA per 365 days) |
| <b>NICOTROL NS</b>                                                                                       | NCS    | QL (6720 ML per 365 days) |
| <i>nifedipine</i>                                                                                        | T2     |                           |
| <b>NIKKI (28)</b>                                                                                        | NCS    |                           |
| <b>NILANDRON</b>                                                                                         | T5     |                           |
| <i>nimodipine</i>                                                                                        | T2     |                           |
| <b>NINLARO</b>                                                                                           | T5     | PA                        |
| <i>nisoldipine</i>                                                                                       | T3     |                           |
| <b>NITRO-BID</b>                                                                                         | T4     |                           |
| <i>nitrofurantoin</i>                                                                                    | T2     |                           |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 50 mg</i>                                            | T2     |                           |
| <i>nitrofurantoin monohydr/m-cryst</i>                                                                   | T2     |                           |
| <i>nitroglycerin sublingual</i>                                                                          | T2     |                           |
| <i>nitroglycerin transdermal patch 24 hour</i>                                                           | T2     |                           |
| <i>nizatidine</i>                                                                                        | T2     |                           |
| <b>NORA-BE</b>                                                                                           | NCS    |                           |
| <i>noreth-ethinyl estradiol-iron oral tablet, chewable 0.8mg-25mcg(24) and 75 mg (4)</i>                 | NCS    |                           |
| <i>norethindrone (contraceptive)</i>                                                                     | NCS    |                           |
| <i>norethindrone acetate</i>                                                                             | T2     |                           |
| <i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i>                             | T3     |                           |
| <i>norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg</i>                                            | NCS    |                           |
| <i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7), 1 mg-20 mcg (24)/75 mg (4)</i> | NCS    |                           |
| <i>norgestimate-ethinyl estradiol</i>                                                                    | NCS    |                           |
| <b>NORLYROC</b>                                                                                          | NCS    |                           |
| <b>NORMAL SALINE FLUSH</b>                                                                               | T2     |                           |
| <b>NORPACE CR</b>                                                                                        | T5     | PA                        |
| <b>NORTREL 0.5/35 (28)</b>                                                                               | NCS    |                           |
| <b>NORTREL 1/35 (21)</b>                                                                                 | NCS    |                           |
| <b>NORTREL 1/35 (28)</b>                                                                                 | NCS    |                           |
| <b>NORTREL 7/7/7 (28)</b>                                                                                | NCS    |                           |
| <i>nortriptyline oral capsule</i>                                                                        | T1     |                           |
| <b>NORVIR ORAL CAPSULE</b>                                                                               | T4     | PA                        |
| <b>NORVIR ORAL POWDER IN PACKET</b>                                                                      | T4     |                           |

| Drug                                                  | Status | Notes                        |
|-------------------------------------------------------|--------|------------------------------|
| <b>NORVIR ORAL SOLUTION</b>                           | T4     | PA                           |
| <b>NOVOLIN 70/30 U-100 INSULIN</b>                    | T3     | QL (60 ML per 30 days)       |
| <b>NOVOLIN N NPH U-100 INSULIN</b>                    | T3     | QL (60 ML per 30 days)       |
| <b>NOVOLIN R REGULAR U-100 INSULN</b>                 | T3     | QL (60 ML per 30 days)       |
| <b>NOVOLOG FLEXPEN U-100 INSULIN</b>                  | T3     | QL (60 ML per 30 days)       |
| <b>NOVOLOG MIX 70-30 U-100 INSULN</b>                 | T3     | QL (60 ML per 30 days)       |
| <b>NOVOLOG MIX 70-30FLEXPEN U-100</b>                 | T3     | QL (60 ML per 30 days)       |
| <b>NOVOLOG PENFILL U-100 INSULIN</b>                  | T3     | QL (60 ML per 30 days)       |
| <b>NOVOLOG U-100 INSULIN ASPART</b>                   | T3     | QL (60 ML per 30 days)       |
| <b>NOXAFIL</b>                                        | T5     | PA                           |
| <b>NP THYROID ORAL TABLET 30 MG, 60 MG, 90 MG</b>     | T2     |                              |
| <b>NUBEQA</b>                                         | T5     | PA; QL (120 EA per 30 days)  |
| <b>NUCALA SUBCUTANEOUS AUTO-INJECTOR</b>              | T5     | PA; QL (3 ML per 28 days)    |
| <b>NUCYNTA</b>                                        | T4     | PA; QL (180 EA per 30 days)  |
| <b>NUCYNTA ER</b>                                     | T4     | PA; QL (60 EA per 30 days)   |
| <b>NULOJIX</b>                                        | T5     | PA                           |
| <b>NURTEC ODT</b>                                     | T5     | PA; QL (15 EA per 30 days)   |
| <b>NUVARING</b>                                       | NCS    |                              |
| <b>NYMALIZE ORAL SYRINGE</b>                          | T5     | PA; QL (1260 ML per 30 days) |
| <i>nystatin oral suspension</i>                       | T2     |                              |
| <i>nystatin oral tablet</i>                           | T2     |                              |
| <i>nystatin topical</i>                               | T2     |                              |
| <i>nystatin-triamcinolone</i>                         | T4     |                              |
| <b>NYSTOP</b>                                         | T2     |                              |
| <b>OCELLA</b>                                         | NCS    |                              |
| <i>octreotide acetate injection solution</i>          | T5     | PA                           |
| <b>ODEFSEY</b>                                        | T5     | PA                           |
| <b>ODOMZO</b>                                         | T5     | PA; QL (30 EA per 30 days)   |
| <i>ofloxacin ophthalmic (eye)</i>                     | T2     |                              |
| <i>ofloxacin oral tablet 400 mg</i>                   | T2     |                              |
| <i>ofloxacin otic (ear)</i>                           | T4     |                              |
| <b>OGESTREL (28)</b>                                  | NCS    |                              |
| <i>olanzapine oral tablet</i>                         | T2     | QL (30 EA per 30 days)       |
| <i>olanzapine oral tablet,disintegrating</i>          | T3     | QL (30 EA per 30 days)       |
| <i>olanzapine-fluoxetine</i>                          | T4     |                              |
| <i>olmesartan</i>                                     | T3     |                              |
| <i>olmesartan-amlodipin-hcthiazid</i>                 | T3     |                              |
| <i>olmesartan-hydrochlorothiazide</i>                 | T3     |                              |
| <i>olopatadine nasal</i>                              | T4     |                              |
| <i>olopatadine ophthalmic (eye)</i>                   | T3     | QL (10 ML per 30 days)       |
| <i>omega-3 acid ethyl esters</i>                      | T3     |                              |
| <i>omeprazole oral capsule,delayed release(dr/ec)</i> | T2     |                              |
| <i>omeprazole oral tablet,delayed release (dr/ec)</i> | T2     |                              |

| Drug                                                                        | Status | Notes                       |
|-----------------------------------------------------------------------------|--------|-----------------------------|
| <b>OMNIPOD DASH 5 PACK POD</b>                                              | T5     | PA                          |
| <b>OMNIPOD DASH PDM KIT</b>                                                 | T5     | PA; QL (1 EA per 365 days)  |
| <b>OMNIPOD INSULIN MANAGEMENT</b>                                           | T5     | PA; QL (1 EA per 365 days)  |
| <b>OMNIPOD INSULIN REFILL</b>                                               | T5     | PA                          |
| <b>OMNITROPE</b>                                                            | T5     | PA                          |
| <i>ondansetron</i>                                                          | T3     |                             |
| <i>ondansetron hcl oral solution</i>                                        | T2     |                             |
| <i>ondansetron hcl oral tablet 24 mg</i>                                    | T2     | QL (30 EA per 30 days)      |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i>                               | T2     | QL (60 EA per 30 days)      |
| <b>OPCICON ONE-STEP</b>                                                     | NCS    |                             |
| <b>ORAL SALINE LAXATIVE</b>                                                 | NCS    |                             |
| <b>ORFADIN ORAL CAPSULE 10 MG, 2 MG, 5 MG</b>                               | T5     | PA                          |
| <b>ORKAMBI</b>                                                              | T5     | PA                          |
| <i>orphenadrine citrate oral</i>                                            | T2     | QL (60 EA per 30 days)      |
| <b>ORSYTHIA</b>                                                             | NCS    |                             |
| <b>OSCIMIN SR</b>                                                           | T2     |                             |
| <i>oseltamivir oral capsule</i>                                             | T3     | QL (60 EA per 30 days)      |
| <i>oseltamivir oral suspension for reconstitution</i>                       | T3     |                             |
| <b>OSMOPREP</b>                                                             | T4     |                             |
| <b>OTEZLA</b>                                                               | T5     | PA                          |
| <b>OTEZLA STARTER</b>                                                       | T5     | PA                          |
| <i>oxandrolone oral tablet 10 mg</i>                                        | T5     | PA; QL (120 EA per 30 days) |
| <i>oxandrolone oral tablet 2.5 mg</i>                                       | T5     | PA; QL (60 EA per 30 days)  |
| <i>oxaprozin</i>                                                            | T3     |                             |
| <i>oxcarbazepine</i>                                                        | T2     |                             |
| <b>OXERVATE</b>                                                             | T5     | PA                          |
| <i>oxiconazole</i>                                                          | T4     | ST                          |
| <i>oxybutynin chloride oral tablet</i>                                      | T2     | QL (120 EA per 30 days)     |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 5 mg</i>    | T2     | QL (30 EA per 30 days)      |
| <i>oxybutynin chloride oral tablet extended release 24hr 15 mg</i>          | T2     | QL (60 EA per 30 days)      |
| <i>oxycodone oral solution</i>                                              | T4     | QL (5400 ML per 30 days)    |
| <i>oxycodone oral tablet 10 mg, 15 mg, 20 mg</i>                            | T3     | QL (180 EA per 30 days)     |
| <i>oxycodone oral tablet 30 mg</i>                                          | T3     | QL (120 EA per 30 days)     |
| <i>oxycodone oral tablet 5 mg</i>                                           | T3     | QL (240 EA per 30 days)     |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i>                        | T3     | QL (180 EA per 30 days)     |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg, 7.5-325 mg</i> | T3     | QL (240 EA per 30 days)     |
| <i>oxycodone-aspirin</i>                                                    | T3     | QL (360 EA per 30 days)     |
| <i>oxymorphone oral tablet</i>                                              | T4     | QL (120 EA per 30 days)     |
| <i>oxymorphone oral tablet extended release 12 hr</i>                       | T4     | QL (60 EA per 30 days)      |
| <b>OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG(2 MG/1.5 ML)</b>     | T3     | QL (1.5 ML per 28 days)     |

| Drug                                                                                        | Status | Notes                       |
|---------------------------------------------------------------------------------------------|--------|-----------------------------|
| <b>OZEMPIC SUBCUTANEOUS PEN INJECTOR 1 MG/DOSE (2 MG/1.5 ML)</b>                            | T3     | QL (3 ML per 28 days)       |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg</i>                    | T5     | PA; QL (30 EA per 30 days)  |
| <i>paliperidone oral tablet extended release 24hr 6 mg</i>                                  | T5     | PA; QL (60 EA per 30 days)  |
| <b>PALYNZIQ</b>                                                                             | T5     | PA                          |
| <i>pamidronate</i>                                                                          | T5     | PA                          |
| <b>PANRETIN</b>                                                                             | T5     | PA                          |
| <i>pantoprazole oral tablet, delayed release (dr/ec)</i>                                    | T2     | QL (60 EA per 30 days)      |
| <b>PARAGARD T 380A</b>                                                                      | NCS    |                             |
| <i>paricalcitol oral</i>                                                                    | T4     | PA                          |
| <b>PAROEX ORAL RINSE</b>                                                                    | T2     |                             |
| <i>paromomycin</i>                                                                          | T3     |                             |
| <i>paroxetine hcl oral tablet</i>                                                           | T2     | QL (90 EA per 30 days)      |
| <i>paroxetine hcl oral tablet extended release 24 hr 12.5 mg</i>                            | T3     | QL (30 EA per 30 days)      |
| <i>paroxetine hcl oral tablet extended release 24 hr 25 mg, 37.5 mg</i>                     | T3     | QL (60 EA per 30 days)      |
| <b>PAXIL ORAL SUSPENSION</b>                                                                | T4     | QL (900 ML per 30 days)     |
| <b>PAZEO</b>                                                                                | T3     |                             |
| <b>PEDIARIX (PF)</b>                                                                        | NCS    |                             |
| <b>PEDVAX HIB (PF)</b>                                                                      | NCS    |                             |
| <i>peg 3350-electrolytes</i>                                                                | NCS    |                             |
| <b>PEG-3350 WITH FLAVOR PACKS</b>                                                           | NCS    |                             |
| <b>PEGANONE</b>                                                                             | T4     |                             |
| <i>peg-electrolyte soln</i>                                                                 | NCS    |                             |
| <b>PEGINTRON SUBCUTANEOUS KIT 50 MCG/0.5 ML</b>                                             | T5     | PA                          |
| <b>PEG-PREP</b>                                                                             | NCS    |                             |
| <b>PEMAZYRE</b>                                                                             | T5     | PA; QL (14 EA per 21 days)  |
| <b>PEN NEEDLE NEEDLE 31 GAUGE X 5/16"</b>                                                   | T3     | QL (200 EA per 30 days)     |
| <i>penicillamine oral capsule</i>                                                           | T5     | PA                          |
| <i>penicillamine oral tablet</i>                                                            | T5     | PA; QL (120 EA per 30 days) |
| <i>penicillin v potassium</i>                                                               | T2     |                             |
| <b>PENTACEL (PF) INTRAMUSCULAR KIT 15 LF UNIT-20 MCG-5 LF/0.5 ML</b>                        | NCS    |                             |
| <b>PENTACEL ACTHIB COMPONENT (PF)</b>                                                       | NCS    |                             |
| <b>PENTACEL DTAP-IPV COMPNT (PF) INTRAMUSCULAR SUSPENSION 15 LF-48 MCG- 5 LF UNIT/0.5ML</b> | NCS    |                             |
| <b>PENTAM</b>                                                                               | T5     | PA                          |
| <i>pentamidine injection</i>                                                                | T4     |                             |
| <i>pentazocine-naloxone</i>                                                                 | T3     |                             |
| <b>PENTIPS NEEDLE 31 GAUGE X 5/16"</b>                                                      | T3     | QL (200 EA per 30 days)     |
| <i>pentoxifylline</i>                                                                       | T2     |                             |
| <i>perindopril erbumine</i>                                                                 | T3     |                             |

| Drug                                                                               | Status | Notes                      |
|------------------------------------------------------------------------------------|--------|----------------------------|
| <i>permethrin topical cream</i>                                                    | T4     |                            |
| <i>perphenazine</i>                                                                | T2     |                            |
| <i>perphenazine-amitriptyline</i>                                                  | T2     |                            |
| <b>PERSERIS</b>                                                                    | T5     | PA; QL (1 EA per 28 days)  |
| <b>PEXEVA</b>                                                                      | T4     |                            |
| <b>PHENADOZ</b>                                                                    | T3     |                            |
| <i>phenazopyridine oral tablet 100 mg, 200 mg</i>                                  | T2     |                            |
| <i>phenelzine</i>                                                                  | T3     |                            |
| <b>PHENERGAN RECTAL</b>                                                            | T3     |                            |
| <i>phenobarbital</i>                                                               | T2     |                            |
| <i>phenytoin sodium extended</i>                                                   | T2     |                            |
| <b>PHILITH</b>                                                                     | NCS    |                            |
| <i>phospha 250 neutral</i>                                                         | T2     |                            |
| <b>PHOSPHATE LAXATIVE ORAL LIQUID</b>                                              | NCS    |                            |
| <b>PHOSPHOLINE IODIDE</b>                                                          | T3     |                            |
| <b>PHYSIOLYTE</b>                                                                  | T4     |                            |
| <b>PICATO</b>                                                                      | T5     | PA                         |
| <b>PIFELTRO</b>                                                                    | T5     | QL (30 EA per 30 days)     |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i>                        | T3     |                            |
| <i>pilocarpine hcl oral</i>                                                        | T3     |                            |
| <i>pimecrolimus</i>                                                                | T4     |                            |
| <i>pimozide</i>                                                                    | T3     |                            |
| <b>PIMTREA (28)</b>                                                                | NCS    |                            |
| <i>pindolol</i>                                                                    | T3     |                            |
| <i>pioglitazone</i>                                                                | T2     | QL (30 EA per 30 days)     |
| <i>pioglitazone-glimepiride</i>                                                    | T3     | QL (30 EA per 30 days)     |
| <i>pioglitazone-metformin</i>                                                      | T3     | QL (90 EA per 30 days)     |
| <b>PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1)</b>                                  | T5     | PA; QL (28 EA per 28 days) |
| <b>PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)</b> | T5     | PA; QL (56 EA per 28 days) |
| <b>PIRMELLA</b>                                                                    | NCS    |                            |
| <i>piroxicam</i>                                                                   | T3     |                            |
| <b>PLAN B ONE-STEP</b>                                                             | NCS    |                            |
| <b>PLEGRIDY</b>                                                                    | T5     | PA; QL (1 ML per 28 days)  |
| <b>PNEUMOVAX-23</b>                                                                | NCS    |                            |
| <b>PNV 29-1</b>                                                                    | T3     |                            |
| <i>podofilox</i>                                                                   | T3     |                            |
| <i>polyethylene glycol 3350</i>                                                    | NCS    |                            |
| <i>polyethylene glycol 3350(bulk) powder</i>                                       | T2     |                            |
| <i>polymyxin b sulfate</i>                                                         | T2     |                            |
| <i>polymyxin b sulf-trimethoprim</i>                                               | T2     |                            |
| <b>POMALYST</b>                                                                    | T5     | PA                         |
| <b>PORTIA 28</b>                                                                   | NCS    |                            |

| Drug                                                                                                                                           | Status | Notes                   |
|------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------|
| <i>potassium chloride oral</i>                                                                                                                 | T2     |                         |
| <i>potassium citrate</i>                                                                                                                       | T3     |                         |
| <b>POTELIGEO</b>                                                                                                                               | T5     | PA                      |
| <b>POWDERLAX ORAL POWDER</b>                                                                                                                   | NCS    |                         |
| <b>PRADAXA</b>                                                                                                                                 | T4     |                         |
| <i>pramipexole oral tablet</i>                                                                                                                 | T2     |                         |
| <i>pramipexole oral tablet extended release 24 hr 0.375 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg</i>                                                  | T5     | PA                      |
| <b>PRAMOSONE TOPICAL LOTION</b>                                                                                                                | T4     |                         |
| <i>pravastatin</i>                                                                                                                             | T2     | QL (30 EA per 30 days)  |
| <i>prazosin</i>                                                                                                                                | T2     |                         |
| <b>PRECISION XTRA MONITOR</b>                                                                                                                  | T3     |                         |
| <b>PRECISION XTRA TEST</b>                                                                                                                     | T3     | QL (200 EA per 30 days) |
| <i>prednicarbate</i>                                                                                                                           | T3     |                         |
| <i>prednisolone acetate</i>                                                                                                                    | T2     |                         |
| <i>prednisolone oral solution 15 mg/5 ml</i>                                                                                                   | T2     |                         |
| <i>prednisolone sodium phosphate ophthalmic (eye)</i>                                                                                          | T2     |                         |
| <i>prednisolone sodium phosphate oral solution 15 mg/5 ml (3 mg/ml), 15 mg/5 ml (5 ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | T2     |                         |
| <i>prednisolone sodium phosphate oral tablet, disintegrating</i>                                                                               | T4     |                         |
| <b>PREDNISONE INTENSOL</b>                                                                                                                     | T2     |                         |
| <i>prednisone oral solution</i>                                                                                                                | T2     |                         |
| <i>prednisone oral tablet</i>                                                                                                                  | T1     |                         |
| <i>prednisone oral tablets, dose pack</i>                                                                                                      | T2     |                         |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i>                                                                     | T4     | QL (90 EA per 30 days)  |
| <i>pregabalin oral capsule 225 mg, 300 mg</i>                                                                                                  | T4     | QL (60 EA per 30 days)  |
| <i>pregabalin oral solution</i>                                                                                                                | T4     |                         |
| <b>PREMARIN ORAL</b>                                                                                                                           | T3     |                         |
| <b>PREMARIN VAGINAL</b>                                                                                                                        | T3     |                         |
| <b>PREMPHASE</b>                                                                                                                               | T3     |                         |
| <b>PREMPRO</b>                                                                                                                                 | T3     |                         |
| <b>PRENATABS FA</b>                                                                                                                            | T2     |                         |
| <b>PRENATABS RX</b>                                                                                                                            | T4     |                         |
| <b>PRETAB</b>                                                                                                                                  | T2     |                         |
| <b>PREVALITE</b>                                                                                                                               | T3     |                         |
| <b>PREVIDENT</b>                                                                                                                               | T4     |                         |
| <b>PREVIDENT 5000 BOOSTER PLUS</b>                                                                                                             | T4     |                         |
| <b>PREVIDENT 5000 DRY MOUTH</b>                                                                                                                | T4     |                         |
| <b>PREVIDENT 5000 ENAMEL PROTECT</b>                                                                                                           | T4     |                         |
| <b>PREVIDENT 5000 PLUS</b>                                                                                                                     | T4     |                         |
| <b>PREVIDENT 5000 SENSITIVE</b>                                                                                                                | T4     |                         |



| Drug                                                                                                                         | Status | Notes                               |
|------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------|
| <b>PREVIFEM</b>                                                                                                              | NCS    |                                     |
| <b>PREVNAR 13 (PF)</b>                                                                                                       | NCS    | QL (0.5 ML Max Qty Per Fill Retail) |
| <b>PREZCOBIX</b>                                                                                                             | T5     | PA                                  |
| <b>PREZISTA ORAL SUSPENSION</b>                                                                                              | T4     | PA                                  |
| <b>PREZISTA ORAL TABLET 150 MG</b>                                                                                           | T4     | PA                                  |
| <b>PREZISTA ORAL TABLET 600 MG, 800 MG</b>                                                                                   | T5     | PA                                  |
| <b>PREZISTA ORAL TABLET 75 MG</b>                                                                                            | T3     | PA                                  |
| <b>PRIFTIN</b>                                                                                                               | T4     |                                     |
| <i>primaquine</i>                                                                                                            | T3     | QL (30 EA per 30 days)              |
| <i>primidone</i>                                                                                                             | T2     |                                     |
| <b>PRISTIQ</b>                                                                                                               | T3     | QL (30 EA per 30 days)              |
| <i>probenecid</i>                                                                                                            | T2     |                                     |
| <i>probenecid-colchicine</i>                                                                                                 | T2     |                                     |
| <i>procainamide injection</i>                                                                                                | T3     |                                     |
| <i>prochlorperazine</i>                                                                                                      | T4     |                                     |
| <i>prochlorperazine edisylate injection solution 10 mg/2 ml (5 mg/ml)</i>                                                    | T4     |                                     |
| <i>prochlorperazine maleate</i>                                                                                              | T2     |                                     |
| <b>PROCORT</b>                                                                                                               | T3     |                                     |
| <b>PROCRT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML</b> | T5     | PA; QL (14 ML per 30 days)          |
| <b>PROCTOFOAM HC</b>                                                                                                         | T4     |                                     |
| <b>PROCTO-PAK</b>                                                                                                            | T2     |                                     |
| <b>PROCTOZONE-HC</b>                                                                                                         | T2     |                                     |
| <i>progesterone</i>                                                                                                          | T2     |                                     |
| <i>progesterone micronized</i>                                                                                               | T2     |                                     |
| <b>PROGLYCEM</b>                                                                                                             | T4     |                                     |
| <b>PROGRAF ORAL CAPSULE</b>                                                                                                  | T4     |                                     |
| <b>PROLIA</b>                                                                                                                | T4     | QL (1 ML per 180 days)              |
| <b>PROMACTA ORAL POWDER IN PACKET 12.5 MG</b>                                                                                | T5     | PA; QL (60 EA per 30 days)          |
| <b>PROMACTA ORAL POWDER IN PACKET 25 MG</b>                                                                                  | T5     | PA                                  |
| <b>PROMACTA ORAL TABLET</b>                                                                                                  | T5     | PA; QL (60 EA per 30 days)          |
| <i>promethazine injection solution</i>                                                                                       | T3     |                                     |
| <i>promethazine oral syrup</i>                                                                                               | T3     |                                     |
| <i>promethazine oral tablet</i>                                                                                              | T2     |                                     |
| <i>promethazine rectal</i>                                                                                                   | T3     |                                     |
| <b>PROMETHAZINE VC</b>                                                                                                       | T3     |                                     |
| <i>promethazine-codeine</i>                                                                                                  | T3     |                                     |
| <i>promethazine-dm</i>                                                                                                       | T2     |                                     |
| <i>promethazine-phenyleph-codeine</i>                                                                                        | T3     |                                     |
| <i>promethazine-phenylephrine</i>                                                                                            | T3     |                                     |
| <b>PROMETHEGAN</b>                                                                                                           | T3     |                                     |

| Drug                                                                         | Status | Notes                       |
|------------------------------------------------------------------------------|--------|-----------------------------|
| <b>PROMISEB</b>                                                              | T4     |                             |
| <i>propafenone oral capsule,extended release 12 hr</i>                       | T3     |                             |
| <i>propafenone oral tablet</i>                                               | T2     |                             |
| <i>propantheline</i>                                                         | T3     |                             |
| <i>proparacaine</i>                                                          | T3     |                             |
| <i>propranolol oral capsule,extended release 24 hr</i>                       | T2     |                             |
| <i>propranolol oral solution</i>                                             | T3     |                             |
| <i>propranolol oral tablet</i>                                               | T2     |                             |
| <i>propranolol-hydrochlorothiazid</i>                                        | T2     |                             |
| <i>propylthiouracil</i>                                                      | T3     |                             |
| <b>PROQUAD (PF)</b>                                                          | NCS    |                             |
| <i>protriptyline</i>                                                         | T3     |                             |
| <b>PRUTECT</b>                                                               | T3     |                             |
| <b>PULMOZYME</b>                                                             | T5     | PA; QL (150 ML per 30 days) |
| <b>PURELAX</b>                                                               | NCS    |                             |
| <i>pyrazinamide</i>                                                          | T2     |                             |
| <i>pyridostigmine bromide oral syrup</i>                                     | T5     |                             |
| <i>pyridostigmine bromide oral tablet 60 mg</i>                              | T3     |                             |
| <i>pyridostigmine bromide oral tablet extended release</i>                   | T4     |                             |
| <i>pyrimethamine (bulk)</i>                                                  | T3     |                             |
| <b>QINLOCK</b>                                                               | T5     | PA; QL (90 EA per 30 days)  |
| <b>QUADRACEL (PF)</b>                                                        | NCS    |                             |
| <i>quetiapine oral tablet</i>                                                | T2     | QL (90 EA per 30 days)      |
| <i>quetiapine oral tablet extended release 24 hr</i>                         | T4     | PA                          |
| <i>quinapril</i>                                                             | T1     |                             |
| <i>quinapril-hydrochlorothiazide</i>                                         | T2     |                             |
| <i>quinidine gluconate oral</i>                                              | T4     |                             |
| <i>quinidine sulfate oral tablet</i>                                         | T2     |                             |
| <i>quinine sulfate</i>                                                       | T4     |                             |
| <b>RABAVERT (PF)</b>                                                         | NCS    |                             |
| <i>rabeprazole oral tablet,delayed release (dr/ec)</i>                       | T4     | QL (30 EA per 30 days)      |
| <b>RAGWITEK</b>                                                              | T3     |                             |
| <i>raloxifene</i>                                                            | T3     | PA; QL (30 EA per 30 days)  |
| <i>ramipril</i>                                                              | T1     |                             |
| <i>ranitidine hcl oral syrup</i>                                             | T2     |                             |
| <i>ranitidine hcl oral tablet</i>                                            | T2     |                             |
| <i>ranolazine</i>                                                            | T4     |                             |
| <b>RAPAMUNE ORAL SOLUTION</b>                                                | T5     |                             |
| <b>REBIF (WITH ALBUMIN)</b>                                                  | T5     |                             |
| <b>REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML</b> | T5     |                             |
| <b>RECLIPSEN (28)</b>                                                        | NCS    |                             |
| <b>RECOMBIVAX HB (PF)</b>                                                    | NCS    |                             |

| Drug                                               | Status | Notes                       |
|----------------------------------------------------|--------|-----------------------------|
| <b>RECTIV</b>                                      | T4     |                             |
| <b>REGRANEX</b>                                    | T4     | PA                          |
| <b>RELENZA DISKHALER</b>                           | T5     | PA; QL (60 EA per 180 days) |
| <b>RELPAX</b>                                      | T4     | ST; QL (18 EA per 30 days)  |
| <b>REMODULIN</b>                                   | T5     | PA                          |
| <b>RENAGEL ORAL TABLET 800 MG</b>                  | T3     | ST                          |
| <b>RENFLEXIS</b>                                   | T5     |                             |
| <b>RENVELA</b>                                     | T5     | ST                          |
| <i>repaglinide</i>                                 | T2     | QL (90 EA per 30 days)      |
| <b>REPATHA PUSHTRONEX</b>                          | T4     | PA; QL (3.5 ML per 28 days) |
| <b>REPATHA SURECLICK</b>                           | T4     | PA; QL (3 ML per 28 days)   |
| <b>REPATHA SYRINGE</b>                             | T4     | PA; QL (3 ML per 28 days)   |
| <b>RESCRIPTOR ORAL TABLET</b>                      | T3     | PA                          |
| <b>RESTASIS</b>                                    | T3     | QL (60 EA per 30 days)      |
| <b>RETACRIT</b>                                    | T4     | QL (14 ML per 30 days)      |
| <b>RETEVMO ORAL CAPSULE 40 MG</b>                  | T5     | PA; QL (60 EA per 30 days)  |
| <b>RETEVMO ORAL CAPSULE 80 MG</b>                  | T5     | PA; QL (120 EA per 30 days) |
| <b>RETROVIR INTRAVENOUS</b>                        | T4     | PA                          |
| <b>REVLIMID</b>                                    | T5     | PA                          |
| <b>REYATAZ ORAL CAPSULE 150 MG, 200 MG, 300 MG</b> | T5     | PA                          |
| <b>REYATAZ ORAL POWDER IN PACKET</b>               | T5     | PA                          |
| <b>REYVOW</b>                                      | T5     | PA; QL (4 EA per 30 days)   |
| <b>RHOPRESSA</b>                                   | T3     |                             |
| <b>RIBASPHERE ORAL CAPSULE</b>                     | T4     | PA                          |
| <i>ribavirin oral capsule</i>                      | T4     | PA                          |
| <i>ribavirin oral tablet 200 mg</i>                | T4     | PA                          |
| <b>RIDAURA</b>                                     | T5     |                             |
| <i>rifabutin</i>                                   | T4     |                             |
| <i>rifampin oral</i>                               | T2     |                             |
| <i>rimantadine</i>                                 | T2     |                             |
| <i>ringer's irrigation</i>                         | T2     |                             |
| <i>risedronate oral tablet 150 mg</i>              | T4     | QL (1 EA per 30 days)       |
| <i>risedronate oral tablet 30 mg, 5 mg</i>         | T4     | QL (30 EA per 30 days)      |
| <i>risedronate oral tablet 35 mg</i>               | T4     | QL (4 EA per 28 days)       |
| <b>RISPERDAL CONSTA</b>                            | T4     | PA; QL (4 EA per 28 days)   |
| <i>risperidone oral solution</i>                   | T2     |                             |
| <i>risperidone oral tablet</i>                     | T2     | QL (120 EA per 30 days)     |
| <i>risperidone oral tablet, disintegrating</i>     | T3     | QL (120 EA per 30 days)     |
| <i>ritonavir</i>                                   | T4     |                             |
| <i>rivastigmine tartrate</i>                       | T3     | QL (60 EA per 30 days)      |
| <i>rizatriptan</i>                                 | T2     | QL (18 EA per 30 days)      |
| <i>ropinirole oral tablet</i>                      | T2     |                             |

| Drug                                                                     | Status | Notes                       |
|--------------------------------------------------------------------------|--------|-----------------------------|
| <i>ropinirole oral tablet extended release 24 hr</i>                     | T4     |                             |
| <b>ROSANIL</b>                                                           | T4     |                             |
| <b>ROSULA CLEANSING CLOTHS</b>                                           | T4     |                             |
| <i>rosuvastatin</i>                                                      | T2     | QL (30 EA per 30 days)      |
| <b>ROTARIX</b>                                                           | NCS    |                             |
| <b>ROTATEQ VACCINE</b>                                                   | NCS    |                             |
| <b>ROZEREM</b>                                                           | T3     | QL (30 EA per 30 days)      |
| <b>ROZLYTREK ORAL CAPSULE 100 MG</b>                                     | T5     | PA; QL (30 EA per 30 days)  |
| <b>ROZLYTREK ORAL CAPSULE 200 MG</b>                                     | T5     | PA; QL (90 EA per 30 days)  |
| <b>RUBRACA</b>                                                           | T5     | PA; QL (120 EA per 30 days) |
| <b>RUKOBIA</b>                                                           | T5     | QL (60 EA per 30 days)      |
| <b>RUZURGI</b>                                                           | T5     | PA; QL (240 EA per 30 days) |
| <b>RYBELSUS</b>                                                          | T3     | QL (30 EA per 30 days)      |
| <b>RYDAPT</b>                                                            | T5     | PA                          |
| <b>SABRIL ORAL TABLET</b>                                                | T5     | PA                          |
| <b>SAFYRAL</b>                                                           | T3     |                             |
| <i>salicylic acid topical cream,extended release</i>                     | T2     |                             |
| <i>salicylic acid topical foam</i>                                       | T2     |                             |
| <i>salicylic acid topical gel</i>                                        | T2     |                             |
| <i>salicylic acid topical lotion,extended release</i>                    | T2     |                             |
| <i>salicylic acid topical shampoo</i>                                    | T2     |                             |
| <b>SAMSCA</b>                                                            | T5     | PA                          |
| <b>SANCUSO</b>                                                           | T5     | PA                          |
| <b>SANDOSTATIN LAR DEPOT INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON</b> | T5     | PA                          |
| <b>SANTYL</b>                                                            | T4     |                             |
| <b>SAPHRIS</b>                                                           | T4     | PA                          |
| <b>SAVELLA ORAL TABLET</b>                                               | T4     | QL (60 EA per 30 days)      |
| <b>SAVELLA ORAL TABLETS,DOSE PACK</b>                                    | T4     | QL (55 EA per 30 days)      |
| <i>scopolamine base</i>                                                  | T4     |                             |
| <b>SECUADO</b>                                                           | T5     | PA; QL (30 EA per 30 days)  |
| <b>SEGLUROMET</b>                                                        | T3     | QL (60 EA per 30 days)      |
| <i>selegiline hcl</i>                                                    | T2     |                             |
| <i>selenium sulfide topical lotion</i>                                   | T2     |                             |
| <i>selenium sulfide topical shampoo 2.25 %</i>                           | T4     |                             |
| <b>SELZENTRY ORAL TABLET</b>                                             | T5     | PA; QL (120 EA per 30 days) |
| <b>SENSIPAR ORAL TABLET 30 MG, 60 MG</b>                                 | T5     | QL (60 EA per 30 days)      |
| <b>SENSIPAR ORAL TABLET 90 MG</b>                                        | T5     | QL (120 EA per 30 days)     |
| <b>SEREVENT DISKUS</b>                                                   | T3     | QL (60 EA per 30 days)      |
| <b>SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HR</b>                    | T4     | PA                          |
| <i>sertraline oral concentrate</i>                                       | T2     | QL (300 ML per 30 days)     |
| <i>sertraline oral tablet</i>                                            | T2     | QL (60 EA per 30 days)      |

| Drug                                                               | Status | Notes                      |
|--------------------------------------------------------------------|--------|----------------------------|
| <b>SETLAKIN</b>                                                    | NCS    |                            |
| <i>sevelamer hcl oral tablet 800 mg</i>                            | T5     | ST                         |
| <b>SF</b>                                                          | T2     |                            |
| <b>SF 5000 PLUS</b>                                                | T2     |                            |
| <b>SHAROBEL</b>                                                    | NCS    |                            |
| <b>SHINGRIX (PF)</b>                                               | NCS    |                            |
| <b>SHINGRIX GE ANTIGEN COMPONENT</b>                               | NCS    |                            |
| <b>SIGNIFOR LAR</b>                                                | T5     | PA                         |
| <i>sildenafil (pulm.hypertension) oral tablet</i>                  | T4     | PA; QL (90 EA per 30 days) |
| <b>SILENOR</b>                                                     | T4     |                            |
| <i>silver sulfadiazine</i>                                         | T2     |                            |
| <b>SIMBRINZA</b>                                                   | T3     |                            |
| <i>simvastatin oral tablet</i>                                     | T1     | QL (30 EA per 30 days)     |
| <i>sirolimus oral solution</i>                                     | T5     |                            |
| <i>sirolimus oral tablet</i>                                       | T4     |                            |
| <b>SKLICE</b>                                                      | T4     |                            |
| <b>SKYLA</b>                                                       | T3     |                            |
| <b>SMOOTHLAX</b>                                                   | NCS    |                            |
| <i>sodium chloride 0.9 % (flush) injection syringe</i>             | T2     |                            |
| <i>sodium chloride 0.9 % injection</i>                             | T2     |                            |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i>       | T2     |                            |
| <i>sodium chloride inhalation</i>                                  | T2     |                            |
| <i>sodium chloride irrigation</i>                                  | T2     |                            |
| <i>sodium phenylbutyrate oral tablet</i>                           | T5     | PA                         |
| <i>sodium polystyrene sulfonate oral powder</i>                    | T3     |                            |
| <i>sodium polystyrene sulfonate oral suspension</i>                | T2     |                            |
| <b>SOFOSBUVIR-VELPATASVIR</b>                                      | T5     | PA; QL (28 EA per 28 days) |
| <i>solifenacin</i>                                                 | T3     | QL (30 EA per 30 days)     |
| <b>SOMATULINE DEPOT</b>                                            | T5     | PA                         |
| <i>somavert subcutaneous recon soln 10 mg</i>                      | T5     | PA                         |
| <b>SOMAVERT SUBCUTANEOUS RECON SOLN 15 MG, 20 MG, 25 MG, 30 MG</b> | T5     | PA                         |
| <b>SORINE</b>                                                      | T2     |                            |
| <b>SOTALOL AF</b>                                                  | T2     |                            |
| <i>sotalol oral</i>                                                | T2     |                            |
| <b>SPIRIVA RESPIMAT</b>                                            | T3     | QL (4 GM per 30 days)      |
| <b>SPIRIVA WITH HANDIHALER</b>                                     | T3     | QL (30 EA per 30 days)     |
| <i>spironolactone</i>                                              | T2     |                            |
| <i>spironolacton-hydrochlorothiaz</i>                              | T2     |                            |
| <b>SPRINTEC (28)</b>                                               | NCS    |                            |
| <b>SPRYCEL</b>                                                     | T5     | PA; QL (30 EA per 30 days) |
| <b>SPS (WITH SORBITOL) ORAL</b>                                    | T2     |                            |
| <b>SRONYX</b>                                                      | NCS    |                            |

| Drug                                                                                         | Status | Notes                        |
|----------------------------------------------------------------------------------------------|--------|------------------------------|
| <b>SSD</b>                                                                                   | T2     |                              |
| <b>SSS 10-5</b>                                                                              | T4     |                              |
| <i>stavudine oral capsule</i>                                                                | T3     | PA                           |
| <b>STEGLATRO</b>                                                                             | T3     | QL (30 EA per 30 days)       |
| <b>STIOLTO RESPIMAT</b>                                                                      | T3     | QL (4 GM per 30 days)        |
| <b>STIVARGA</b>                                                                              | T5     | PA; QL (84 EA per 28 days)   |
| <b>STRATTERA ORAL CAPSULE 10 MG, 18 MG, 25 MG, 40 MG</b>                                     | T3     | QL (60 EA per 30 days)       |
| <b>STRATTERA ORAL CAPSULE 100 MG, 60 MG, 80 MG</b>                                           | T3     | QL (30 EA per 30 days)       |
| <i>streptomycin</i>                                                                          | T3     |                              |
| <b>STRIBILD</b>                                                                              | T5     | PA                           |
| <b>STRIVERDI RESPIMAT</b>                                                                    | T3     |                              |
| <i>sucralfate oral suspension</i>                                                            | T3     |                              |
| <i>sucralfate oral tablet</i>                                                                | T2     |                              |
| <i>sulfacetamide sodium (acne)</i>                                                           | T2     |                              |
| <i>sulfacetamide sodium ophthalmic (eye)</i>                                                 | T2     |                              |
| <i>sulfacetamide sodium topical</i>                                                          | T4     |                              |
| <i>sulfacetamide sodium-sulfur topical cleanser 10-2 %, 10-5 % (w/w), 9-4.5 %, 9.8-4.8 %</i> | T4     |                              |
| <i>sulfacetamide sodium-sulfur topical cream</i>                                             | T4     |                              |
| <i>sulfacetamide sodium-sulfur topical lotion 10-5 % (w/v)</i>                               | T4     |                              |
| <i>sulfacetamide sodium-sulfur topical pads, medicated 10-4 %</i>                            | T4     |                              |
| <i>sulfacetamide sodium-sulfur topical suspension 10-5 %</i>                                 | T4     |                              |
| <i>sulfacetamide sod-sulfur-urea topical cleanser</i>                                        | T4     |                              |
| <i>sulfadiazine</i>                                                                          | T3     |                              |
| <i>sulfamethoxazole-trimethoprim intravenous</i>                                             | T3     |                              |
| <i>sulfamethoxazole-trimethoprim oral suspension</i>                                         | T2     |                              |
| <i>sulfamethoxazole-trimethoprim oral tablet</i>                                             | T1     |                              |
| <b>SULFAMYLON TOPICAL CREAM</b>                                                              | T4     |                              |
| <i>sulfasalazine oral tablet</i>                                                             | T2     |                              |
| <i>sulindac</i>                                                                              | T2     |                              |
| <i>sumatriptan succinate oral</i>                                                            | T2     | QL (18 EA per 30 days)       |
| <i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i>                           | T4     | QL (8 ML per 30 days)        |
| <i>sumatriptan succinate subcutaneous solution</i>                                           | T4     | QL (8 ML per 30 days)        |
| <b>SUNOSI</b>                                                                                | T4     | PA; QL (30 EA per 30 days)   |
| <b>SUPREP BOWEL PREP KIT</b>                                                                 | T3     |                              |
| <b>SUSTIVA</b>                                                                               | T4     | PA                           |
| <b>SUTENT</b>                                                                                | T5     | PA; QL (30 EA per 30 days)   |
| <b>SYEDA</b>                                                                                 | NCS    |                              |
| <b>SYMBICORT</b>                                                                             | T3     | ST; QL (10.2 GM per 30 days) |

| Drug                                                                          | Status | Notes                       |
|-------------------------------------------------------------------------------|--------|-----------------------------|
| <b>SYMFI</b>                                                                  | T5     | QL (30 EA per 30 days)      |
| <b>SYMFI LO</b>                                                               | T5     | QL (30 EA per 30 days)      |
| <b>SYMLINPEN 120</b>                                                          | T5     |                             |
| <b>SYMLINPEN 60</b>                                                           | T5     |                             |
| <b>SYMTUZA</b>                                                                | T5     | QL (30 EA per 30 days)      |
| <b>SYNAREL</b>                                                                | T5     |                             |
| <b>SYNERA</b>                                                                 | T4     | PA                          |
| <b>SYNJARDY</b>                                                               | T3     |                             |
| <b>SYNJARDY XR</b>                                                            | T3     |                             |
| <b>SYNTHROID</b>                                                              | T3     |                             |
| <b>SYPRINE</b>                                                                | T5     |                             |
| <b>TABLOID</b>                                                                | T5     | PA                          |
| <i>tacrolimus oral</i>                                                        | T3     |                             |
| <i>tacrolimus topical</i>                                                     | T4     | PA                          |
| <i>tadalafil (pulm. hypertension)</i>                                         | T5     | PA                          |
| <i>tadalafil oral tablet 20 mg</i>                                            | T5     | PA                          |
| <b>TAFINLAR</b>                                                               | T5     | PA; QL (120 EA per 30 days) |
| <b>TAGRISSO ORAL TABLET 40 MG</b>                                             | T5     | PA; QL (30 EA per 30 days)  |
| <b>TAGRISSO ORAL TABLET 80 MG</b>                                             | T5     | PA; QL (60 EA per 30 days)  |
| <b>TAKE ACTION</b>                                                            | NCS    |                             |
| <b>TAKHZYRO</b>                                                               | T5     | PA                          |
| <b>TALZENNA ORAL CAPSULE 0.25 MG</b>                                          | T5     | PA; QL (90 EA per 30 days)  |
| <b>TALZENNA ORAL CAPSULE 1 MG</b>                                             | T5     | PA; QL (30 EA per 30 days)  |
| <i>tamoxifen</i>                                                              | T2     | PA                          |
| <i>tamsulosin</i>                                                             | T2     |                             |
| <b>TARCEVA</b>                                                                | T5     | PA; QL (30 EA per 30 days)  |
| <b>TARGRETIN TOPICAL</b>                                                      | T5     | PA                          |
| <b>TARINA FE 1/20 (28)</b>                                                    | NCS    |                             |
| <b>TASIGNA ORAL CAPSULE 150 MG, 200 MG</b>                                    | T5     | PA; QL (120 EA per 30 days) |
| <b>TAVALISSE</b>                                                              | T5     | PA; QL (60 EA per 30 days)  |
| <i>tazarotene</i>                                                             | T4     |                             |
| <b>TAZORAC</b>                                                                | T4     |                             |
| <b>TAZTIA XT</b>                                                              | T2     |                             |
| <b>TAZVERIK</b>                                                               | T5     | PA; QL (240 EA per 30 days) |
| <b>TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG</b>                   | T5     | PA; QL (14 EA per 365 days) |
| <b>TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG (14)- 240 MG (46)</b> | T5     | PA; QL (60 EA per 365 days) |
| <b>TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 240 MG</b>                   | T5     | PA; QL (60 EA per 30 days)  |
| <b>TEKTURNA</b>                                                               | T3     |                             |
| <b>TEKTURNA HCT</b>                                                           | T3     |                             |
| <i>telmisartan</i>                                                            | T2     |                             |

| Drug                                                                              | Status | Notes                      |
|-----------------------------------------------------------------------------------|--------|----------------------------|
| <i>temazepam oral capsule 15 mg, 30 mg</i>                                        | T2     | QL (30 EA per 30 days)     |
| <i>temozolomide</i>                                                               | T5     | PA                         |
| <b>TENIVAC (PF)</b>                                                               | NCS    |                            |
| <i>tenofovir disoproxil fumarate</i>                                              | T5     | PA                         |
| <i>terazosin</i>                                                                  | T2     | QL (60 EA per 30 days)     |
| <i>terbinafine hcl oral</i>                                                       | T2     | QL (30 EA per 30 days)     |
| <i>terbutaline oral</i>                                                           | T2     |                            |
| <i>terconazole</i>                                                                | T4     |                            |
| <i>testosterone cypionate intramuscular oil 100 mg/ml</i>                         | T3     | QL (10 ML per 28 days)     |
| <i>testosterone cypionate intramuscular oil 200 mg/ml</i>                         | T3     | QL (4 ML per 28 days)      |
| <i>testosterone enanthate</i>                                                     | T3     | QL (5 ML per 28 days)      |
| <i>testosterone transdermal gel</i>                                               | T3     | QL (60 GM per 30 days)     |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)</i> | T3     | QL (150 GM per 28 days)    |
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram)</i>                 | T3     | QL (150 GM per 30 days)    |
| <i>testosterone transdermal gel in packet 1 % (50 mg/5 gram)</i>                  | T3     | QL (60 GM per 30 days)     |
| <i>tetanus,diphtheria tox ped(pf)</i>                                             | NCS    |                            |
| <i>tetracycline</i>                                                               | T4     |                            |
| <b>THALOMID</b>                                                                   | T5     | PA                         |
| <i>theophylline oral tablet extended release 12 hr</i>                            | T2     |                            |
| <i>thioridazine</i>                                                               | T2     |                            |
| <i>thiothixene</i>                                                                | T2     |                            |
| <b>THYMOGLOBULIN</b>                                                              | T5     | PA                         |
| <i>tiagabine oral tablet 12 mg, 16 mg</i>                                         | T4     |                            |
| <i>tiagabine oral tablet 2 mg, 4 mg</i>                                           | T5     |                            |
| <b>TIBSOVO</b>                                                                    | T5     | PA; QL (60 EA per 30 days) |
| <b>TIGAN INTRAMUSCULAR</b>                                                        | T4     | PA                         |
| <b>TILIA FE</b>                                                                   | NCS    |                            |
| <i>timolol maleate ophthalmic (eye) drops</i>                                     | T2     |                            |
| <i>timolol maleate oral</i>                                                       | T2     |                            |
| <b>TIVICAY</b>                                                                    | T5     | PA                         |
| <i>tizanidine oral tablet</i>                                                     | T2     |                            |
| <b>TOBRADEX OPHTHALMIC (EYE) OINTMENT</b>                                         | T3     |                            |
| <b>TOBRADEX ST</b>                                                                | T3     |                            |
| <i>tobramycin in 0.225 % nacl</i>                                                 | T5     | PA                         |
| <i>tobramycin ophthalmic (eye)</i>                                                | T2     |                            |
| <i>tobramycin-dexamethasone</i>                                                   | T3     |                            |
| <b>TODAY CONTRACEPTIVE SPONGE</b>                                                 | NCS    |                            |
| <i>tolcapone</i>                                                                  | T5     |                            |
| <i>tolmetin</i>                                                                   | T3     |                            |
| <i>tolterodine oral tablet</i>                                                    | T3     | QL (60 EA per 30 days)     |



| Drug                                                                  | Status | Notes                   |
|-----------------------------------------------------------------------|--------|-------------------------|
| <i>topiramate oral capsule, sprinkle</i>                              | T3     |                         |
| <i>topiramate oral tablet</i>                                         | T2     |                         |
| <b>TOPOSAR</b>                                                        | T5     | PA                      |
| <i>toremifene</i>                                                     | T5     | QL (60 EA per 30 days)  |
| <i>torsemide oral</i>                                                 | T2     |                         |
| <b>TOUJEO SOLOSTAR U-300 INSULIN</b>                                  | T3     | QL (21 ML per 30 days)  |
| <b>TOVIAZ</b>                                                         | T4     | QL (30 EA per 30 days)  |
| <b>TRACLEER</b>                                                       | T5     | PA                      |
| <b>TRADJENTA</b>                                                      | T3     | QL (30 EA per 30 days)  |
| <i>tramadol oral tablet 50 mg</i>                                     | T3     | QL (240 EA per 30 days) |
| <i>tramadol oral tablet extended release 24 hr</i>                    | T4     | QL (30 EA per 30 days)  |
| <i>tramadol oral tablet, er multiphase 24 hr</i>                      | T4     | QL (30 EA per 30 days)  |
| <i>tramadol-acetaminophen</i>                                         | T3     | QL (240 EA per 30 days) |
| <i>trandolapril</i>                                                   | T2     |                         |
| <i>tranexamic acid intravenous</i>                                    | T3     | PA                      |
| <i>tranexamic acid oral</i>                                           | T2     |                         |
| <i>tranylcypromine</i>                                                | T3     |                         |
| <b>TRAVATAN Z</b>                                                     | T3     | QL (5 ML per 30 days)   |
| <i>travoprost</i>                                                     | T3     | QL (5 ML per 30 days)   |
| <i>trazodone oral tablet 100 mg, 150 mg, 50 mg</i>                    | T2     |                         |
| <i>trazodone oral tablet 300 mg</i>                                   | T4     |                         |
| <b>TRECATOR</b>                                                       | T4     |                         |
| <b>TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG</b> | T4     |                         |
| <i>treprostinil sodium</i>                                            | T5     |                         |
| <b>TRESIBA FLEXTOUCH U-100</b>                                        | T3     | QL (60 ML per 30 days)  |
| <b>TRESIBA FLEXTOUCH U-200</b>                                        | T3     | QL (36 ML per 30 days)  |
| <i>tretinoin</i>                                                      | T3     |                         |
| <i>tretinoin (antineoplastic)</i>                                     | T5     | PA                      |
| <i>tretinoin (emollient)</i>                                          | T3     |                         |
| <i>tretinoin microspheres</i>                                         | T3     |                         |
| <i>triamcinolone acetonide dental</i>                                 | T3     |                         |
| <i>triamcinolone acetonide injection suspension 40 mg/ml</i>          | T4     |                         |
| <i>triamcinolone acetonide topical aerosol</i>                        | T4     |                         |
| <i>triamcinolone acetonide topical cream</i>                          | T2     |                         |
| <i>triamcinolone acetonide topical lotion</i>                         | T2     |                         |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | T2     |                         |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i>         | T2     |                         |
| <i>triamterene-hydrochlorothiazid oral tablet</i>                     | T2     |                         |
| <i>triazolam</i>                                                      | T2     |                         |
| <b>TRIBENZOR</b>                                                      | T3     |                         |

| Drug                                                | Status | Notes                       |
|-----------------------------------------------------|--------|-----------------------------|
| <b>TRICITRATES</b>                                  | T4     |                             |
| <i>trientine</i>                                    | T5     |                             |
| <b>TRI-ESTARYLLA</b>                                | NCS    |                             |
| <i>trifluoperazine</i>                              | T2     |                             |
| <i>trifluridine</i>                                 | T3     |                             |
| <i>trihexyphenidyl</i>                              | T2     |                             |
| <b>TRIJARDY XR</b>                                  | T3     | QL (30 EA per 30 days)      |
| <b>TRIKAFTA</b>                                     | T5     | PA; QL (84 EA per 28 days)  |
| <b>TRI-LEGEST FE</b>                                | NCS    |                             |
| <b>TRI-LINYAH</b>                                   | NCS    |                             |
| <b>TRI-LO-SPRINTEC</b>                              | NCS    |                             |
| <b>TRILYTE WITH FLAVOR PACKETS</b>                  | NCS    |                             |
| <i>trimethobenzamide oral</i>                       | T2     |                             |
| <i>trimethoprim</i>                                 | T2     |                             |
| <i>trimipramine</i>                                 | T4     |                             |
| <b>TRINTELLIX</b>                                   | T3     | QL (30 EA per 30 days)      |
| <b>TRI-PREVIFEM (28)</b>                            | NCS    |                             |
| <b>TRI-SPRINTEC (28)</b>                            | NCS    |                             |
| <b>TRIUMEQ</b>                                      | T5     | PA                          |
| <b>TRIVORA (28)</b>                                 | NCS    |                             |
| <i>tropicamide</i>                                  | T3     |                             |
| <i>trospium oral capsule, extended release 24hr</i> | T2     | QL (30 EA per 30 days)      |
| <i>trospium oral tablet</i>                         | T4     |                             |
| <b>TRUMENBA</b>                                     | NCS    |                             |
| <b>TRUVADA</b>                                      | T5     | PA                          |
| <b>TUKYSA</b>                                       | T5     | PA; QL (120 EA per 30 days) |
| <b>TURALIO</b>                                      | T5     | PA; QL (120 EA per 30 days) |
| <b>TWINRIX (PF) INTRAMUSCULAR SYRINGE</b>           | NCS    |                             |
| <b>TYBOST</b>                                       | T3     | QL (30 EA per 30 days)      |
| <b>TYKERB</b>                                       | T5     | PA; QL (180 EA per 30 days) |
| <b>TYMLOS</b>                                       | T5     | PA                          |
| <b>TYPHIM VI</b>                                    | NCS    |                             |
| <b>TYSABRI</b>                                      | T5     |                             |
| <b>TYZINE NASAL DROPS 0.05 %</b>                    | T3     |                             |
| <b>UBRELVY</b>                                      | T5     | PA; QL (16 EA per 30 days)  |
| <b>ULESFIA</b>                                      | T4     |                             |
| <b>ULORIC</b>                                       | T4     | ST                          |
| <b>UNITHROID</b>                                    | T2     |                             |
| <i>urea topical cream 20 %, 39 %</i>                | T2     |                             |
| <i>urea topical foam</i>                            | T2     |                             |
| <i>urea topical gel 45 %</i>                        | T2     |                             |
| <i>urea topical lotion 40 %</i>                     | T2     |                             |
| <i>ursodiol</i>                                     | T4     |                             |

| Drug                                                                 | Status | Notes                        |
|----------------------------------------------------------------------|--------|------------------------------|
| <i>valacyclovir</i>                                                  | T2     | QL (90 EA per 30 days)       |
| <b>VALCHLOR</b>                                                      | T5     | PA                           |
| <b>VALCYTE ORAL RECON SOLN</b>                                       | T5     | PA                           |
| <i>valganciclovir oral tablet</i>                                    | T5     | PA                           |
| <i>valproic acid</i>                                                 | T2     |                              |
| <i>valproic acid (as sodium salt) oral solution</i>                  | T2     |                              |
| <i>valsartan</i>                                                     | T2     |                              |
| <i>valsartan-hydrochlorothiazide</i>                                 | T2     |                              |
| <b>VALTOCO</b>                                                       | T5     | QL (10 EA per 30 days)       |
| <i>vancomycin intravenous recon soln 1,000 mg, 500 mg</i>            | T2     |                              |
| <i>vancomycin oral capsule</i>                                       | T5     | PA                           |
| <i>vancomycin oral recon soln</i>                                    | T3     |                              |
| <b>VAQTA (PF)</b>                                                    | NCS    |                              |
| <b>VARIVAX (PF)</b>                                                  | NCS    |                              |
| <b>VARIZIG INTRAMUSCULAR SOLUTION</b>                                | NCS    |                              |
| <b>VARUBI</b>                                                        | T5     | PA                           |
| <b>VASCEPA ORAL CAPSULE 1 GRAM</b>                                   | T3     |                              |
| <b>VELIVET TRIPHASIC REGIMEN (28)</b>                                | NCS    |                              |
| <b>VELTIN</b>                                                        | T5     |                              |
| <b>VENCLEXTA</b>                                                     | T5     | PA                           |
| <b>VENCLEXTA STARTING PACK</b>                                       | T5     | PA                           |
| <i>venlafaxine oral capsule,extended release 24hr 150 mg</i>         | T2     | QL (60 EA per 30 days)       |
| <i>venlafaxine oral capsule,extended release 24hr 37.5 mg, 75 mg</i> | T2     | QL (90 EA per 30 days)       |
| <i>venlafaxine oral tablet</i>                                       | T2     | QL (90 EA per 30 days)       |
| <b>VENTAVIS</b>                                                      | T5     | PA                           |
| <b>VENTOLIN HFA</b>                                                  | T3     | QL (36 GM per 30 days)       |
| <i>verapamil oral</i>                                                | T2     |                              |
| <b>VEREGEN</b>                                                       | T3     |                              |
| <b>VERZENIO</b>                                                      | T5     | PA                           |
| <b>VESICARE</b>                                                      | T3     | QL (30 EA per 30 days)       |
| <b>VIBERZI</b>                                                       | T5     | PA                           |
| <b>VICTOZA 2-PAK</b>                                                 | T3     | QL (9 ML per 30 days)        |
| <b>VICTOZA 3-PAK</b>                                                 | T3     | QL (9 ML per 30 days)        |
| <b>VIDEX 2 GRAM PEDIATRIC</b>                                        | T4     | PA                           |
| <i>vigabatrin oral powder in packet</i>                              | T5     | PA                           |
| <i>vigabatrin oral tablet</i>                                        | T5     | QL (180 EA per 30 days)      |
| <b>VIGAMOX</b>                                                       | T3     |                              |
| <b>VIIBRYD ORAL TABLET</b>                                           | T4     | ST; QL (30 EA per 30 days)   |
| <b>VIIBRYD ORAL TABLETS,DOSE PACK 10 MG (7)-20 MG (23)</b>           | T4     | ST; QL (30 EA per 30 days)   |
| <b>VIMPAT ORAL SOLUTION</b>                                          | T5     | PA; QL (1200 ML per 30 days) |

| Drug                                 | Status | Notes                       |
|--------------------------------------|--------|-----------------------------|
| VIMPAT ORAL TABLET                   | T5     | PA; QL (60 EA per 30 days)  |
| VIMPAT ORAL TABLETS,DOSE PACK        | T5     | PA                          |
| VIORALE (28)                         | NCS    |                             |
| VIRACEPT ORAL TABLET 250 MG          | T4     | PA                          |
| VIRACEPT ORAL TABLET 625 MG          | T5     | PA                          |
| VIREAD                               | T5     | PA                          |
| VITAFOL-OB+DHA                       | T3     |                             |
| VITAMIN D2                           | NCS    | QL (4 EA per 28 days)       |
| VITRAKVI ORAL CAPSULE                | T5     | PA; QL (60 EA per 30 days)  |
| VIVITROL                             | T5     | QL (1 EA per 28 days)       |
| VIVOTIF                              | NCS    |                             |
| VIZIMPRO                             | T5     | PA; QL (30 EA per 30 days)  |
| <i>voriconazole oral</i>             | T5     | PA                          |
| VOTRIENT                             | T5     | PA; QL (120 EA per 30 days) |
| VUMERITY                             | T5     | PA; QL (60 EA per 30 days)  |
| VUSION                               | T4     |                             |
| VYFEMLA (28)                         | NCS    |                             |
| VYTORIN 10-10                        | T4     | QL (30 EA per 30 days)      |
| VYTORIN 10-20                        | T4     | QL (30 EA per 30 days)      |
| VYTORIN 10-40                        | T4     | QL (30 EA per 30 days)      |
| VYTORIN 10-80                        | T4     | QL (30 EA per 30 days)      |
| VYVANSE ORAL CAPSULE                 | T4     | PA; QL (30 EA per 30 days)  |
| VYXEOS                               | T5     | PA                          |
| WAKIX                                | T5     | PA; QL (60 EA per 30 days)  |
| <i>warfarin</i>                      | T1     |                             |
| <i>water for irrigation, sterile</i> | T2     |                             |
| WERA (28)                            | NCS    |                             |
| WIDE-SEAL DIAPHRAGM 60               | NCS    |                             |
| WIDE-SEAL DIAPHRAGM 65               | NCS    |                             |
| WIDE-SEAL DIAPHRAGM 70               | NCS    |                             |
| WIDE-SEAL DIAPHRAGM 75               | NCS    |                             |
| WIDE-SEAL DIAPHRAGM 80               | NCS    |                             |
| WIDE-SEAL DIAPHRAGM 85               | NCS    |                             |
| WIDE-SEAL DIAPHRAGM 90               | NCS    |                             |
| WIDE-SEAL DIAPHRAGM 95               | NCS    |                             |
| WOMAN'S LAXATIVE (BISACODYL)         | NCS    |                             |
| WOMEN'S GENTLE LAXATIVE(BISAC)       | NCS    |                             |
| WOMEN'S LAXATIVE (BISACODYL)         | NCS    |                             |
| WYMZYA FE                            | NCS    |                             |
| XALKORI                              | T5     | PA; QL (60 EA per 30 days)  |
| XARELTO                              | T3     |                             |
| XARELTO DVT-PE TREAT 30D START       | T3     |                             |
| XCOPRI MAINTENANCE PACK              | T5     | PA; QL (56 EA per 28 days)  |

| Drug                                                       | Status | Notes                       |
|------------------------------------------------------------|--------|-----------------------------|
| <b>XCOPRI TITRATION PACK</b>                               | T5     | PA; QL (28 EA per 28 days)  |
| <b>XELJANZ ORAL TABLET 10 MG</b>                           | T5     | PA; QL (60 EA per 30 days)  |
| <b>XELJANZ ORAL TABLET 5 MG</b>                            | T5     | PA                          |
| <b>XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG</b> | T5     | PA                          |
| <b>XERMELO</b>                                             | T5     | PA; QL (90 EA per 30 days)  |
| <b>XIFAXAN ORAL TABLET 200 MG</b>                          | T5     | PA; QL (9 EA per 30 days)   |
| <b>XIFAXAN ORAL TABLET 550 MG</b>                          | T5     | PA; QL (90 EA per 30 days)  |
| <b>XOFLUZA</b>                                             | T3     | QL (2 EA per 30 days)       |
| <b>XOLAIR</b>                                              | T5     | PA                          |
| <b>XOSPATA</b>                                             | T5     | PA; QL (90 EA per 30 days)  |
| <b>XPOVIO ORAL TABLET 100 MG/WEEK (20 MG X 5)</b>          | T5     | PA; QL (20 EA per 30 days)  |
| <b>XPOVIO ORAL TABLET 40 MG/WEEK (20 MG X 2)</b>           | T5     | PA; QL (8 EA per 28 days)   |
| <b>XPOVIO ORAL TABLET 40MG TWICE WEEK (80 MG/WEEK)</b>     | T5     | PA; QL (16 EA per 28 days)  |
| <b>XPOVIO ORAL TABLET 60 MG/WEEK (20 MG X 3)</b>           | T5     | PA; QL (12 EA per 30 days)  |
| <b>XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK)</b>    | T5     | PA; QL (24 EA per 28 days)  |
| <b>XPOVIO ORAL TABLET 80 MG/WEEK (20 MG X 4)</b>           | T5     | PA; QL (16 EA per 30 days)  |
| <b>XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK)</b>    | T5     | PA; QL (32 EA per 28 days)  |
| <b>XTAMPZA ER</b>                                          | T4     | QL (60 EA per 30 days)      |
| <b>XTANDI</b>                                              | T5     | PA; QL (120 EA per 30 days) |
| <b>XULANE</b>                                              | NCS    |                             |
| <b>XULTOPHY 100/3.6</b>                                    | T3     | QL (15 ML per 30 days)      |
| <b>XYREM</b>                                               | T5     | PA                          |
| <b>YASMIN (28)</b>                                         | T4     |                             |
| <b>YAZ (28)</b>                                            | T4     |                             |
| <b>YF-VAX (PF)</b>                                         | NCS    |                             |
| <b>YONSA</b>                                               | T5     | PA; QL (120 EA per 30 days) |
| <i>zafirlukast</i>                                         | T3     | QL (60 EA per 30 days)      |
| <i>zaleplon</i>                                            | T2     | QL (30 EA per 30 days)      |
| <b>ZARAH</b>                                               | NCS    |                             |
| <b>ZAVESCA</b>                                             | T5     | PA                          |
| <b>ZEJULA</b>                                              | T5     | PA; QL (90 EA per 30 days)  |
| <b>ZELBORAF</b>                                            | T5     | PA                          |
| <b>ZEMAIRA</b>                                             | T5     | PA                          |
| <b>ZENATANE</b>                                            | T4     |                             |
| <b>ZENCHENT (28)</b>                                       | NCS    |                             |
| <b>ZEPOSIA</b>                                             | T5     | PA; QL (30 EA per 30 days)  |
| <b>ZEPOSIA STARTER KIT</b>                                 | T5     | PA; QL (7 EA per 7 days)    |
| <b>ZEPOSIA STARTER PACK</b>                                | T5     | PA; QL (7 EA per 7 days)    |
| <b>ZETIA</b>                                               | T3     | QL (30 EA per 30 days)      |
| <b>ZIAGEN ORAL SOLUTION</b>                                | T3     | PA                          |

| Drug                                                                    | Status | Notes                       |
|-------------------------------------------------------------------------|--------|-----------------------------|
| <b>ZIANA</b>                                                            | T5     |                             |
| <i>zidovudine</i>                                                       | T3     | PA                          |
| <b>ZIOPTAN (PF)</b>                                                     | T4     |                             |
| <i>ziprasidone hcl</i>                                                  | T2     | QL (60 EA per 30 days)      |
| <b>ZIRGAN</b>                                                           | T4     |                             |
| <i>zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml</i> | T5     | PA                          |
| <b>ZOLINZA</b>                                                          | T5     | PA; QL (120 EA per 30 days) |
| <i>zolmitriptan</i>                                                     | T4     | ST; QL (18 EA per 30 days)  |
| <i>zolpidem oral tablet</i>                                             | T2     | QL (30 EA per 30 days)      |
| <b>ZOMIG NASAL</b>                                                      | T4     | ST; QL (12 EA per 30 days)  |
| <b>ZONALON</b>                                                          | T4     |                             |
| <i>zonisamide</i>                                                       | T2     |                             |
| <b>ZONTIVITY</b>                                                        | T3     |                             |
| <b>ZORTRESS ORAL TABLET 0.25 MG, 0.5 MG, 0.75 MG</b>                    | T5     | PA                          |
| <b>ZOSTAVAX (PF)</b>                                                    | NCS    |                             |
| <b>ZOVIA 1/35E (28)</b>                                                 | NCS    |                             |
| <b>ZYDELIG</b>                                                          | T5     | PA; QL (60 EA per 30 days)  |
| <b>ZYFLO</b>                                                            | T5     | PA; QL (120 EA per 30 days) |
| <b>ZYKADIA ORAL TABLET</b>                                              | T5     | PA; QL (90 EA per 30 days)  |
| <b>ZYLET</b>                                                            | T4     |                             |
| <b>ZYTIGA ORAL TABLET 500 MG</b>                                        | T5     | PA; QL (60 EA per 30 days)  |



For more recent information or other questions, please contact Health First Health Plans Customer Service at 1.800.716.7737 or, for TTY users, 1.800.955.8771, weekdays from 8 a.m. to 8 p.m. and Saturdays from 8 a.m. to noon. From October 1 through March 31, we are available seven days a week from 8 a.m. to 8 p.m. or visit [myHFHP.org](http://myHFHP.org).

Customer Service has language interpreter services available for non-English speakers at no cost.

This information is also available at no cost in other formats. By contacting Customer Service you may request your materials be read aloud, emailed, or mailed in large print.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, premium and/or copayments/coinsurance may change on January 1, 2021, and from time to time during the year.

Health First Health Plans is an HMO plan with a Medicare contract. Enrollment in Health First Health Plans depends on contract renewal.

The Formulary, pharmacy network, may change at any time. You will receive notice when necessary.



## Nondiscrimination Notice

Health First Health Plans complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. Health First Health Plans does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Health First Health Plans:

- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, accessible electronic formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, please contact Civil Rights Coordinator.

If you believe that Health First Health Plans has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Civil Rights Coordinator, 6450 US Highway 1, Rockledge, FL 32955, 321-434-4521, 1-800-955-8771 (TTY), Fax: 321-434-4362, [civilrightscordinator@health-first.org](mailto:civilrightscordinator@health-first.org). You can file a grievance in person or by mail, fax or email. If you need help filing a grievance our Civil Rights Coordinator, is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1-800-368-1019, 800-537-7697 (TDD).

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Health First Health Plans is an HMO plan with a Medicare contract. Enrollment in Health First Health Plans depends on contract renewal.

**English:** ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Call 1-800-716-7737 (TTY: 1-800-955-8771).

**Spanish:** ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-716-7737 (TTY: 1-800-955-8771).

**French Creole:** ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 1-800-716-7737 (TTY: 1-800-955-8771).

**Vietnamese:** CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-800-716-7737 (TTY: 1-800-955-8771).

**Portuguese:** ATENÇÃO: Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 1-800-716-7737 (TTY: 1-800-955-8771).

**Chinese:** 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1-800-716-7737 (TTY : 1-800-955-8771)。

**French:** ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-800-716-7737 (ATS : 1-800-955-8771).

**Tagalog:** PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-800-716-7737 (TTY: 1-800-955-8771).

**Russian:** ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-800-716-7737 (телетайп: 1-800-955-8771).

**Arabic:**

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1-800-716-7737 (رقم والبكم الصم هاتف: 1-800-955-8771).

**Italian:** ATTENZIONE: In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 1-800-716-7737 (TTY: 1-800-955-8771).

**German:** ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-800-716-7737 (TTY: 1-800-955-8771).

**Korean:** 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-800-716-7737 (TTY: 1-800-955-8771)번으로 전화해 주십시오.

**Polish:** UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 1-800-716-7737 (TTY: 1-800-955-8771).

**Gujarati:** સચુ ના: જો તમેગજુ રાતી બોલતા હો, તો નન:શલ્કુક ભાષા સહાય સેવાઓ તમારા માટે ઉપલબ્ધ છે. ફોન કરો 1-800-716-7737 (TTY: 1-800-955-8771).

**Thai:** เรียน: ถ้าคุณพูดภาษาไทยคุณสามารถใช้บริการช่วยเหลือทางภาษาได้ฟรี โทร 1-800-716-7737 (TTY: 1-800-955-8771).